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Abstract 
Fourteen novel comb shaped amphiphilic polymers were successfully synthesised to 
determine the effect of polymer architecture on the potential of these amphiphilic polymers 
for hydrophobic drug delivery. Polyallylamine (PAA) was grafted with four different types 
of hydrophobic pendant groups (Cholesteryl (Ch), (Fmoc), (Dansyl)and (Naphth)). Some 
amphiphilic polymers were further reacted with methyl orange to form quaternary 
ammonium moieties. The polymers were characterised by elemental analysis and nuclear 
magnetic resonance spectroscopy (NMR). In the aqueous environment the amphiphilic 
polymers formed nano self assemblies with particle size from 99 to 284 nm. The critical 
aggregation concentration (CAC) of the self assemblies was successfully determined by 
surface tension measurement. The CAC ranged from the lowest value of 0.093 to the 
highest 1.5 mgmL-1 (Ch5 and Fmoc5 respectively). The Fmoc and Naphth grafted polymers 
showed the presence of two CMC values, this phenomenon was due to stacking of the 
planar hydrophobic ring structures resulting in excimer formation. The theory of excimer 
formation was confirmed by the observation of peak shifting on the emission spectra of 
the compounds in water over a large concentration range (0.023 – 3 mgmL-1). 
The drug loading potential of the polymers was investigated using five model hydrophobic 
drugs, propofol, prednisolone griseofulvin, etoposide and novel anticancer agent 
BNIPDaoct. The Ch5 and Dansyl10 showed excellent drug solubilisation capacities. At 6 
mgmL-1 the Ch5 achieved propofol solubility 70-fold greater than its aqueous solubility, 
prednisolone, griseofulvin and etoposide solubility’s were increased 20-fold, 30-fold and  
7-fold respectively. Similarly at 6 mgmL-1 the Dansyl10 achieved a 200-fold increase on the 
aqueous solubility of propofol and increased the solubility of prednisolone, griseofulvin 
and etoposide by 100-fold and 400-fold and 12-fold respectively. The Ch5 (at 1 mgmL-1) 
was also used to solubilise the novel anticancer agent  Bisnaphthalimidopropyl 
diaminooctane (BNIPDaoct) which was otherwise insoluble achieving a solubilisation of 
0.3 mgmL-1. The sizes of the optimal formulations differed greatly for both modified 
polymers. This was possibly due to the varying architectures of both the drug and the 
modified polymers and their ability to expand the hydrophobic core and shield the drugs 
from the ‘hostile’ aqueous environment. 
The in vitro drug release profiles, showed controlled release of the hydrophobic drugs 
from the core of the nano aggregates (Ch5 and Dansyl10), the time span for 100% of the 
drugs to be released ranged from 48- 96 h. Biological characterisation of the polymers 
found that most of the polymers showed negligible haemolytic activity over the 
concentrations tested (0.05 – 1 mgmL-1), the IC50 values for the cytotoxicity assay ranged 
from 0.01740 - 0.05585 mgmL-1 on Caco-2 cells (Fmoc5 to QCh5 respectively). The 
quaternized polymers showed a slightly better safety profile than their unquaternized 
counterparts, despite exhibiting low drug solubilisation capacities. The optimal 
 xx 
formulations of Ch5 and Dansyl10 loaded with etoposide and BNIPDaoct were tested for 
their cytotoxicity in vitro on Caco-2 and HEK293 cells. All formulations were capable of 
lowering the IC50 values when compared with the free anticancer drugs, thus increasing 
their therapeutic effect. The Ch5 decreased the solubility of etoposide 2.2-fold and 
BNIPDaoct 1.3-fold on Caco-2 cells, with Dansyl10 achieving a 14 -fold and 16–fold 
reduction respectively. In vivo oral administration of Ch5 and Dansyl10, griseofulvin 
formulations demonstrated significantly enhanced the absorption of griseofulvin 
absorption in rats compared with griseofulvin in water (8.89-fold and 5.20-fold increase 
respectively on total concentration of griseofulvin solubilised over 24 h study). A 
formulation of Ch5, BNIPDaoct was also shown to significantly decrease the tumour 
growth when treated on tumour bearing nude mice over a 4 week period. This is the first 
time these novel PAA’s grafted with cholesteryl and dansyl have shown promising 
potential in hydrophobic drug delivery.  
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Drug delivery describes the delivery of a pharmaceutical compound into humans or 
animals. Traditionally inert excipients were used as carriers for the active ingredient and 
as bulking agents for formulations enabling convenient and accurate dosage. However, 
modern excipients can increase the bioavailability of the therapeutic agent and control its 
release site and rate [1]. 
The mode of drug delivery is usually chosen by investigation into the physiochemical 
properties of the drug, the desired site of action, the duration of action and the biological 
barriers (e.g. degradation) [1]. The most common forms of drug delivery available at 
present are oral, nasal, rectal, parenteral, transdermal and aerosol administration [2].  
Approximately 40% of all new drugs in the developmental stage are hydrophobic [3]. As a 
result a large number of potentially beneficial compounds do not reach clinical trials due to 
their poor bioavailability [4]. Therefore formulation technologies are required in order to 
effectively administer hydrophobic drugs. 
1.1. Hydrophobic Drugs 
Hydrophobic drugs do not dissolve in water. The British Pharmacopoeia classes drugs as 
sparingly soluble and practically insoluble if they possess an aqueous solubility below 1 
and 0.1 mgmL-1 at 25 °C respectively [5]. These drugs cannot be formulated as aqueous 
based injections.  In order for a drug to be delivered via the parenteral route, the drug 
must be in solution (or suspension). Hydrophobic drugs are unable to form hydrogen 
bonds with the polar water molecules and therefore they cannot be readily absorbed by 
the body. In order for a drug to be administered orally, it must have good aqueous 
solubility to dissolve in the gastrointestinal (GI) fluid facilitating crossing through the GI 
tract [6]. 
1.1.1. Physiochemical properties of drugs 
1.1.1.1. Solubility of drugs 
The degree of drug solubility can be influenced by a number of factors. Firstly, the size 
and shape of the drug molecule is important. In order for a drug to become solvated within 
a given solvent, its molecules must be able to be accommodated within the cavities 
between the solvent molecules [2]. This is more accurately explained using the Noyes–
Whitney equation (1). 
 = k(cs – c)                                                    
where 
k = DA / δ 
(1)
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The Noyes-Whitney equation relates the rate of dissolution of solid particles in the 
dissolution medium [2]. The rate of dissolution of the solid is dw/dt, A is the surface area, c 
indicates the concentration in the bulk of the medium, cs is the saturation solubility of the 
solid in the dissolution layer. The diffusion coefficient is denoted by D, k is representative 
of the rate constant of dissolution and δ is the thickness of the diffusion layer. The 
relevance of this equation is due to the influence of A (particle size). A reduction in particle 
size results in larger surface area which increases the solubility in solution cs. If the rate 
limiting factor in bioavailability is the dissolution properties of the drug, then a change in cs 
will result in a change in bioavailability [2]. Thus, the smaller the drug molecule, usually 
the higher solubility exhibited. This may be true for non-polar compounds, however polar 
compounds behave in a different manner. Polar compounds are compound which 
possess inherent charges due the presence of electronegative functional groups or ions 
within their structure. Polar compounds are notably more water soluble [2]. Their ionic 
charge enables the formation of electrostatic and hydrogen bonds with the water 
molecules facilitating solubilisation.   
1.1.1.2. Partition coefficient 
In solution drug molecules can partition (P) between the phases of two immiscible 
solvents relative to their concentration and affinity for each phase. In vivo, drugs can move 
from the hydrophilic gut lumen into the lipid gut epithelial cells depending on their ability to 
partition between the two phases. The partition coefficient is the measure of 
hydrophobicity of a molecule and hence are useful for example in estimating distribution of 
drugs within the body. The partition coefficient, P, (2) is usually quoted as log P whereby, 
C0 is the concentration of a drug in the hydrophobic organic phase and Cw is the 
concentration of drug in the hydrophilic water phase. 
P = C0 / Cw     
Hence drugs with a high log P value mainly dissolve in the lipophilic phase whilst drugs 
with a low log P value have higher affinity for the hydrophilic phase. Log P offers an 
estimation of bioavailability where drugs with high log P in theory achieve higher 
bioavailability as they can easily partition across the intestinal epithelium. However, in vivo 
this is not always the case, as drugs which exhibit a high degree of hydrophobicity are 
unable to initially dissolve in the aqueous GI fluid and therefore cannot cross the GI tract. 
Delivery systems are required to increase the solubility and bioavailability of these 
therapeutic compounds. To overcome this problem, traditional formulation technologies 
such as surfactants, liposomes, microemulsions and others have been used.  
 
 
(2) 
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1.2. Existing Technologies for the Delivery of Hydrophobic Drugs 
1.2.1. Surfactants 
In recent years the most common form of excipient for the delivery of hydrophobic drugs 
was surfactants [7]. Surfactants are low molecular weight amphiphilic compounds which 
possess one hydrophobic moiety and one hydrophilic moiety (Fig. 1) [8]. The hydrophobic 
region usually consists of saturated or unsaturated hydrocarbon chains, heterocyclic or 
aromatic ring systems [2]. 
 
 
Figure 1. Schematic diagram of a surfactant molecule. 
 
Surfactants are classified based upon the hydrophilic group present in their structure, for 
example, anionic (sodium dodecyl sulphate (SDS)) [9], cationic (cetyl pyridinium chloride 
(CPC)) [10], zwitterionic (cocamidopropyl betaine (CAPB)) [11]  or non-ionic (oleyl alcohol) 
[12] (Fig. 2). 
In aqueous environments the surfactants spontaneously aggregate to form micelles [8,13]. 
Micellar structure is described as a core/shell arrangement whereby a hydrophobic core is 
surrounded by a hydrophilic shell (Fig. 3). The driving force for micelle formation is the 
desire of the hydrophobic segment of the surfactant to shield itself from the ‘hostile’ 
aqueous environment. Micelles are dynamic structures, possessing stability ranging from 
milliseconds to seconds [14]. 
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Figure 2. Examples of each of the classifications of surfactants. 
 
 
 
Figure 3. Schematic diagram of a micelle. 
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The stereochemistry of the surfactant has a direct impact on the shape of the micelles 
being formed [2]. For a surfactant which consists of a hydrophobic chain and a hydrophilic 
head, the micelles formed will be spherical (Fig.4a). If a secondary alkyl chain 
(hydrophobic) is present, a bilayer is produced (Fig 4b). Another possible scenario is 
where a reverse micelle is formed. This occurs when the surfactant is in a non-aqueous 
medium (Fig. 4c). 
 
 
Figure 4. Types of aggregation formed by surfactants in solution. 
The spherical structures achieved by ionic surfactants in aqueous environments gradually 
change in shape as the surfactant concentration in solution is increased [13]. The micelles 
elongate at higher concentrations and form cylinder like aggregates which have a rod-like 
structure (Fig. 5) [15].  
 
Figure 5. Change in shape of Ionic surfactant micelles at high concentrations. 
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Micellar systems only form above the critical micellar concentration (CMC). This is the 
lowest surfactant concentration required for aggregation to occur. The lower the CMC of 
the micelle, the more stable it shall be [16]. The CMC can be effected by a number of 
factors including the structure and nature of the hydrophobic group, the addition of 
electrolytes, temperature etc. [2,17,18,19]. 
The hydrophobic core of the micelle acts as a non-aqueous reservoir for hydrophobic 
drugs whilst the shell reacts with the biological milieu allowing absorption into the body 
and enabling transport to the target area [8]. The ability to encapsulate hydrophobic 
molecules such as drugs and increase their aqueous solubility is called solubilisation. The 
solubilisation process only occurs if the surfactant is present above its CMC value [8]. The 
hydrophobic drug is also referred to as the solubilisate. The chain length of the 
hydrophobic moiety on the surfactant has a direct effect on solubility [20]. In general, a 
decrease in CMC is experienced when the alkyl chain length of the surfactant is increased 
[2]. The solubility also decreases with increase of alkyl chain length of the solubilisate [2]. 
In most cases the solubilisation capacity increases with increasing temperature [21]. 
To date the commercial surfactants available for human consumption include SDS [22], 
Tween [23] and Cremophor EL [24].  
The major problem with surfactants is that they possess a relatively high CMC making 
their micelles relatively unstable [25]. Once administered in vivo, they become highly 
diluted in the blood and disruption of the micelle occurs resulting in premature release of 
the drug [7]. This lowers the efficiency of the desired drug delivery. Another disadvantage 
is the extremely high excipient/drug ratios (15:1 - 1000:1) drug. A high excipient:drug ratio 
indicates that the delivery system is inefficient [3]. The use of surfactants can cause pain 
on administration as some form viscous oily solutions [26]. The high levels of excipient 
required for drug solubilisation also poses safety concerns, often causing unnecessary 
side effects. 
1.2.2. Microemulsions 
Traditionally emulsions were used as conventional pharmaceutical excipients. Emulsions 
are liquid dispersions consisting of a oil phase and a water phase. Oil in water emulsions 
(o / w) enable hydrophobic drug solubilisation into the oil phase and being dispersed into 
the bulk aqueous solution. Water in oil (w / o) emulsions solubilise hydrophilic drugs into 
water droplets dispersed into the hydrophobic oil phase. However, these systems did not 
possess long stability periods.  
Modern advances in pharmaceutical technology have led to the development of 
microemulsions. Microemulsions are liquid mixtures of oil, water and surfactants (or 
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cosurfactants) [27]. They are usually clear and are thermodynamically stable [18,27]. 
Microemulsions are essentially swollen micellar systems [2]. It is difficult to make clear a 
distinction between emulsification and solubilisation as there is a very gradual transition 
from one process to the other [28]. At the transition the swollen micelles (also known as 
microemulsions) occur [28]. The microdroplet size formed is usually less than 100 nm. 
Microemulsions are used to enhance solubilisation and bioavailability of hydrophobic 
compounds [7,29,30]. They possess high solubilisation capacities and offer increased 
stability, however addition of drug can compromise the stability [14]. They assemble 
spontaneously in short preparation times, without the use of mechanical force [7]. Two 
immiscible phases such as oil and water can only mix if a surfactant is present. The 
surfactant forms a monolayer at the interface of the oil and water. The hydrophobic tail of 
the surfactant has affinity for the oil layer whilst the hydrophobic head resides in the 
aqueous phase [31]. The three phases of oil water and surfactant aggregate to form the 
swollen micelles where the internal phase is the hydrophobic moiety (Fig. 6) [32].  
                                                                 
                                                              
                  Droplet                             Surfactant                    •      Hydrophobic drug 
Figure 6. Schematic representation of oil in water microemulsion where drug is solubilised 
within the micro droplet. 
Microemulsions are a complex mix of solute, solution, reversed micelles and normal 
micelles, and microemulsion droplets [2]. As a result changes in temperature, 
concentration or pressure can have an effect on equilibrium and stability of the system. 
Microemulsions of water in oil (w / o), the water is dissolved the tiny water droplets known 
as nano-scale pools [33]. These pools can be used to solubilise hydrophilic molecules 
such as proteins, amino acids etc. [34,35,36,37]. In oil in water (o / w) microemulsions, oil 
is dissolved in the nano-scale pools into which hydrophobic moieties are dissolved [38]. 
Many commercial microemulsions are commercially available including Neoral® for 
delivery of immunosuppressant drug cyclosporin A, Fortovase®, Norvir® and Agenerase® 
for the delivery of antiretroviral drugs saquinavir, ritonavir and amprenavir respectively 
[39]. However, despite commercial success, large amounts of surfactant are required to 
make a microemulsion, this results in a high excipient:drug ratio due to the water oil 
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interface has a very large surface area [7]. This makes them inefficient systems which are 
not cost effective.  
1.2.3. Liposomes  
Liposomes are spherical structures composed of a phospholipid bilayer surrounding an 
aqueous reservoir (Fig. 7) [32,40] Liposome vesicles are composed of unilamellar or 
multilamellar lipid bilayers which have alternative aqueous layers sandwiched between the 
bilayers [31]. Upon aggregation multilayered liposomes are formed however, these are 
easily converted to unilamellar entities by sonication [2]. 
 
 
Figure 7. Schematic of a unilamellar liposome. 
Hydrophilic or hydrophobic drugs can become encapsulated inside the aqueous or lipid 
phase of the liposomes respectively [40,41]. Liposomes have been shown to improve the 
therapeutic efficacy of pharmaceutical drugs including ibuprofen, amphotericin B and 
doxorubicin [40,42,43,44,45].  
A number of liposomes are commercially available for drug solubilisation including 
VesicALL®, for the delivery of anticancer agents [46], Doxil™ for doxorubicin [47]  and 
AmBisome to deliver amphotericin B [47]. 
The net charge of a liposome can be varied by incorporation of different molecules onto 
the structure [48]. Positively charged liposomes are commonly used for gene delivery and 
DNA vaccines [43,49,50]. Gregoriadis fabricated ImuXen®, which is a commercially 
available liposomal vaccine delivery system used for the delivery of proteins, 
polysaccharides and DNA [46]. 
In general hydrophilic compounds are not well entrapped in liposomes compared to 
lipophilic compounds which are well retained in these drug carriers [41]. Their major 
disadvantage as drug carriers is their instability on drug entrapment [44]. The inclusion of 
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drug into the lipid bilayer causes penetration and results in premature drug release 
[44,51]. To combat this problem cholesterol is incorporated into the phospholipid bilayer, 
consequently the liposome possess higher rigidity leading to more stable vesicles [50,52]. 
Furthermore, poor stability is experienced on storing in aqueous phase. 
However, lyophilisation and cryoprotection of the liposomal formulation have been 
reported to minimise this problem [44,53]. Saccahrides such as sucrose, trehalose and 
lactose are the most commonly used cryoprotectant for the freeze drying process, 
however, these are required at high concentrations of up to 30:1 cryoprotectant:liposome 
which can compromise the liposomal viscosity and induce adverse side effects in patients 
[44]. 
Mohammed and colleagues reported that amino acids could be used as successful 
cryoprotectants during the freeze drying process. They prepared a liposomal formulation 
consisting of phosphatidylcholine (PC) and cholesterol and ibuprofen [44]. They 
concluded that lysine offered an alternative cryoprotectant to the traditional saccharides 
as it offered comparable cryoprotection to trehalose at only 4:1 cryoprotectant: liposome 
[44]. This work shows great potential enabling increased stability of liposomal formulation 
stability without compromising the integrity of the preparation. 
1.2.4. Cyclodextrins  
Cyclodextrins are cyclic oligosaccharides that possess a rigid conical structure (Fig. 8) 
[54,55,56]. They consist of a hydrophilic exterior and a hydrophobic inner core [54,55]. 
The hydroxyl groups on the exterior of the cyclodextrin structure form hydrogen bonds 
with water resulting in the formation of inclusion complexes [57,58,59]. 
 
 
 
 
 
 
 
 
Figure 8. Schematic representation of the conical structure of cyclodextrins. 
Hydrophilic exterior 
Hydrophobic inner cavity  
Hydroxyl rim 
      Hydroxyl rim 
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An inclusion complex is formed when a water molecule located in the lipophilic central 
cavity of the cyclodextrin is removed and is replaced by a lipophilic guest (i.e. a 
hydrophobic drug) (Fig. 9) [54,58]. The central cavity plays host to hydrophobic moieties 
of suitable size through non covalent hydrophobic interactions [55,59]. This forms an 
alternative to micellar solubilisation. 
 
Figure 9. Schematic representation of complexation of alkyl reagent with cyclodextrin 
[60]. 
The solubility of hydrophobic drug is enhanced by physical entrapment inside the central 
cavity of the cyclodextrin. Cyclodextrins have been reported to increase solubility, 
enhance bioavailability and protect drugs throughout their journey in vivo [54]. Worldwide 
35 drugs are commercially marketed as solid dosage or liquid based cyclodextrin 
formulations [59]. However, cyclodextrins are not a generic solubilising agent to 
hydrophobic drugs. Their solubilising capacity is drug dependant on size and steric 
structure. In order for the hydrophobic drug to reside within the central core, it must 
physically fit into the well structured environment of the cyclodextrin [61]. 
1.2.5. Calixarenes 
Calixarenes are a family of cyclic oligomers which possess three-dimensional structures 
[62]. They are commonly used as starting materials or building blocks in the design of 
supramolecular systems [63]. Calixarenes form 3D cup-like structures with well defined 
upper and lower rims containing a central cavity in both the solid state and in solution (Fig. 
10) [62,64,65]. 
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Figure 10 .General structure of a calixarene showing stereochemistry of cup like 
structure, where R can be replaced by functional groups [66]. 
They possess a metal binding site and a hydrophobic pocket for host guest interaction 
with organic molecules [67]. Calixarenes enhance the solubility of hydrophobic drugs via 
hydrophobic interaction. Yang and de Villers investigated the solubilising effect of 4-
sulphonic calix[n]arenes on poorly soluble antianginal drug nifedipine [62]. The maximum 
solubilisation of nifedipine was achieved using 4-sulphonic calix[8]arene resulting in a 3 
fold increase on the aqueous drug solubility [62].  
Calixarenes are not completely rigid molecules as their shape can be varied with different 
solvents, functional groups and temperature [67]. They possess a number of advantages 
over cyclodextrins, they can be chemically modified easily using low toxicity chemical 
reactions. Functional groups can easily incorporated via the upper or lower rim of the 
structure to enable targeted delivery or to further enhance aqueous solubility [62]. They 
have relatively low production costs and are less toxic than the cyclodextrins [68]. 
However like cyclodextrins, calixarenes exhibit drug specificity, whereby the drugs need to 
be physically small enough and sterically able to reside within the central cavity. Therefore 
calixarenes do not form generic drug solubilisers.  
1.2.6. Cosolvents 
Cosolvents such as propylene glycol, glycerine or ethanol mixed with water are also used 
to enhance the solubility of hydrophobic drugs [69]. Cosolvents are usually required where 
drug solubility in one solvent is limited, the presence of two solvents increases the drug 
solubility [2,31]. In 2002 Millard and colleagues reported that cosolvents made up 13 % of 
all Food and Drug Administration agency (FDA) approved parenteral products [69].Two 
miscible solvents are mixed, where one solvents is the desired media (e.g. water), the 
second solvent is usually an organic solvent in which the drug candidate is readily soluble. 
This method allows solvation of the drug. However, it is not a preferred method as 
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residual organic solvents remaining in the formulation may be toxic to the patient which is 
a major disadvantage.  
There is a growing need to design novel delivery systems due to the growing number of 
hydrophobic drugs discarded in the development stage. It is essential to create a delivery 
system which is not only capable of encapsulating high levels of active ingredient but is 
also able to achieve site specific delivery. Furthermore, it is of utmost importance that the 
delivery system developed exhibits an excellent safety profile. Currently one of the 
promising strategies is the use of different types of amphiphilic polymers to deliver 
hydrophobic drugs. 
1.3. Amphiphilic Polymers  
Amphiphilic polymers have been widely investigated in recent times [70,71,72,73]. The 
amphiphilic polymers consist of hydrophobic and hydrophilic domains [74]. In the aqueous 
environments, the amphiphilic molecules associate through weak non-covalent 
hydrophobic-hydrophobic interactions whereby, the hydrophilic moiety will remain in 
contact with the aqueous phase whilst the hydrophobic moiety will ‘shield’ themselves, 
thus forming a polymeric micelle [74,75]. Amphiphilic polymers have been reported to 
form a wide range of structures in aqueous environments including polymeric micelles, 
vesicles and nano-particles [72,76,77,78]. 
Their ability to form spontaneous self-assembled polymeric micelles and nano-particles in 
aqueous environments demonstrated great potential for drug solubilisation [72]. Like 
traditional micelles the hydrophobic core of the micelles can encapsulate hydrophobic 
drugs and thus increase the water solubility [72,79]. The lowest concentration required for 
a polymeric micelle to form in an aqueous environment is called the critical aggregation 
concentration (CAC). The CAC is affected by a number of factors including the structure 
and nature of the hydrophobic group and the addition of electrolytes [76]. 
Polymeric micelles have several advantages compared to traditional surfactant micelles. 
They possess lower CAC values (approximately 1000 times lower) than traditional 
micelles [72,80,81]. This makes their aggregates more stable in aqueous solution and 
hence reduce the risk of disruption upon dilution in vivo [16]. The size of the self-
assemblies formed in aqueous environments are usually between 30 - 100 nm, this size 
can increase or decrease on drug loading depending on the molecular architecture of the 
polymer and of the drug [79]. 
Drugs, including those which cannot enter the cell passively by diffusion, may enter cells 
by endocytosis when the drugs are entrapped inside the polymeric micelles (Fig. 11) 
[82,83]. The polymeric micelles’ core-shell structure can also mimic naturally occurring 
transport systems such as plasma lipoproteins and viruses [73].  
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Figure 11. Schematic representation of the cellular internalisation of free drugs and drug 
loaded micelles. (A) Drug diffuses through the cell membrane and slowly in the cytoplasm, 
(B) micelle loaded drug enters the cytoplasm by endocytosis, (C) in the cell, drug 
molecules from micelle diffuse out and distribute through cytoplasm and (D) some 
micelles disassemble into single chains and act locally to internalise into the cellular 
organelles (dotted arrows) [83]. 
The micelle protects the drug from chemical degradation or being metabolised during its 
journey to the desired target area, therefore making the delivery more efficient [73]. The 
nanoscopic size of micelles enables quick and easy sterilisation by simple filtration [73]. 
The major advantage of polymeric micelles is that the required polymer/drug ratio can be 
as little as 5:1 which significantly increases the efficiency and decreases the toxicity of the 
delivery system [3]. 
An amphiphilic polymer can be formed from diverse architectures, these are usually 
classified into four main groups. Block copolymers [72,75,84,85,86], graft polymers [76], 
star shaped polymers [87,88] and dendrimers [89.90]. 
1.3.1. Block copolymers 
Block copolymers are fabricated from the polymerization of two or more types of monomer 
unit (Fig. 13) [74]. Typically one hydrophobic moiety and one hydrophilic moiety is 
polymerized together giving an amphiphilic diblock copolymer e.g. poly(ethylene oxide)-
block-poly(lactic acid) (PEO-b-PLA) [79]. Triblocks, tetrablocks, pentablocks etc. can also 
be synthesised using the same reaction. In aqueous solution amphiphilic block 
copolymers form polymeric micelles (Fig. 12).                                                            
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Figure 12. Schematic representation of dynamic micellation of diblock copolymers in 
aqueous environment. 
 
As drug delivery vehicles, the hydrophobic moiety of block copolymers is usually 
composed of biodegradable and biocompatible monomers such as polyesters e.g. 
poly(caprolactone) (PCL) and poly(lactic aid) (PLA) or poly(amino acids) e.g. poly(aspartic 
acid) (Fig. 13) [74,75,91].  
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Figure 13. Chemical structure of hydrophobic monomers commonly used in block 
copolymers A) poly(caprolactone), B) poly(lactic acid) and C) poly(aspartic acid). 
 
The most common hydrophilic segment for block copolymers is poly(ethylene glycol) 
(PEG), however other hydrophilic monomers have also been reported e.g. poly(ethylene 
oxide) (PEO), and poly(N-isopropylacrylamide) (PNIPAAm) (Fig. 14) [72,92,93]. 
 
Hydrophilic block 
Hydrophobic block 
Hydrophobic drug encapsulated inside the micelle core 
In aqueous environment 
 16 
HO
O
OH
n H
O
OHn
H2
C
CH
C
O NH
CH
H3C CH3
n
A B
C
 
Figure 14. Chemical structure of hydrophilic monomers commonly used in block 
copolymers A) poly(ethylene glycol), B) poly(ethylene oxide) and C) poly(N-isopropyl 
acrylamide). 
PEG is an FDA approved polymer for intravenous administration [75]. It is highly 
biocompatible and resistant to protein adsorption and cellular adhesion due to its steric 
repulsion effect [72,75]. PEG is commonly used due to its highly soluble, non toxic nature 
[85,91]. It has been reported that PEG can be excreted through renal filtration out of the 
body [85,91]. 
Block copolymers have been extensively investigated as potential delivery vehicles for 
many hydrophobic drugs. Formulation of hydrophobic drugs range from simple drugs such 
as propofol [94] through to anticancer drugs such as doxorubicin [95,96], etoposide [97], 
paxlitaxel [98,99,100] and camptothecin [101,102].  
Polymer chains have a much wider range of physiochemical properties than the low 
molecular weight surfactants [2]. Varying the molecular weight or hydrophobicity of the 
polymer allows a degree of control of the properties of the subsequent nano aggregates 
[2]. Polymeric micelles formed from block copolymers possess greater kinetic stability 
upon dilution, the length of hydrophobic segment of the block copolymer influences the 
stability of the nano aggregates formed whereby increased hydrophobic content results in 
increased stability [103]. The length of the hydrophobic chain also effects drug loading 
capacity of the nano aggregates [103,104]. Lee and colleagues investigated polymeric 
micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-carprolactone) as potential drug delivery 
systems for a hydrophobic anticancer drug, paclitaxel. The studies showed that the higher 
the content of the hydrophobic block in the copolymer, the higher the loading efficiency for 
the drug [100]. 
Higher hydrophilic content in a block copolymer results in a higher degree of solubility in 
aqueous environments. The hydrophilic monomer forms weak hydrogen interactions with 
the water molecules. Gaucher reported that increasing the hydrophilic chain of the block 
copolymer resulted in longer circulation times and greater ‘stealth’ effect whereby the 
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blood protein adsorption of the polymeric micelles was hindered [103]. However, 
increasing the hydrophilic content excessively will result in unstable micellation or even no 
micellation occurring. This is due to the hydrophobic interaction driving forces becoming 
too weak for self-assemblies to occur. The weaker hydrophobic forces present in higher 
hydrophilic content amphiphiles also result in lower levels of drug loading efficiency and 
greater instability. 
The level of compatibility between hydrophobic drug and amphiphilic block copolymer has 
an influence on self-assembly stability, drug loading capacity and release rate 
[103,104,105]. Shaui loaded monomethoxy poly(ethylene glycol)-b- poly(ε-caproclactone) 
(MPEG-B-PCL) micelles with doxorubicin and concluded the drug loading capacity was 
dependant on both hydrophobic associations and hydrogen bonding between the drug 
and block copolymer [95]. 
The solubility of amphiphilic polymers is determined using the same considerations that 
apply to low molecular weight surfactants e.g. chain length, nature of solubilisate, effect of 
temperature etc. [2]. However, due to the extensive size of polymers, their interactions 
with water are a lot more complex than for the smaller molecules, as a result some 
polymers do not possess a saturation point [2]. Water soluble polymers increase the 
intrinsic viscosities of their solvents when they are present in low concentrations [106].  
Cross-linking of block copolymers is a technique frequently used to enhance structural 
integrity of their nanostructures in aqueous environments [107,108]. Crosslinking is 
achieved at either the core or the corona of the micelle, and results in a decrease in 
hydrodynamic radius [105,107]. Crosslinking efficiency of polymeric micelles is dependent 
on molecular weight of the polymer [105]. By crosslinking the core of the micellar 
structure, the outer shell structure is unaffected, giving rise to functional group attachment 
for the design of smart polymers [107]. 
1.3.2. Graft Polymers 
Amphiphilic graft polymers consists of a homo polymer as the backbone to which 
hydrophobic pendant groups are ‘grafted’ to form a comb like structure. The hydrophobic 
pendant groups of a comb shaped polymer may consist of homopolymers, copolymers or 
small molecular weight hydrophobic molecules. In the aqueous environment, self-
assemblies are formed with a hydrophobic core stabilised by a hydrophilic corona (Fig. 
15) [76,109,110]. 
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Figure 15. Schematic representation of self-assembly formation of comb shaped 
polymers in aqueous environment.  
 
Graft polymers are a relatively new area of interest in drug delivery. In 1998 Chiu 
developed amphiphilic graft copolymers consisting of stearyl methacrylate, methyl acrylate 
(Fig. 16), acrylic acid and PEG acrylate [111]. 
Hydrophobic drug 
Aqueous environment 
Hydrophobic 
pendants 
Hydrophilic moieties 
Hydrophilic 
polymer 
backbone 
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Figure 16. Chemical structure of the amphiphilic graft copolymers A) stearyl methacrylate 
and B) methyl acrylate [111]. 
They reported the amphiphilic graft copolymers formed polymeric micelles in aqueous 
environments, these aggregates showed a bimodal size distribution whereby two size 
populations of 50 and 389 nm were observed [111]. The rationale behind such 
aggregation was proposed due to loose aggregates and large association complexes 
being formed which were in dynamic equilibrium with smaller more compact micelles 
[111]. The aggregate formed showed potential for encapsulation of hydrophobic drugs. 
However, they concluded that more work needed to be carried out in this area to further 
investigate the properties of these systems i.e. biocompatibility, bioavailability, cytotoxicity 
etc [111]. Sugimoto fabricated poly(N-hydroxyethyl L-glutamine)-graft-poly(L-tryptophan) 
(PHEG-graft-poly(Trp)) and successfully incorporated hydrophobic azobenzene into 
hydrophobic region of the polymeric micelles showing their potential for hydrophobic drug 
solubilisation [112].  
The type of aggregates formed in the aqueous environments include polymeric micelles, 
nano-particles and vesicles [76,77,78]. The physical properties of the amphiphilic comb 
shaped polymers can be controlled by adjustment of structural components, e.g. type of 
hydrophobic pendant group and level of grafting [76,113]. Hydrophilic moieties such as 
quaternary ammonium ions or poly(ethylene glycol) (PEG) can also be attached to the 
homopolymer backbone to improve the safety profile and determine the in vivo fate of the 
self assemblies [114,115]. Zhu and colleagues attached PEG monomers onto a chitosan-
N- trimethylaminoethylmethacrylate (CS-TM-PEG) graft polymer [115]. They investigated 
the haemolytic activity when red blood cells were exposed to 250 – 2000 µgmL-1 polymer 
solutions [115]. The CS-TM-PEG polymer showed a reduction in haemolytic activity when 
compared to its un-pegylated counterpart, the percentage haemolysis was reduced from 
10 – 13 % (CS-TM) to 5 – 7 % (CS-TM-PEG) [115]. This reduction in haemolytic effect 
results in higher biocompatibility of the polymer. Recently Thompson and colleagues 
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reported that addition of hydrophilic quaternary ammonium ions onto the polymer 
backbone of modified poly(allylamine) (PAA) polymers not only increased the aqueous 
solubility  of the polymers but also made the polymers less cytotoxic against  human 
epithelial colorectal adenocarcinoma (Caco-2) cells [76,116]. 
Lin and colleagues investigated the aggregation of poly(ß-benzyl-L-aspartate)-graft-
poly(ethylene glycol) (PBLG-g-PEG) [113]. They concluded that lower CMC values were 
observed at higher grafting levels of hydrophobic PBLG [113]. This perhaps due to the 
increased hydrophobicity driving aggregation into the core – shell formation [113].  The 
polymeric micelles formed were spherical at lower concentrations, however they found 
that as the concentration was increased the conformation of the aggregates changed to 
rhombic and further increase of the polypeptide content and backbone length resulted in 
aggregates with a spindle-like morphology [113]. 
Polymeric micelles formed by comb shaped polymers are generally smaller in size than 
those formed by block copolymers. This can be attributed to the phenomenon known as 
intramolecular aggregation whereby, a single polymeric chain has the ability to aggregate 
with itself forming the self-assembly [117,118]. However, a number of groups have 
reported larger particles formation, possibly due to the hydrophobic pendant groups in the 
self-assemblies being in close proximity to the water, hence multiple micelle aggregation 
occurs [117,119]. 
Amphiphilic graft polymers are commonly synthesised from soluble polyamine backbones 
such as poly(allylamine) (PAA) [76,120,121], poly(ethylenimine) (PEI) [3,122,123], poly(L-
lysine) (PL)  [78,124]. Carbohydrate polymers have also been reported using glycol 
chitosan [125,126] and dextran [127]. The hydrophobic pendant groups grafted onto the 
homopolymer backbone are usually alkyl chains [3,76,123], acyl groups [128,129] or 
cholesterol moieties [76,121,130].  
The hydrophobic core of the amphiphilic comb shaped polymer is capable of 
encapsulating hydrophobic drug through hydrophobic or electrostatic interactions [103]. 
When the drugs are encapsulated inside the core, their fate is dependent on the micellar 
properties instead of their own intrinsic properties [131]. Cheng and colleagues showed 
that varying concentrations of cyclosporine A were absorbed orally in vivo into the 
bloodstream of male Wistar rats when encapsulated inside a range of poly(ethylenimine) 
amphiphilies [3].  Graft polymers have previously been reported to achieve solubilisation 
of hydrophobic drugs such as cyclosporine A [3], doxorubicin [131] and paclitaxel [132]. 
They have also been reported to be good solubilising agents for other therapeutic agents 
such as proteins and genes [120,133]. 
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McPhail and colleagues studied the combination of liposomes and graft polymers for drug 
delivery. They developed a vesicle in vesicle system whereby polymeric vesicles were 
encapsulated inside liposomes to yield a more advanced excipient for enhanced 
controlled release of drugs, enzymes, vaccines or proteins from the polymeric nano-
carrier [134]. They fabricated the vesicle in vesicle system using palmitoyl glycol chitosan 
polymers and cholesterol polymers and egg phosphatidylcholine (egg PC) and cholesterol 
liposomes [134]. The structural formation was confirmed using freeze fracture electron 
microscopy. The polymeric vesicle was loaded with 5(6)-carboxyfluorescein (CF) [134]. 
Drug release studies concluded that the vesicle in vesicle structure slowed down the 
release of the drug compared to a normal polymeric micelle [134]. This system has huge 
implications not only for controlled release of therapeutic agents but also for the possibility 
of administering more than one active ingredient in combination therapy etc.  
1.3.3. Star shaped polymers 
Star shaped amphiphilic polymers are made up of 3 or more linear polymer chains linked 
to a central polymeric core (Fig. 17) [87,135]. The arms are of comparable lengths and 
consist of homo-, co- or terpolymers [87].  
 
 
 
 
 
 
 
 
Figure 17. Schematic representation of star shaped polymer. 
The nano aggregates formed in aqueous solutions possess a lower hydrodynamic radius 
and viscosity in solution when compared to linear polymers of the same molecular weight 
and composition [136,137,138]. The star shaped polymers form unimolecular micelles 
with increased stability compared to block copolymers [136,137]. The physical properties 
of the polymer can be altered by changing the chemical structure and composition of the 
arm chains [87,137]. Star shaped polymers have been reported to enhance the aqueous 
solubility of hydrophobic drugs such as paclitaxel [88,138,139] and prednisolone acetate 
[140]. 
Polymer arms 
Polymeric 
central core 
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Ooya and colleagues reported that 5 armed poly(oligo(ethylene glycol) methacrylate) 
(poly(OEGMA)) star polymers increased the aqueous solubility of paclitaxel 130 fold and 
achieved sustained release over long time periods with only 50 % of drug release after 96 
h [88]. 
Wei fabricated a star shaped polymer consisting of hydrophobic poly(methyl methacrylate 
(PMMA) arm and 4 hydrophilic poly(N-isopropylacrylamine PNIPAAm arms [140]. These 
self-assembled into polymeric micelles in aqueous environments with the PMMA as the 
core and the PNIPAAm as the hydrophilic corona. The self assemblies produced from the 
star shaped amphiphilic polymers were reported to enhance the aqueous solubility of 
prednisolone acetate with 55 % encapsulation efficiency [140]. Previously Wei had 
reported an 11 % encapsulation efficiency using the same drug but with the block 
copolymer, poly(methyl methacrylate-block-poly(N-isopropylacrylamide) PMMA-b-
PNIPAAm [141]. They speculated the reason for the marked increase was due to 
repulsions forces existing between the large hydrophilic PNIPAAm blocks preventing tight 
contraction of the hydrophobic core [140]. The resultant core would be ‘looser’ in size thus 
enabling larger drug loading capacities and improved encapsulation efficiencies [140]. 
Investigation into star shaped polymers is still relatively novel, however as growing 
interest arises new research is emerging. The use of star polymer as thermo responsive 
delivery vehicles is at the forefront of today’s research [136,140]. 
1.3.4. Dendrimers 
Dendrimers are highly branched 3 dimensional macromolecules [142,143,144]. Their 
structure consists of a central root core from which regular layered branching occurs, their 
surface is made up of abundance of terminal groups to which funtional groups such as 
targeting moeities, bioresponsive moeities, solubilising groups or drug molecules can be 
attached (Fig. 18) [89,137,142]. Repeated layers of branching can be well defined due to 
sophisticated layer by layer chemical synthesis, each layer is called a generation 
[137,145]. 
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Figure 18. Schematic representation of dendrimer structure [146].  
Amphiphilic dendrimers form intramolecular aggregates (unimolecular micelles) in 
aqueous environments. Aggregation can involve hydrophobic or electrostatic interactions 
or hydrogen bonding [147]. The aggregates formed possess increased stability at lower 
concentrations in comparison with block copolymers as the micelles do not disrupt upon 
dilution [137]. The aggregates are more uniform in size (i.e. monodisperse) than the 
formation of micelles from block copolymers, due to the nature of the chemistry used in 
the addition of generations [137,142,148]. The intramolecular hydrophobic core of the 
dendrimer is capable of encapsulation and controlled release of hydrophobic moeities 
such as drugs, genes and imaging agents [144,145]. Morgan and colleagues reported 
solubilisation of hydrophobic anticancer agent 10-hydroxycamptothecin inside 
poly(glycerol-succinic acid) dendrimers (PGLSA) of generation 4.5. They reported by non-
covalent interaction inside the  dendrimer core which increased the aqueous solubility of 
the drug by 20 fold [90,149,150]. 
Entrapment is also achieved within the multivalent branching network or through 
adsorption onto the outer shell [145,151]. When a drug is covalently attached to the outer 
shell of a dendrimer, it will exhibit a decreased release rate when compared to drug 
encapsulation by hydrophobic or electrostatic interactions [149]. Dendrimers with high 
drug conjugation can swiftly enter the cell and localise in the nucleus [149]. Kohle and 
colleagues conjugated ibruprofen onto a generation 4 poly(amidoamine) dendrimer 
PAMAM via an ester bond [152]. Approximately 58 drug molecules were successfully 
attached to the 64 functional terminal [152]. They found that this high drug payload system 
was capable of enhaced cellular delivery which could produce a faster pharmacological 
response time leading to improved drug efficacy [152]. Further in vivo investigation is 
currently been carried out by Kohle and coleagues. 
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Dendrimers hold great potential as carriers of hydrophobic compounds as they can be 
tailor made by adapting their surface groups and branches [89,143,144]. Generation and 
nature of packing of the dendrimer effects aggregation size, physiochemical properties, 
stability and drug loading capacity of the intramolecular aggregates formed [137,143,148]. 
Ooga and colleagues synthesised polyglycerol dendrimers (PGD’s) with 3 - 5 generations 
[153]. The drug loading potential of the dendrimers were investigated. Ooga reported that 
the PGD’s were capable of enhancing aqueous solubility of paclitaxel by 3 orders of 
magnitude [153]. They concluded that as the generation number increased paclitaxel 
solubility also increased [153]. This indicated that the drug was not solubilised inside the 
dendritic core, instead the high concentrations of ethylene glycol provided a hydrotropic 
environment whereby the hydrophobic drugs would enter the hydrophilic layers of the 
dendrimers stabilising the layered structure [153,154]. 
1.3.5. Smart Polymers for cancer therapy 
Over the past decade polymer science has gone from strength to strength. As new 
research groups establish, scientists strive to achieve more controlled delivery of 
therapeutics with increased efficacy and reduced side effects [72,92]. Stimuli responsive 
or ‘smart polymers’ as they have affectionately been named have emerged as new front 
runners in the race for the perfect delivery system.  Stimuli responsive polymers undergo 
active responses to environmental signals or external change, making them ideal 
candidates for active targeting [92,155].  The stimuli include physical (temperature, 
ultrasound, light), chemical (pH, ionic strength) and biological (biomolecules) [92,156,157]. 
The major application for this technology is in the delivery of anti cancer therapeutics. 
Temperature responsive polymeric micelles are the most extensively studied to date 
[92,157,158]. Cancerous tissues posses increased metabolic rate compared to normal 
healthy tissues [155,159]. As a result they exist at higher temperatures of 40 – 44 ºC 
[155,159]. This condition makes thermoresponsive polymeric micelles ideal carrier 
vehicles as once inside the cell, the temperature increase will cause the polymeric micelle 
to release its payload into the surrounding cytoplasm. 
Thermoresponsive poly(2-(N,N-dimethylamino) ethyl methacrylate)-b-poly (caprolactone)-
b-poly(2-N,N-dimethylamino) ethyl acrylate (PDMAEMA-b-PCL-b- PDMAEMA) polymers 
were synthesised by San Miguel and colleagues [160]. The polymer showed a reversible 
dispersion/aggregation pattern in response to temperature change [160]. The lower critical 
solution temperature (LCST) was 54⁰C. Slight changes in the temperature below or above 
the LCST can activate disruption of micelle structure and result in drug release [158]. 
They reported that the polymer possessed lower CMCs and better drug loading capacity 
for anti cancer drug chlorambucil compared to PDMAEMA non-responsive polymers [160].  
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The in vitro release results suggest that the thermoresponsive polymers would be suitable 
for transport of anticancer therapeutics, however no in vivo data has been reported to date 
[160]. 
However many thermoresponsive polymers created possessed poor biocompatibility and 
were not approved for in vivo use [161]. Recently mixed micellar systems consisting of 
simple block copolymer methoxy poly(ethylene glycol)-b-poly(D,L-lactide) (mPEG-b-PLA) 
and temperature sensitive polymer methoxypoly(ethylene glycol)-b-poly(N-n-
propylacrylamide-co-vinylimidazone) (mPEG-b-P(NnPAAm-co-Vlm) have been 
synthesised [161]. It was reported that the mixed micellar systems successfully 
encapsulated the anticancer agent doxorubicin. In vitro cytotoxicity was reduced when 
exposing human cervical epithoidal carcinoma (HeLa) cells to the formulation, this 
indicated increased biocompatibility [161]. Confocal microscopy was used for cellular 
visualisation of the mixed micelle fate in vitro. The mixed micellar system showed 
increased drug in the cytoplasm after 1 h in comparison with the free drug [161]. Lo and 
colleagues concluded that this system showed great potential for intravenous delivery of 
hydrophobic drugs [161]. 
pH responsive micelles are also useful in cancer treatment. The external pH of tumour 
tissue cells have been reported to have a lower pH (6.75) than normal healthy tissue cells 
(pH 7.4) [155,156]. pH sensitive micelles are formed by conjugation of drugs into the 
monomer blocks of polymeric micelles (Fig. 19) [91]. 
 
Figure 19. Representation of A) pH responsive polymeric micelle showing B) drug 
conjugation through acid sensitive linker to amphiphilic polymer [162]. 
The drug is attached via an acid cleavable bond [163]. These micelles disrupt upon acidic 
pH ranges hence releasing their payload [163]. Furthermore, if the polymeric 
nanostructures enter the cell by endocytosis, the micelles will become localised within the 
endosomes or lysosomes which have pH 5 - 5.5 [156,163]. The release of drugs from the 
 26 
endosomes and lysosomes into the cytosol is important to achieve high therapeutic effect 
and thus killing the cancer cells [155]. 
pH sensitive micelles of poly(ethylene glycol)-pol(aspartate hydrazide) (PEG-p(Asp-Hyd) 
were synthesised [91,162]. It was reported that 75 – 80 % hydrazide substitution onto the 
polymer gave the optimal drug release when loaded with anticancer agent Adriamycin 
[162]. The micelles were shown to undergo disruption at lower pH’s [162]. Confocal 
microscopy was used to determine cellular localisation, the micelles were trapped inside 
the lysosomes where they were ‘programmed’ to disrupt through hydrolysis of the 
hydrazone linker [162]. The results indicated that PEG-p(Asp-Hyd) had great potential for 
the transport and targeting of cancer therapies. 
Gu and colleagues fabricated comb shaped polymers with hydrophobic cholic acid groups 
grafted onto a poly(L-lysine) backbone [164]. They then grafted hydrophilic poly(ethylene 
glycol) groups onto the comb shaped polymer via benzoic imine bonds to form 
poly(ethylene glycol)-g-poly(L-lysine)-g-cholic acid [164]. Benzoic imine bonds are known 
for their pH responsive nature [164]. The membrane disruptive ability of the nano self-
assemblies was investigated using a haemolysis assay at the extracellular pH of solid 
tumours (pH 6.0) and physiological pH (pH 7.4) [164]. Gu found that at pH 6 the self-
assemblies exhibited a large increase in haemolytic activity towards the red blood cells in 
comparison with pH 7.4, from 37.5 % to 90 % haemolysis at 0.75 mgmL-1 respectively 
[164]. Gu concluded that the micelles showed a pH responsive nature with a higher 
degree of membrane disruption occurring at extracellular pH’s hence showing potential for 
drug delivery to tumours with intracellular transport [164]. 
Thus far all the amphiphilic polymers mentioned have been used to passively target 
cancerous tumours through the phenomenon known as the enhanced permeability and 
retention effect (EPR) (Fig. 20). Cancerous tissue multiplies at an increased metabolic 
rate in comparison with normal tissues resulting in the formation of tumours. As a result of 
the rapid growth rate the blood capillaries in the tumours are under developed forming 
defective, dilated or ‘leaky capillaries’ [165]. The tumour tissues also experience poor 
lymphatic drainage [165]. Polymeric nano-particles from 10 – 500 nm are capable of 
entering the highly permeable blood capillaries which supply the rapidly growing 
cancerous site [156,165,166]. Once inside the capillaries they accumulate and are 
retained in the tumour as a result of the poor lymphatic drainage [166]. The accumulation 
of drug loaded nano particles in tumour tissue allows for successful passive targeting of 
anticancer drugs [165]. This however does not occur in normal tissue as the blood vessels 
are well formed and non porous.  
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Figure 20. Schematic diagram of passive tumour targeting of drug loaded nano-particles 
through the permeable tumour vasculature. Heat and pH are used to trigger 
destabilisation of micelle and drug release into tumour [156]. 
Amphiphilic polymers can be actively targeted to specific sites by conjugating recognition 
moieties for receptors or components which are upregulated in the cancerous cells [167]. 
Ligands specific to receptor sites that are over expressed in cancer cells can be attached 
to amphiphilic polymers e.g. folate, galactose [156,167]. Folate receptors are often used 
for active targeting of cancerous tumour sites [156,168,169]. Prabaharan and colleagues 
synthesised a folate conjugated amphiphilic polymer based on Boltorn®H40 a 
hyperbranched aliphatic polyester called Boltorn – poly(L-lactide)-b-methoxy poly(ethylene 
glycol) / folate conjugated poly(ethylene glycol) (H40-PLA-b-MPEG/PEG-FA) [170]. They 
incorporated anticancer therapeutic doxorubicin into the polymeric micelle which showed 
prolonged release of up to 40 h. In vitro analysis was carried out on 4T1 mice mammalian 
carcinoma cell lines [170]. The results showed that the folate conjugated polymer 
exhibited a greater cytotoxic effect on the cells than the non-targeted polymer [170]. They 
suggested that this was perhaps due to folate receptor - mediated endocytosis improving 
uptake into the cells [170]. 
1.3.6. Fluorescent polymers 
Fluorescent polymers have emerged in recent years as a new class of multifunctional 
smart delivery systems. Incorporation of fluorophores such as pyrene or naphthalene into 
monomer units of amphiphilic polymers results in the nano aggregates formed possessing 
inherent fluorescence [171,172]. Fluorescent polymers have a range of potential 
applications in medicine, e.g. fluorescent probes for cell labelling and visualisation of cell 
localisation, bacteria detection, in vivo tracer for brain research [171,173]. Previously, 
fluorescent dyes were used to tag well established polymeric delivery systems for in vitro 
and in vivo visualisation [173]. However, the presence of these dyes could affect the 
physical and chemical properties of the self assemblies altering tissue interactions and 
cytotoxicity [173]. To avoid such issues inherently fluorescent amphiphilic polymers have 
been developed.  
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Recently, Suchao-in and colleagues have reported the synthesis of a novel amphiphilic 
thermoresponsive, pH responsive and inherently fluorescent graft polymer [174]. The 
polymer consists of thermosensitive poly(N-isopropyl-acrylamide-co-N-vinyl carbazole) 
monomers conjugated to pH responsive poly(dimethylamino) ethyl acryate (PNIPPAm-co-
PNVC)-b-PDMAEA) (Fig. 21) [174]. Carbazole compounds have been investigated and 
shown to possess intrinsic fluorescent properties [174,175]. Suchao-in concluded that the 
successful fabrication of the fluorescent, pH thermo responsive nature of the polymer will 
be of great importance for the successful imaging of therapeutics [174]. This could be an 
important stepping stone to fully understand the in vivo fate of drug targeted molecules. 
 
Figure 21. Chemical structure of (PNIPPAm-co-PNVC)-b-PDMAEA) [174]. 
Wu developed a fluorescent galactosylated polymer for targeted drug delivery to liver 
cells. The polymer consisted of galactose-polycaprolactone-g-dextran-fluorescein 
isothiocyanate (Gal-PCL-g-Dex-FTIC) [176]. Galactose is a common recognition moiety 
for liver cells. Galactose selectively binds onto the ASGPr on HEPG2 cell surfaces 
allowing active targeting of cells (Fig. 22) [176]. 
 
 
 
Figure 22. Schematic diagram of A) Gal-PCL-g-Dex-FTIC nano aggregates and B) 
mechanism of liver tissue targeting via receptor mediated transport [176]. 
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The polymers were found to form stable self assemblies in aqueous environments both in 
vitro and in vivo systems [176]. Confocal microscopy enabled cellular localisation through 
fluorescent imaging of the FTIC moiety. The aggregates were found to accumulate within 
the liver cells of mice, which was demonstrated using fluorescence imaging of the liver 
tissue. It was concluded that the polymeric nano aggregates showed great potential for 
liver targeting drug carriers [176]. 
1.3.7. Commercial Success of Polymeric Micelles 
The major frontrunner in the field of polymeric micelles to date is the discovery of 
poloxamer also known as Pluronic®. Pluronic is the brand name of a triblock copolymer 
used as an excipient for the delivery of hydrophobic drugs. The Pluronic structure 
comprises of hydrophilic poly(ethylene oxide) (PEO) and hydrophobic poly(propylene 
oxide)  (PPO) monomers, usually in the PEO-PPO-PEO form. The Pluronic polymer forms 
unimers below the critical aggregation concentration and forms polymeric micelles in the 
aqueous environment above this concentration [177]. The micellar structure protects the 
active ingredient from degradation in vivo enabling successful journey to its target 
destination. Pluronics has attracted a lot of attention because of their low toxicity in the 
body and the ability to solubilise biologically active lipophilic substances [178,179]. 
Pluronics are available in many forms, with different ratios of the hydrophobic to 
hydrophilic monomers and molecular weight. Each variation possesses slightly different 
characteristic properties. Pluronic polymers have a unique nomenclature whereby the 
name starts with an F (solid),P (paste) or L (liquid) depending on their physical properties. 
The letter is followed by three numbers, the first two numbers when multiplied by 100 give 
the estimated molecular weight of the poly(propylene oxide) polymer, the final digit when 
multiplied by 10 gives the % poly(ethylene oxide) content for example P105 equates to 
poly(propylene oxide) mass of 1,000 gmoL-1 with 50% poly(ethylene oxide) content. 
Husseini used an ultrasonic chamber with real time fluorescence detection to measure 
acoustic release of doxorubicin (DOX) and its paramagnetic analogue ruboxyl (Rb) from 
Pluronic P-105 in aqueous solution [180]. The ultimate goal was to produce a formulation 
which could enhance drug release at the tumour sites. The use of ultrasound to enhance 
the drug permeability of cell membranes had been previously reported [181,182]. Husseini 
observed that the released drug was re-encapsulated in between the pulses of the 
ultrasound by the dynamic equilibrium theory [180]. This led to the hypothesis that upon 
separation of the sonicated volume, the non-extravasated drug would re-encapsulate in 
the polymeric micelles and circulate in its encapsulated form, preventing drug interaction 
with healthy tissues and cells [177,178,180]. This work showed Pluronic’s ability to control 
the release of the encapsulated drug. 
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Pluronics have helped to overcome the phenomenon known as multidrug resistance 
(MDR) in tumour cells. This phenomenon arises when tumour cells have the ability to 
develop a resistance to the cytotoxic drugs which are designed to destroy them. They also 
develop cross-resistance to other compounds which are structurally and functionally 
unrelated [183]. Cells treated with the anticancer agent paclitaxel often develop MDR 
[184]. Paclitaxel is an anticancer agent which requires site specific delivery using an 
excipient or vehicle due to its cytotoxic nature causing adverse side effects. Wang and 
colleagues loaded the paclitaxel drug into Pluronic P-105 and L-101 polymeric micelles, 
the polymers were modified with folic acid to enable binding to the folate receptors on the 
tumour cells [184]. From the results it was concluded that the combined mechanisms of 
folate-mediated active internalization and Pluronic-mediated overcoming MDR may be 
beneficial in the treatment of MDR solid tumours [184]. 
The major problem encountered with Pluronic polymers is the significantly high CMC 
value. This has resulted in the polymeric micelles dissociating at low concentrations and 
the therapeutic agent which they encapsulated being prematurely released [185]. Cross-
linking of the Pluronic structure has led to further advancement within the drug delivery 
area.  
Yang and colleagues, carried out research into the possibility of forming cross linkages 
within the polymer structure which would decrease the CMC [186]. They successfully 
cross linked the outer shells, by converting the two terminal alcohols on the Pluronic-L121 
to aldehydes. Diamines were then used to form a bridge between the aldehyde terminals 
[186]. The micelles formed were spherical, they were found to possess a much lower 
CMC value (5.0 x 10-4 % wt) than that of the unmodified L121 polymer (5.0 x 10-3 % wt) 
enhancing the stability of the micelles [186,187]. The cross-linked micelles were found to 
be less cytotoxic than their unmodified counterparts when treated on human foreskin 
fibroblast (Hs68) cells [186]. The unmodified micelles also appeared to be taken up 
quicker and in greater abundance than the cross-linked micelles when viewed using a 
fluorescent microscope, however the CMC for the unmodified micelles was much higher 
resulting in dissociation upon dilution [186].  
1.4. Aims and Objectives 
The aim of this project was to fabricate novel amphiphilic comb shaped polymers which 
form polymeric self assemblies capable of encapsulating hydrophobic drugs. Fourteen 
amphiphilic PAA polymers were synthesised to determine the effect of hydrophobic 
pendant group, level of molar grafting and hydrophilic modification on physiochemical and 
biological properties of these polymers. The hydrophobic pendant groups used were 
aromatic structure which possess inherent fluorescent properties. Structural 
characterisation of the modified polymers was carried out using elemental analysis, 
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nuclear magnetic resonance (NMR) and fourier transform infrared spectroscopy (FTIR). 
The nano aggregates formed in aqueous environments were characterised by using 
methyl orange as a hydrophobic probe and surface tension measurement. Photon 
correlation spectrometry (PCS) was used to determine hydrodynamic radius of the nano 
aggregates. Drug solubilisation capacity was investigated using five model hydrophobic 
drugs: propofol, prednisolone, griseofulvin, etoposide and a novel anti cancer agent 
BNIPDaoct. The optimal formulations were imaged using transmission electron 
microscopy (TEM) and sized using PCS. In vitro drug release studies and stability studies 
were carried out and analysed by high performance liquid chromatography (HPLC). 
Biological characterisation was carried out in vitro to determine the haemolytic and 
cytotoxic effect of the polymers. Confocal microscopy allowed visualisation of the cellular 
localisation of the formulations. In vivo studies were also carried out to determine the 
ability of the formulations to enhance bioavailability of hydrophobic drugs. 
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2.1.Introduction 
Amphiphilic polymers have been explored in recent years as one of the promising delivery 
systems for hydrophobic drugs [72]. Comb shaped amphiphilic polymers are formed by 
grafting a ‘pendant’ group onto a homopolymer backbone, whereby one group is 
hydrophilic and the other is hydrophobic [188,189]. Here a comb shaped amphiphilic 
polymer was synthesised by introducing hydrophobic group onto a water soluble 
poly(allylamine) (PAA) backbone.  
CH2 CH
CH2
NH2 n
 
 
Figure 23.Chemical Structure of poly(allylamine) (PAA). 
Poly(allylamine) (PAA) (Fig. 23) is a cationic polymer which is relatively non toxic, making 
it an ideal biomaterial to be explored in drug delivery [176,190] The cross-linked PAA is 
available clinically as an oral phosphate binder [176,190]. However, modification of PAA 
to form amphiphilic polymers to date has not been explored for biomedical application 
[121,176]. Poly(allylamine) can undergo chemical modification via its primary amine 
functional groups enabling grafting of various hydrophobic moieties by a simple 
nucleophilic substitution reaction. Thompson and colleagues have reported that varying 
the hydrophobic groups on the PAA backbone has a significant impact on the polymer 
properties and the self-assemblies formed in the aqueous environment [76]. To date no 
reports of aromatic hydrophobic groups attached to comb shaped PAA polymers have 
been reported.  
In this study cholesteryl, 9-fluorenylmethoxy (Fmoc), dimethylamino-1-
naphthalenesulfonyl (Dansyl) and naphthalene moieties will be grafted onto the PAA 
backbone. Cholesterol is a commonly occurring sterol within the body which regulates 
membrane fluidity. It plays an important part in the spontaneous association of molecules 
within biological pathways [191]. Yusa and colleagues reported the copolymerization of 
sodium 2-(acrylamido)-2-methylpropanesulfonate with cholesteryl methacrylate (CholMA) 
and cholesteryl 6-methacryloyloxyhexanoate (Chol-C5-MA). They found that even at low 
cholesteryl grafting ratios, the polymers still possessed a strong tendency for self 
assembly [192].  Xu and colleagues also reported that the use of cholesterol as a 
hydrophobic cap on poly(2-methacryloyloxyethyl phosphorylcholine) acted as a 
biomimetic and improved cytotoxicity of the polymer alone [191]. Fmoc, Dansyl and 
Naphthalene are common aromatic moieties with similar planar architectures. These 
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compounds possess inherent fluorescent properties due to the presence of the 
conjugated aromatic ring systems. The attachment of aromatic groups with fluorescent 
properties eliminates the need to attach fluorescent tags in later biological 
characterisation, thus giving a more accurate representation of its in vivo fate. However, 
the presence of the fluorescent tag may alter the physical properties and cytotoxicity of 
the polymer [173]. 
Wang previously found that the molar grafting level of hydrophobic pendant groups 
significantly influenced the physical properties of the polymer [78]. Cholesterol-PAA (Ch-
PAA), 9-Fluorenylmethoxy-PAA (Fmoc-PAA),  Dimethylamino-1-naphthalenesulfonyl-PAA 
(Dansyl-PAA) and Naphthalene-PAA (Naphth-PAA) amphiphilic graft polymers of 5 % and 
10 % molar ratio (monomer: hydrophobic group) were synthesised as described below. 
The structure of purified PAA (15 kDa) is shown in Fig.23. 
It has been previously reported that hydrophilic substitution such as addition of 
poly(ethylene glycol) (PEG) or quaternary ammonium moieties onto amphiphilic polymers 
increases their solubility, bioavailability and safety profile [122,125]. Hence all the 
hydrophobic modified polymers were subsequently quaternized as described below 
(2.2.2.1.4). Characterisation of the novel polymers was carried out using a number of 
analytical techniques including elemental analysis, nuclear magnetic resonance (NMR) 
and fourier transform infrared spectroscopy (FTIR). 
2.1.1. Elemental Analysis 
Elemental analysis is a useful tool in analytical chemistry. It allows the quantitative 
measurement of elements in a sample [193]. A schematic diagram of an Elemental 
Analyser can be seen in Fig.24. 
 
Figure 24.Schematic diagram of an Elemental Analyser. 
 35 
The analysis can be carried out on solid, liquid or gas samples [194]. The most common 
type of elemental analysis is C, H, N analysis, where the composition by the mass of 
carbon, hydrogen and nitrogen in a sample is determined [194]. The analysis is carried 
out by the combustion (up to 1000 ⁰C) of the sample in oxygen under controlled conditions 
in the presence of a catalyst [194,195]. The gases formed (CO2, H2O, N2) are separated 
by gas chromatography and measured by thermal analysis [195]. The composition of 
halogen (X, such as Cl- or I-) is measured as HX and the sulphur content is measured as 
SO2. For the purposes of this study C, H, N, X and S analysis was carried out. 
2.1.2. Nuclear Magnetic Resonance 
Nuclear magnetic resonance is one of the most powerful analytical tools used to elucidate 
the structure and dynamics of unknown organic compounds (Fig.25) [194,196,197].  
When the protons within the nucleus of a particular molecule is placed inside a magnetic 
field, the nucleus vibrates in which is characteristic to the atom. The frequency of the 
resonance occurring is proportional to the strength of the magnetic field [198]. Protons in a 
molecule resonate at slightly different frequencies when they exist in different 
environments resulting in distinct chemical shifts on the NMR spectra [194,196]. The 
chemical shift is measured in parts per million (ppm, or δ) and is used to determine 
structural information about the molecules in a sample [194]. 
 
Figure 25.Schematic diagram of NMR spectrometer. 
Chemical shift arises due to electronegative atoms (e.g. O, Cl) within the molecule having 
the ability to de-shield the nucleus from the magnetic field, thus influencing their nuclear 
resonance frequencies. Deshielded protons appear downfield in the spectra when 
compared to shielded protons as they require less applied magnetic field to change their 
Sample 
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spin state. This phenomena is due to the removal of the electron ‘cloud’ from the nucleus 
allowing direct impact of the magnetic field on the protons. The chemical shift allows the 
NMR signals to be distinguished by functional group [194,198]. 
An additional effect on the spectral appearance is observed if neighbouring atoms within 
the molecule also possess spin. The spin of nearby atoms can affect the magnetic 
environment of the nucleus in question. This is called spin-spin coupling [199]. Typically a 
singlet signal is observed in the spectra if there is no influence from the nearby atoms. 
However, if spin-spin coupling occurs a duplet, triplet or multiplet will be present 
(depending on the surrounding environment) [199]. 
2.1.3. Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier Transform Infrared Spectroscopy (FTIR) is a more advanced form of IR 
spectroscopy. Traditionally Infrared spectroscopy (IR) was used to identify the functional 
groups in a chemical compound hence aiding with the elucidation of its molecular 
structure. The samples used in FTIR spectroscopy can be in solid, liquid or gas form 
[194]. IR spectroscopy works on the basis that molecules possess specific frequencies 
arising from the internal vibrations in the bonds of the functional groups they possess 
[194,198,200]. When a beam of IR radiation (200-4000 cm-1) is passed through a 
compound, it absorbs radiation at frequencies associated to its vibrational frequency and 
the remaining frequencies are transmitted [194,201]. Each chemical structure has different 
characteristic vibration and hence its identification is possible through examination of its 
unique IR spectrum [194]. 
In FTIR however the radiation applied to the sample is passed through an interferometer 
instead of a monochromator [194]. In this case the spectrum is indirectly measured using 
its interferogram. An interferometer combines two waves together and as a result of their 
combination and amplification, the data can be digitalised to produce a spectrum [201]. 
This results in an improved resolution of the peaks and a higher energy flow [200]. The 
signal/noise ratio is also increased and the measurement times are reduced making it a 
very powerful and sensitive method [194]. 
2.1.4. Aims and Objectives 
The polymers were characterised to ensure the correct structures were synthesised. 
Structural characterisation was carried out by elemental analysis, nuclear magnetic 
resonance (NMR) and fourier transform infrared (FTIR) spectroscopy. These techniques 
were used to confirm the hydrophobic groups attachment onto the PAA backbone and the 
presence of the quaternary ammonium ions.  
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2.2. Materials and Methods 
2.2.1. Materials used 
Material Supplier 
Poly(allylamine) Hydrochloride 
(ave.Mw=15 kDa) 
Sigma-Aldrich Co., UK 
Cholesterol Chloroformate  Sigma-Aldrich Co., UK 
5-Dimethylamino-1-naphthalenesulfonyl 
chloride 
Sigma-Aldrich Co., UK 
1-Naphtholyl chloride Sigma-Aldrich Co., UK 
9-Fluorenylmethoxy carbonyl chloride AlfaAesar, UK 
Triethylamine  Sigma-Aldrich Co., UK 
Methyl iodide Sigma-Aldrich Co., UK 
Sodium iodide Sigma-Aldrich Co., UK 
Sodium hydroxide Fisher Scientific, UK 
Organic solvents Fisher Scientific, UK 
Amberlite  - 96 resin Fluka, UK 
Dialysis tubing membranes Medicell International Ltd, UK 
Deuterated Methanol Cambridge Isotope Laboratories Inc., 
USA 
 
2.2.2. Methods 
2.2.2.1. Synthesis of modified polymers 
2.2.2.1.1. Conversion of PAA to free base 
PAA-HCl (10 g) salt was dissolved in doubly distilled water. Sodium hydroxide pellets (8 g) 
were added slowly until pH 13 was achieved. The mixture was stirred for 1 h. The polymer 
was exhaustively dialysed against water using 7000 Dalton visking tubing membrane for 
24 h with at least 6 changes of 5 L distilled water (at 2 h intervals for the first 8 h) in this 
time. The dialysate was freeze-dried on a 48 h cycle to obtain a cotton like white solid (4.8 
g, 78 % yield) [76]. 
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2.2.2.1.2. Synthesis of 5 % Cholesterol-PAA (Fig. 26)  
Synthesis was carried out as described by Thompson and colleagues [76]. Purified PAA (2 
g) was dissolved in 100 mL chloroform:methanol (1:1 v/v). Triethylamine  (2 mL) was 
added and the mixture was stirred for 0.5 h. Cholesteryl chloroformate (0.6678 g) was 
dissolved in 20 mL chloroform:methanol (1:1 v/v), and then added drop wise to the 
polymer solution over 2 h at 37 °C. The mixture was then left stirring for 24 h at 37 °C. 
After 24 h the solvent was removed using a rotary film evaporator, and the residue 
washed with diethyl ether (3 x 100 mL). The viscous liquid residue was dissolved in 
doubly distilled water (50 mL) and the solution was exhaustively dialysed (molar weight 
cut-off = 7 kDa) against 5 L doubly distilled water for 24 h (6 water changes). The solution 
was freeze-dried for 48 h and the product was recovered as white cotton like solid (2.2 g , 
79 % yield).  
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Figure 26.Chemical synthesis of Cholesterol-PAA (Ch-PAA). 
 
2.2.2.1.3. Synthesis of Fmoc-PAA, Dansyl-PAA and Naphth-PAA 
Purified PAA (2 g) was dissolved in 150 mL dioxane:water (1:1 v/v) with stirring, sodium 
carbonate was added (in 5% or 10% mole ratio with the hydrophobic moiety). The 
appropriate mass (0.1855 g for 5 %, 0.371 g for 10 %) based on the molar ratio of 9-
Fluorenylmethoxy carbonyl chloride (Fmoc chloride) was dissolved in 20 mL dioxane. The 
mixture was then added drop wise to the polymer solution over 2 h at 0 °C. The final 
solution was left stirring for 4 h at 0 °C followed by 8 h at room temperature. After 
evaporation of solvents, the viscous liquid residue was washed three times with 100 mL 
diethyl ether and subsequently dissolved in doubly distilled water and exhaustively 
dialysed (molar weight cut-off = 12 - 14 kDa) against water (5 L) for 24 h (with 6 water 
changes). The solution was freeze-dried for 48 h and the product was recovered (Fig. 27 
a).  
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The above method was repeated with 5-Dimethylamino-1-naphthalenesulfonyl chloride 
(Dansyl chloride - 0.472 g, 5 % and 0.847 g, 10 %) and 1-Naphthoyl chloride (239 µL, 5 % 
and 477 µL, 10 %) (Fig. 27 b & c). The Fmoc-PAA (2.0 g, 79 % yield) and the Naphth-PAA 
(1.8 g, 81 %) had a white cotton like solid appearance while the Dansyl-PAA (1.9 g, 76 %) 
had a yellow cotton like fluffy appearance. 
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Figure 27.Chemical synthesis of A) Fmoc-PAA, B) Dansyl-PAA and C) Naphthalene-PAA 
(Naphth-PAA). 
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2.2.2.1.4. Quaternization of Modified Polymers 
This method was an adaptation of Domard and colleagues work [202] and had been 
previously reported [3,76]. 
The modified polymer (0.6 g) was dissolved in methanol (100 mL) with stirring. Sodium 
hydroxide (0.58 g) and sodium iodide (0.25 g) were added to the solution, followed by 
methyl iodide solution (3.5 mL). The mixture was left stirring under nitrogen at 36 ⁰C for 3 
h. The product was precipitated out by the addition of diethyl ether (400 mL) and left 
overnight. The ether was then decanted off. The precipitates were dissolved in 40 mL 
ethanol:water (1:1 (v/v)) and the solution was dialysed (molecular weight cut-off = 12 – 
14kDa) against water for 24 h with 6 water changes. A column of Amberlite 176 resin was 
washed with 2 M hydrochloric acid solution followed by deionised water until a neutral pH 
was established. The dialysate was then passed through the column and the eluant was 
collected and freeze-dried. The general reaction for the quaternization reaction is shown 
in Fig. 28.  The 1º amine groups left on the PAA backbone are converted to quaternary 
ammonium ions in a nucleophilic substitution reaction. 
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Figure 28.Quaterisation of hydrophobic modified PAA where R= Cholesterol, 9-
Fluorenylmethoxy carbonyl, 5-Dimethylamino-1-naphthalenesulfonyl or Naphthalene. 
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Table 1. Molar feeds of modified polymers.  
Polymer Initial monomer: 
hydrophobic pendant group 
molar feed ratio 
Type of hydrophobic 
pendant group 
Quaternization 
(Q) 
Ch5 1:0.05 Cholesterol No 
QCh5 1:0.05 Cholesterol Yes 
Fmoc5 1:0.05 Fmoc No 
QFmoc5 1:0.05 Fmoc Yes 
Fmoc10 1:0.10 Fmoc No 
QFmoc10 1:0.10 Fmoc Yes 
Dansyl5 1:0.05 Dansyl No 
QDansyl5 1:0.05 Dansyl Yes 
Dansyl10 1:0.10 Dansyl No 
QDansyl10 1:0.10 Dansyl Yes 
Naphth5 1:0.05 Naphthalene No 
QNaphth5 1:0.05 Naphthalene Yes 
Naphth10 1:0.10 Naphthalene No 
QNaphth10 1:0.10 Naphthalene Yes 
*Nomenclature based on molar grafting level of PAA for example Ch5 = 5 % cholesteryl 
grafting 
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2.2.2.2. Characterisation of Polymers 
2.2.2.2.1. Elemental Analysis 
2.2.2.2.1.1. Simultaneous determination of carbon, hydrogen and nitrogen content 
of polymers 
Modified polymer samples were analysed for their abundance of carbon, hydrogen, 
nitrogen and halogen. Dansyl grafted polymers were also analysed for the abundance of 
sulphur. Samples (1 mg) were analysed using a Perkin Elmer series 2 elemental analyser 
(Perkin Elmer, UK). Sample absorbance values were compared to a standard of 
acetanilide for determination of elemental abundance. 
2.2.2.2.1.2. Determination of halogen content of polymers 
The polymer (20 mg) was combusted in a flask containing pure O2, H2O2 and KOH for 0.5 
h. The flask was then filled with distilled water and cooled back down to room 
temperature. Ethanol was added before acidified with HNO3. The final solution was titrated 
against mercuric nitrate with diphenyl carbazone indicator. The percentage of halogen 
was determined relative to sample weight. The sulphur content was analysed using similar 
techniques with the level of sulphur dioxide quantified by measurement relative to sample 
weight, 
2.2.2.2.2. Nuclear magnetic resonance spectroscopy (NMR) 
1H NMR was carried out on all modified polymers in deuterated methanol (MeOD) (15 
mgmL-1) at 25 ⁰C, using a Bruker 400MHz Ultrashield NMR spectrometer (Bruker BioSpin, 
Germany). Sonication of samples using a Soniprep 150 (MSE Ltd, UK) was undertaken 
for 10 mins to ensure that the polymers were completely dissolved in the deuterated 
methanol before analysis.  
2.2.2.2.3. Fourier transform infrared spectroscopy (FTIR) 
FTIR analysis of all the polymers was carried out with a Perkin Elmer (Spectrum BX, UK), 
fitted with a diamond powder tip. The polymers (5 mg) were placed under the diamond tip 
and 20 scans were run following a background correction. 
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2.3. Results 
Polymer synthesis was performed in accordance to Table 1 (pg. 48). Table 2 (pg. 51) 
shows the percentage yield of each modified polymer. The yield was calculated as 
follows: 
 
For hydrophobic substitutions: 
% Yield =  Product weight / Weight of reactants X 100 % 
E.g. For Ch5 
= [Weight of Ch5 / Weight of PAA + Cholesterol Chloroformate] X 100 % 
 
For hydrophilic substitutions: 
% Yield = Product weight / Weight of reactants X 100 % 
E.g. For QCh5 
= [Weight of QCh5 / Weight of Ch5 and CH3I] X 100 % 
 
The percentage yield was high for all the hydrophobic modified polymers ranging from 60 
– 89 %. The percentage yield much lower however for the quaternized polymers, this was 
due to the methyl iodide being added in excess. 
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Table 2. Percentage yield of modified polymers showing mean and standard deviation. 
Polymer % Yield (mean ±SD (n≥3) or 
individual values (n ≤2)) 
Number of batches 
synthesised 
PAA 78.26 (8.896) 11 
Ch5 79.2 (10.376) 4 
QCh5 17.6 (2.859) 3 
Fmoc5 79.2 (6.554) 4 
QFmoc5 15.4/16.4 2 
Fmoc10 74 (72/86) 2 
QFmoc10 16.7/17.2 2 
Dansyl5 76/76 2 
QDansyl5 17.6 1 
Dansyl10 71.5 (3.811) 3 
QDansyl10 82.5 1 
Naphth5 81/89 2 
QNaphth5 16 1 
Naphth10 60/73 2 
QNaphth10 14.3 1 
 
2.3.1. Elemental analysis 
The PAA polymer backbone and the novel modified polymers synthesised were analysed 
to determine their constituent elements. The main objective when looking at the elemental 
analysis results for the PAA and modified polymers was to determine if correct structure 
had been synthesised. However, it was also useful to look at the halogen content of the 
samples. This would establish whether any unreacted materials were still present in the 
sample and hence confirming its purity. (Elemental analysis is unable to distinguish 
between specific halogen atoms, however only Cl- ions were present in the hydrophobic 
modifications and Cl- and I- ions were present in the hydrophilic modifications. 
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Table 3 (pg. 55) shows the total halogen content in the hydrophobic grafted polymers (and 
PAA backbone) to be less than 5 %. It was therefore assumed that the majority of Cl- ions 
had been successfully converted to NaCl and that the salt molecules had been removed 
during the dialysis step of the synthesis. The quaternized polymers showed higher 
chloride ion content, this was due to the final step in the synthesis where the dialysate 
was passed through an ion exchange resin to exchange iodide with chloride ions.The 
degree of hydrophobic and hydrophilic modification were determined using simple 
calculations as follows: 
PAA 
Divide the % element obtained in elemental analysis (Table 3) by its molecular weight. 
      C  :    H   :   N 
57.07/12 :     12.27/1 :     21.77/14 
 =  4.76 :      12.27 :         1.56 
=   3.05 :        7.87 :   1 
The above results from the elemental analysis confirm the predicted structure of the 
monomer unit with 3 C’s, 7 H’s and 1 N atom (Fig. 23, pg. 38). 
 
Ch5 
     C  : H : N 
63.35/12 :     13.80/1 :       16.57/14 
=   5.28 :       13.80 :          1.18 
=   4.46 :       11.66 :   1 
Deduct PAA values 
=   1.41 :      3.79 :    0 
For every 1 mole of nitrogen present there are 1.41 extra moles of Carbon from PAA 
Chemical formula of Cholesteryl formate = C28H45O2 
Every mole of nitrogen has 1.41/28 = 0.050 moles of cholesteryl group. Cholesteryl 
attachment occurs at the 1 º amine of the PAA monomer.  
Therefore: 
0.05 X 100 % = 5.0 % mole of PAA monomer unit has been modified with cholesteryl 
group. 
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The following calculation was based on the assumption that the remaining primary amines 
on the PAA backbone after quaternization were fully methylated and that no secondary or 
tertiary intermediates were formed, as these are the energetically favourable 
intermediates before complete methylation will occur [3]. However, intermediates are 
unlikely as methyl iodide was added in excess in the reaction.
 
QCh5 
     C  : H : N 
  46.42/12     :      10.20/1 :      8.70/14 
=   3.87 :       10.20 :         0.62 
=   4.23 :       16.43 :   1 
Deduct Ch5 values 
=   1.77 :      4.76 :    0 
 
For every 1 mole nitrogen there is 1.77 moles extra carbon. 
Since every nitrogen requires 3 carbon for quaternization to occur: 
1.77/3 X 100 % = 59 % mole per PAA monomer has been quaternized. 
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Table 3.Elemental analysis results for hydrophobic and hydrophilic modification of PAA. 
Showing % C,H,N,Cl and S present with mean and standard deviation.  
Polymer Carbon    (mean 
±SD (n≥3) or 
range (n ≤2)) 
Hydrogen (mean 
±SD (n≥3) or 
range (n ≤2)) 
Nitrogen (mean 
±SD (n≥3) or 
range  (n ≤2))  
Chlorine     
(mean ±SD 
(n≥3) or range (n 
≤2)) 
Sulphur 
(mean 
±SD (n≥3) 
or range 
(n ≤2)) 
% mole 
grafting per 
PAA 
monomer 
(mean ±SD 
(n≥3) or 
range (n 
≤2)) 
PAA 57.21 (3.439) 
 
12.16 (0.818) 22.52 (1.725) 0.73 (0.280)   - - 
Ch5 59.58 (2.758) 
 
12.12 (0.824) 15.71 (1.606) 1.53 (0.280)   - 4.7 (1.251) 
QCh5 45.21 (1.049) 
 
10.64 (0.391) 8.68 (0.245) 16.07 (5.260) - 66.2(10.843) 
Fmoc5 51.53 (9.174) 
 
10.25 (1.336) 16.34 (3.189) 4.70 (4.925) - 4.3 (1.002) 
QFmoc5 44.86(43.5/46.2) 
 
10.96(10.8/11.1) 9.56 (9.7/9.4) 20.76(24.5/17.0) - 64 (66/62) 
Fmoc10 57.60(57.1/58.1) 
 
9.49  (8.9/10.1) 15.02(13.9/16.2) 0.30 (0.5/0.1) - 9.3(11.0/7.6) 
QFmoc10 45.42(45.6/45.2) 
 
10.52(10.4/10.6) 8.99 (8.8/19.2) 20.81(10.2/31.5) - 61.5 (60/63) 
Dansyl5 53.19(52.8/53.5) 10.79(10.7/10.8) 17.14(17.6/16.7) 0.86 (0.7/1.0) 1.4 
(1.0/1.8) 
4.3 (3.0/5.6) 
QDansyl5 47.56 
 
1.040 9.87 15.56 1.00  63 
Dansyl10 54.91  (0.142) 10.12 (0.127) 8.99 (0.113) 0.70 (0.021) 
 
2.98 
(0.140) 
9.3 (0.416) 
QDansyl10 55.84 
 
11.52 17.37 20.81  2.94 63 
Naphth5 54.52(55.7/53.4) 
 
11.42(12.3/10.6) 18.64(20.5/16.8) 0.63 (0.5/0.7) - 7.1 (8.7/5.5) 
QNaphth5 42.83 
 
10.50 9.03 20.75 - 61 
Naphth10 55.64(55.3/56.0) 
 
10.63 (9.6/11.6) 15.96(16.5/15.3) 0.39 (1.49/0.29) - 7.55(7.1/8.0) 
QNaphth10 43.01 
 
9.42 8.60 0.31 - 60 
 
 
 48 
2.3.2. Nuclear Magnetic Resonance of PAA amphiphiles 
2.3.2.1. 1H NMR spectra of PAA 
The 1H NMR  data showed the protons on the PAA backbone (Fig. 29) were as follows: 
δ1.0 = CH2, δ1.5 = CH , δ2.5 = CH2. 
 
 
 
Figure 29.1H NMR spectra of PAA in MeOD carried out using 400MHz NMR at 25 ⁰C. 
 
Peak assignments on the 1H NMR spectra of the PAA backbone were as follows: δ1.0 = 
CH2 (Fig. 29a), δ1.5 = CH (Fig. 29b) and δ2.5 = CH2 (Fig. 29c). The peaks at δ3.25  and δ4.75 
were due to water and MeOD respectively. Water peaks are commonly broad when 
observed on the NMR spectra, however the sharp peak suggests hydrogen bonding 
occurring between the water molecules and the polymer. 
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2.3.2.2. 1H NMR spectra of Ch5 
 
 
 
  
 
Figure 30.1H NMR spectra of Ch5 in MeOD carried out using 400MHz NMR at 25 ⁰C. 
 
The Ch5 spectra (Fig. 30) had peak assignments at: δ0.75, δ1.10, δ1.15 and δ1.25 =  CH3 
(Cholesteryl), δ1.4-2.0 = CH2 (Cholesteryl, PAA), δ2.60 = CH2 (Cholesteryl), δ2.75-3.00= CH2 
(attached to –NH and –NH2 groups on PAA), δ4.5=  CH=O (Carbonyl bond), δ5.5 = C=CH 
(Cholesteryl). The peaks at δ3.25 and δ4.75 were due to water and MEOD respectively. 
The degree of hydrophobic modification could be calculated by comparing the peak at δ0.75 
(cholesteryl) with the peaks at δ2.75-3.20 (-CH2 attached to –NH and –NH2 groups) on PAA 
backbone as follows: 
(Integration at δ0.75 / 3) / (Integration at  δ2.75-3.00 / 2) x 100 % 
= 3.6 % hydrophobic substitution. 
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2.3.2.3. 1H NMR spectra of Fmoc5 
 
 
 
 
 
Figure 31.1H NMR spectra of Fmoc5 in MeOD carried out using 400MHz NMR at 25 ⁰C. 
 
 
The peak assignments for Fmoc were as follows (Fig. 31): δ1.3 = CH2 (PAA), δ1.6 = CH 
(PAA), δ2.5 = CH2 (attached to -NH2 of PAA), δ3.0 = CH2 (PAA), δ3.4 = CH (Fmoc), δ4.0 = CH2 
(Fmoc), δ6.0 = N-H and N-H2 (PAA) and δ7.2-7.8 = aromatic H’s (i.e. g and h) (Fmoc). The 
peaks at δ3.3 and δ4.8 were due to water and MEOD respectively. 
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2.3.2.4. 1H NMR spectra of Dansyl5 
 
 
 
 
 
 
Figure 32.1H NMR spectra of Dansyl5 in MeOD carried out using 400MHz NMR at 25 ⁰C. 
 
The Dansyl peak assignments were as follows (Fig. 32): δ1.0 = CH2 (PAA), δ1.5 = CH (PAA), 
δ2.5 = CH2 (PAA), δ2.8 = CH2 (PAA), δ3.6 = CH3 (Dansyl), δ7.3-8.5 = aromatic H’s of 
naphthalene ring (i.e. f, g, h, I and j) (Dansyl). The peaks at δ3.3  and δ4.8  were due to 
water and MeOD respectively. 
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2.3.2.5. 1H NMR spectra of Naphth5 
 
 
 
 
Figure 33.1H NMR spectra of Naphth5 in MeOD carried out using 400MHz NMR at 25 ⁰C. 
 
 
The Naphth 1H NMR spectra (Fig. 33) has peak assignments as follows: δ1.0 = CH2 (PAA), 
δ1.5 = CH (PAA), δ2.5 and δ3.1 = CH2 (attached to –NH2 and –NH on PAA respectively), δ7.5-
8.5 = aromatic H’s of naphthalene ring (i.e. e, f, g and h) (Naphth). 
 
The 1H NMR spectra for Fmoc10, Dansyl10 and Naphth10 can be seen in Appendix 1.0 
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2.3.2.6. 1H NMR spectra of QCh5 
For the quaternary ammonium compound (QCh5) (Fig. 34) the proton assignments were 
as follows:- δ0.5-2.0 CH2’s and CH3’s (PAA backbone and cholesteryl moiety Ch5), δ3.3-3.6 = 
CH2’s and CH3’s (on quaternary ammonium ion), δ4.3 = CH-O, and δ5.4 due to CH 
(cholesteryl moiety) 
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Figure 34.1H NMR spectra of QCh5 carried out in MeOD on 400MHz NMR at 25 ⁰C. 
 
 
The corresponding quaternized polymers for the Fmoc, Dansyl and Naphth can be seen 
In Appendix 1.0 
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2.3.3. Fourier Transform Infrared Spectroscopy (FTIR) 
The FTIR spectra of  PAA and modified PAA polymers were run between 4000 – 650 cm-1 
to identify the characteristic functional groups present. 
 
Figure 35.FTIR spectrum of PAA carried out using a diamond powder tip (64 scans). 
 
The FTIR spectrum for PAA (Fig. 35) shows the presence of absorbance for the bonds 
present within the polymer (Table 4). The peak at 2357 cm-1 is due to C-O arising from 
background CO2 and the broad peak at 3293 cm-1 is due to O-H of water which has been 
absorbed by the hygroscopic polymer. 
 
Table 4. Peak bandwidth assignment occurring on FTIR spectrum of PAA using diamond 
powder tip (64 scans). 
Polymer / Formulation Bandwidth ( cm-1 ) Bond type Functional Group 
3361 
1595 
N-H Stretch 1  ̊ Amine 
 
2913 
2854 
1373 
1316 
C-H Stretch Alkyl 
1450 C-C Bend  Alkyl 
PAA 
 
 
 
925 
909 
C-N Bend  
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The FTIR spectra of all the modified polymers looked identical to that of PAA between 
4000 – 1800 cm-1, but showed significant difference in the region between 1600 – 700 cm-
1
. In order to accurately assign and identify the peaks, the modified polymers were 
therefore run in their fingerprint region (1600 - 700 cm-1). 
 
Figure 36. FTIR spectrum of Ch5 carried out using a diamond powder tip (64 scans). 
 
The spectrum of Ch5 (Fig. 36), showed the presence of C=O and C-O peaks due to 
absorbance at 1464 cm-1 and 1141 cm-1 respectively indicating the presence of the 
carbonyl group between the backbone and the cholesteryl moiety.  
 
Table 5.  Peak bandwidth assignment occurring on FTIR spectrum of Ch5 using diamond 
powder tip (64 scans). 
Polymer / Formulation Bandwidth ( cm-1 ) Bond type Functional Group 
1645 C=O Stretch Carbonyl 
1568 N-H Bend  1 ⁰ Amine 
1464 
815 
 
C=C Bend Aromatic  
1457 C-C Bend  Alkyl 
1383 
1312 
C-H Bend 
 
Alkyl 
 
Ch5 
 
 
 
 
 
 
1141 
930 
C-O Bend  Carbonyl 
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Figure 37. FTIR spectrum of Fmoc5 carried out using a diamond powder tip (64 scans). 
The IR spectrum confirms the presence of the fmoc attachment via an oxycarbonyl bond. 
Peaks where observed at 1306 and 1738 cm-1 due to the C-O and C=O respectively. 
Further peaks were also present between 1557 – 668 cm-1, these peaks were due to the 
C=C bonds within the aromatic ring systems of the fmoc moiety.  
 
Table 6. Peak bandwidth assignment occurring on FTIR spectrum of Fmoc5 using 
diamond powder tip (64 scans). 
Polymer / Formulation Bandwidth ( cm-1 ) Bond type Functional Group 
1738 
1229 
C=O Stretch 
 
Carbonyl 
 
1656 N-H Stretch 1  ̊ Amine 
1557 
1446 
780 
726 
815 
668 
C=C Bend  Aromatic  
Substituted benzene 
1478 C-C Bend  Alkyl 
1382 C-H Bend Alkyl 
1306 
1149 
1119  
C-O Bend 
 
Oxyarbonyl 
 
Fmoc5 
1217 
881 
C-N Bend  
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Figure 38. FTIR spectrum of Dansyl5 carried out using a diamond powder tip (64 scans). 
The FTIR spectrum of Dansyl5 (Fig. 38) showed absorbance responsible for the dansyl 
moiety. The presence of methyl peaks (1232 and 1202 cm-1) were attributed to the methyl 
groups attached to the amine of the dansyl moiety. The peak present at 790 cm-1 
suggested the presence of aromatic substituted benzene and the most relevant peak at 
1739 cm-1 showed the prescence of a sulfonyl group (from dansyl) to the PAA backbone.  
Table 7. Peak bandwidth assignment occurring on FTIR spectrum of Dansyl5 using 
diamond powder tip (64 scans). 
Polymer / Formulation Bandwidth ( cm-1 ) Bond type Functional Group 
Dansyl5 1739 S=O Stretch Sulfonyl 
1639 N-H Stretch 1⁰ Amine  
1559 
1455 
790 
678 
C=C Bend  
 
Aromatic  
Mono Substituted 
Benzene 
1479 C-C Bend  Alkyl 
1382 
1310 
C-H Bend Alkyl 
1232 
1202 
C-H Bend  Methyl 
 
1141 
1072 
1016 
873 
815 
940 
C-N Bend  
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Figure 39.FTIR spectrum of Naphth5 carried out using a diamond powder tip (64 scans). 
 
 
The presence of aromatic alkene protons (1561 cm-1) on the FTIR of Naphth5 (Fig. 39) 
suggested the attachment of the naphthalene moiety had been successful. This was 
further confirmed by carbonyl peaks (1738 cm-1) arising from the carbonyl bond between 
the PAA and the naphthalene moiety.  
 
Table 8. Peak bandwidth assignment occurring on FTIR spectrum of Naphth5 using 
diamond powder tip (64 scans). 
Polymer / Formulation Bandwidth ( cm-1 ) Bond type Functional Group 
1738 
1637 
1216 
C=O Stretch 
 
 
Carbonyl 
 
1561 
1450 
780 
690 
C=C Bend  
 
Aromatic  
Mono Substituted 
Benzene 
 
1478 C-C Bend  Alkyl 
1383 
1310 
C-H Bend 
 
Alkyl 
 
Naphth5 
1147 
931 
814 
C-N Bend  
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The FTIR spectrum for QCh5 (Fig. 40) and all the quaternary compounds were run from 
4000 – 650 cm-1, this was due to vital peaks present at the higher region of the spectrum.  
 
Figure 40.FTIR spectrum of QCh5 carried out using a diamond powder tip (64 scans). 
The peak assignment for the FTIR spectra of QCh5 (Fig. 40) showed the presence of the 
broad band between 3600 – 3000 cm-1. These peaks indicated quaternization had 
occurred, this was further confirmed by the prescence of CH3 peaks at 1249 cm-1, that 
resulted from the methyl groups from the ammonium ion. 
Table 9. Peak bandwidth assignment occurring on FTIR spectrum of QCh5 using diamond 
powder tip (64 scans). 
Polymer / Formulation Bandwidth ( cm-1 ) Bond type Functional Group 
QCh5 
 
3600 - 3000 N-H Stretch Ammonium Ion 
 
3022 
1634 
C=O Stretch Carbonyl 
 
2953 C-H Stretch Alkyl 
1538 N-H Bend  1 ⁰ Amine 
1480 
815 
C=C Bend Aromatic  
1418 C-C Bend  Alkyl 
1249 C-H Bend Methyl 
 
 
 
 
 
 1170 
961 
C-O Bend Carbonyl 
 
The FTIR spectra for Fmoc10, Dansyl10, Naphth10 and all their corresponding quaternized 
derivatives can be viewed in appendix 2.0.  
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2.4. Discussion 
Grafted polymers were successfully synthesised. The percentage of grafted values 
calculated using elemental analysis results were in good agreement with the theoretical 
values (Table 3). The hydrophobicity of a polymer may be altered by changing its initial 
molar feed ratios in the reactions. However excessive grafting of hydrophobic groups can 
lead to precipitation [203]. This phenomenon was witnessed for Ch-PAA. Ch-PAA could 
not be synthesised above 5 % grafting level as the highly hydrophobic nature of the 
cholesterol facilitate the polymer to precipitate out of solution rendering the modified 
polymer insoluble.  
Hydrophilic modification of amphiphilic polymers can be achieved by quaternization of the 
primary amines on the polymer backbone [125]. The degree of hydrophilic grafting after 
quaternization ranged from 52-63 %. Elemental analysis is a commonly used technique 
for characterisation of block and graft polymers [123,132,204,205]. The percentage 
hydrophobic modification achieved were close to the theoretical values for the level of 
grafting based on the initial molar feed ratios (Table 1). Further characterisation was 
carried out by two qualitative methods (1H NMR and FTIR). For Ch5, the level of 
hydrophobic grafting was estimated using the NMR spectra by comparison of the 
cholesteryl CH3 peak at δ0.75 with the CH2 multiplet of the PAA at δ2.75–3.2 [76]. The level of 
modification was 4.4 mol% for Ch5, showing close agreement between the cholesteryl 
levels estimated using 1H NMR and elemental analysis (Table 1). Previously the use of 
this technique for quantitative analysis of polymer structures has been published 
[3,125,206]. 
 
For Fmoc, Dansyl and Naphth polymers 1H NMR could only be used to qualitatively show 
the presence of the hydrophobic and hydrophilic groups with respect to PAA alone. This 
was due to the extensive overlapping of peaks making this type of analysis very difficult.  
The NMR spectra of the PAA backbone shown in Fig. 29 shows the presence of peaks at 
δ1.0 and δ1.5, these peaks arise from the presence of the CH2 and CH groups of the 
polymer backbone. At δ2.5 the peak wasdue to the CH2 attached to the amine group. The 
amino groups adjacent to the CH2 deshield the protons resulting in a downfield shift in 
their NMR spectra.  
The Ch5 spectrum (Fig. 30) shows additional peaks at δ4.5, assigned as the H attached to 
the carbonyl bond of the cholesteryl moiety (CH=O). Further peaks at δ0.75 - δ1.25, were due 
to the –CH3 groups on the cholesteryl structure. At δ5.5 the peak can be attributed to the 
alkene protons (C=C-H) in the B ring of the cholesteryl group (Fig. 41). The presence of 
these additional peaks strongly suggests the attachment of the cholesteryl moiety on the 
polymer backbone.  
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Figure 41. Chemical structure of Ch-PAA. 
The NMR spectra for Fmoc5 and Naphth5 (Fig. 31 & 33) both showed the presence of 
further peaks occurring between δ7.0-8.0. These peaks arise from the hydrogen atoms on 
the aromatic rings of fmoc and naphthalene structures. Aromatic protons characteristically 
occur between δ7.0-8.0 on the 1H NMR spectra [193]. However on closer inspection, peak 
splitting characteristic properties for each group can be assigned. Peak splitting arises 
from a proton existing in a magnetic field environment which is shared with neighbouring 
protons. The sharing of environments effect the total magnetic field strength experienced 
by the proton and thus peak splitting occurs [207]. 
In the Fmoc5 spectrum (Fig. 31) two sets of triplets are observed between δ7.2-7.4, these 
were due to the C-H’s on the aromatic rings with two neighbouring protons (indicated by 
‘g’), therefore forming a triplet (Fig. 42).  
CH2 CH CH2 CH
CH2 CH2
NH NH2
a b
C
O O
 
 Figure 42. Chemical structure of Fmoc-PAA. 
The two sets of triplets were observed because there were two equivalent environments 
existing. The two doublets observed δ7.6-7.8 were attributed to the C-H’s in the aromatic ring 
systems of the fmoc group where only one neighbouring proton was present indicated by 
‘h’ (Fig.42). Again two equivalent environments existed for this scenario hence producing 
two sets of doublets on the spectra. 
In the NMR spectrum of the Naphth5 polymer (Fig. 33), the aromatic region showed 
different spectral patterns than the fmoc polymer. This is due to the aromatic hydrogen on 
the Naphth5 having a larger number of hydrogen in  different environments. A triplet was 
A 
B C 
D 
g 
g 
g 
g 
h 
h 
h 
 h 
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observed at δ7.5, this was due to the C-H’s with two neighbouring protons on the aromatic 
ring indicated by ‘e’ (Fig. 43). 
CH2 CH CH2 CH
CH2 CH2
NH NH2
a b
C
O
 
Figure 43. Chemical structure of Naphth-PAA. 
Interestingly two sets of doublets were observed on the spectra, however they were quite 
separate (δ7.7 and δ8.5). These peaks were due to C-H’s in the rings with only one 
neighbouring proton indicated by ‘f’ and ‘h’ respectively. However, the doublet at δ7.8 was 
shifted downfield on the spectra. This was because of the proximity of this proton to the 
electromagnetic O atom, thus causing deshielding. A triplet was present at δ7.9 denoted by 
‘g’, this was expected to be a duplet due to the C-H with one neighbouring protons 
indicated by ‘e’, perhaps slight impurities where present within the polymer causing this 
irregularity. 
The addition of dansyl to the polymer backbone produced extra peaks at δ3.6 (Fig. 32), due 
to the hydrogen’s attached to the nitrogen on the dansyl moiety. More importantly peaks 
are present between δ7.3-8.5, these peaks are due to the aromatic rings on the dansyl 
moiety. However, it was more difficult to distinguish the peak splitting patterns on the 
Dansyl5 spectra. Perhaps this was due to abundant equivalent protons causing peak 
overlap in the spectra or due to poor spectral resolution. However the presence of these 
peaks did indicate the presence of aromatic groups and when considered alongside the 
aforementioned peaks at δ3.6, it strongly indicated that the dansyl moiety had successfully 
attached to the PAA backbone. 
In the NMR spectra for the QCh5, the presence of peak at δ3.3-3.6 confirms the presence of 
the CH3 of the quaternary ammonium ion (Fig. 34), suggesting quaternization was 
successful [76,208]. This peak was present in all quaternized polymer spectra. 
Fourier transform infrared spectroscopy was carried out for all the modified polymers. The 
FTIR spectra positively identified the grafting of each of the hydrophobic and hydrophilic 
groups. Although it is not a quantitative technique, it is still widely used for the 
confirmation of chemical structure within the amphiphilic polymer field [109,110,131,132, 
209]. 
e 
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Further characterisation could be carried out using gel permeation chromatography 
(GPC). GPC separates its analytes on the basis of its molecular size and not its chemical 
structure like other analytical techniques [210]. GPC is carried out by passing a mobile 
phase through a column packed with hydrophobic porous beads. The sample is injected, 
its retention is determined by its molecular size (using the principle of steric size 
exclusion) [211]. Smaller molecules are capable of penetrating the porous beads of the 
stationary phase and thus are retained longer on the column [211]. This method has been 
extensively used for the quantitative analysis of polymers [100,136,212,213]. GPC is 
useful in the characterisation of block copolymers as they are synthesised from monomers 
which may result in a range of molecular weight products being formed. GPC is used to 
measure the molecular weight distribution of the monomers within the polymer structure 
[214]. However it is not used frequently within the comb shaped polymer field. This is 
because a homopolymer backbone is grafted with small hydrophobic pendant groups, and 
the synthesis is a lot easier to control. For graft polymers GPC can only be used to give a 
rough value for the grafting level which is not accurate for this application. 
 
2.5. Conclusion 
Polymers were successfully grafted in good agreement with predicted molar feed ratios in 
initial reactions. Full characterisation indicated that the correct polymer structures where 
produced. 
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Chapter Three 
Characterisation of polymeric self-
assemblies in aqueous environment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
3.1. Introduction 
In aqueous environments amphiphilic polymers spontaneously self assemble to form 
polymeric self-assemblies [75]. These self-assemblies formed can be polymeric micelles, 
nano-particles or vesicles [74]. The driving force behind aggregate formation is due to 
non-polar and hydrophobic-hydrophobic interactions between the amphiphilic polymer and 
the aqueous media [103]. Amphiphilic polymers have an equivalent value to the CMC 
known as the critical aggregation concentration (CAC) [215,216]. The ability of the nano 
aggregates to encapsulate hydrophobic drug molecules has been extensively investigated 
[72,217,218]. 
3.1.1. Photon correlation spectroscopy 
Photon correlation spectroscopy (PCS) or dynamic light scattering (DLS) is a powerful 
technique used for estimating hydrodynamic size of particles or macromolecules in 
solution [194,197]. The size is measured by passing a beam of light through the desired 
sample. Upon collision with the macromolecular structures in the sample the beam 
scatters. These structures randomly move and vibrate by the phenomenon known as 
Brownian motion. The scattering of the light beam will result in changes in intensity, which 
led to the formation of a moving pattern. The moving pattern is used to deduce particle 
size as smaller particles move at a faster rate than larger heavier ones and scatter less 
light. The rate of change of light fluctuation is used to determine size distribution of the 
particles in the sample scattering light.  The size measured by PCS is a representation of 
the hydrodynamic radius. The size is fractionally larger than that of the sample particle. 
This is due to the presence of a hydration layer surrounding the particles from the solvent 
[194]. This technique is very useful for macromolecules as it is capable of measuring 
sample sizes from only a few nanometres up to as large as five micrometers [194].   
The distribution of particle size in solution indicates the degree of monodipersity or 
polydispersity. The polydispersity index (PDI) indicates the variation of size distribution 
within the sample. The PDI is measured on a scale of 0 to 1. A PDI of 0 indicates the size 
of self assemblies in the sample are uniform whereas a PDI of 1 indicates non-uniformity 
where numerous size distributions are present.    
3.1.2. UV Visible spectroscopy 
UV-Visible spectroscopy is a useful technique for identification and quantification of 
chemical and biological samples [219]. The basic principle is the measurement of the 
intensity of radiation at specific spectral wavelengths which are characteristic to the 
samples involved [219]. 
Atoms or molecules absorb radiation with a specific photon energy (matching to the 
difference in energy between their ground state and excited state); the wavelength at 
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which this occurs depends upon the bonding of the atom or molecules’ electrons [195]. 
The electrons involved in single bonds are held tightly, making them difficult to excite. 
Whereas, the electrons are held less tightly in double and triple bonds and are a lot more 
excitable and therefore producing well defined absorption spectra [195]. When UV/Visible 
light is passed through a liquid or gaseous sample, the light emerging from the sample is 
then analysed by a spectrometer producing an absorption spectra [195]. 
3.1.3. Surface tension  
Water molecules in the bulk solution will be surrounded by other molecules in all 
directions which possess equal attractive forces [28]. However, at the liquid air interface 
this is not the case. Molecules at the surface of the liquid have fewer neighbouring 
molecules and therefore cohesive forces can only form with the limited number of 
molecules which are directly situated below or beside them [2, 28,31]. As a result a net 
inward force is experienced by the molecules at the interface towards the bulk of solution 
[28,31]. The net inward attraction described results in the molecules being pulled together, 
contracting the surface [31]. The surface is now said to be in a state of lateral tension, this 
is also known as surface tension [28]. A minimum free energy state is achieved. In order 
to expand the newly contracted surface an increase in free energy is required [2]. 
 
When amphiphilic molecules such as surfactants or amphiphilic polymers accumulate at 
the surface of a liquid interface, their hydrophobic moiety protrudes from the surface layer 
into the gaseous phase above (here we assume that the surfactant amphiphiles are 
soluble in the aqueous phase). The intrusion of the surface layer results in the 
replacement of some water molecules with non-polar groups such as hydrocarbons [2]. 
The attractive forces between water molecules and non-polar groups are considerably 
less than that of water-water interactions and a reduction in surface tension is 
experienced [28,31]. The surface tension is decreased with the addition of very low 
concentrations of amphiphile, and continues to decrease as the concentration of the 
amphiphile is increased [2]. When the interface of the aqueous environment is ‘saturated’ 
with amphiphilic molecules addition of further amphiphile does not result in the decline of 
surface tension [79]. The remaining molecules in solution find other means of shielding 
their hydrophobic groups from the aqueous environment. They self assemble into 
aggregates known as micelles. A graph of surfactant concentration is plotted against 
surface tension, the point at which the gradient plateau is determined as the critical 
micellar concentration or critical aggregation concentration.  
3.1.4. UV hydrophobic probes 
UV hydrophobic probes such as methyl orange and N-phenyl-1-naphthylamine (PNA) 
have been used to investigate the self-assembly formation of surfactant micelles and 
polymeric nano-particles in aqueous media [76,220,221]. 
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In the aqueous environment methyl orange favours the hydrophobic domains in surfactant 
or polymeric self assemblies. The hydrophobic interaction of the methyl orange inside the 
self-assemblies results in a hypsochromic shift in the λmax on the methyl orange absorption 
spectra over varying polymer concentrations. The hypsochromic shift can be identified 
using a UV spectrometer (Fig. 44) [3,123,222]. UV probes can be used to deduce the 
CAC of amphiphilic polymers as the hypsochromic shift is experienced when the self-
assembly formation occurs. 
 
 
Figure 44.Hypsochromic shift occurring when methyl orange is partitioned inside the 
hydrophobic core of a micelle. 
 
3.1.5.Fluorescence spectroscopy 
Fluorescence spectroscopy is a very sensitive analytical method for quantification of 
fluorescent compounds. Compounds which possess fluorescent properties are usually 
those with rigid molecular structures like aromatic ring systems, double and triple bonds 
[200]. 
When an atom or molecule absorbs a photon of energy due to UV radiation, the resultant 
excited electronic state causes a change in the energy of that molecule. However as the 
molecule returns to its ground state the excess electronic energy is emitted as a photon of 
light giving rise to the phenomenon known as fluorescence [223,224]. 
Fluorescent excitation can lead to the formation of diatomic molecules between atoms or 
molecules which would not bond if they were in their unexcited ground states. This 
phenomenon is known as excimer formation. An excimer is a short-lived dimeric molecule 
formed from two species, at least one of which is in an excited electronic state. They are 
often diatomic and are formed between two atoms or molecules that would not bond if 
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they were both in their ground states [225]. Excimer formation causes a shift in the 
emission wavelength of a fluorophore [225]. 
3.1.6. Transmission electron microscopy 
The transmission electron microscope is an extremely useful piece of equipment which 
can be used to study the aggregation structure of a sample [194]. The instrument passes 
a beam of electrons through a thin layer of sample causing interactions [194]. The 
interactions allow a high resolution image of the aggregation architecture to be produced. 
Samples less than 1 µm can be imaged using this technology [194]. 
3.1.7. Aims and Objectives 
The modified polymers were characterised using surface tension measurements, a UV 
hydrophobic probe and PCS to determine whether they formed self-assemblies in 
aqueous solution. To fully understand their physical properties in aqueous solution, 
fluorescent studies were also carried out for Fmoc5 to investigate whether excimer 
formation was occurring upon spontaneous aggregation. The properties of nano 
aggregates (e.g. CAC, size) can give indication to their drug loading potential and hence 
their success as vehicles for drug delivery. 
 
3.2. Materials and Methods 
3.2.1. Materials used 
Material Supplier 
Modified PAA polymers Synthesised in Chapter Two 
Methyl orange Sigma-Aldrich Co., UK 
Sodium Tetraborate Sigma-Aldrich Co., UK 
Acetone Fisher Scientific, UK 
0.45µm GDX PVDF filters Whatman, UK 
Highly purified water MillexQ system (UK) 
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3.2.2. Methods 
3.2.2.1. Photon correlation spectroscopy 
Polymeric self-assemblies were formed by probe sonication of the polymers (1 mgmL-1) in 
doubly distilled water before filtering with 0.45 µm syringe filter.  Hydrodynamic diameters 
and polydispersity index measurements were carried out using a photon correlation 
spectrometer (Zetasizer Nano-ZS, Malvern Instruments, UK). All measurements were 
conducted in triplicate at 25 °C and an average value was determined. A simple t-test was 
carried out in excel to determine the statistical significance of results, whereby p≤0.01 was 
significant. 
3.2.2.2. CAC determination 
3.2.2.2.1. UV Hydrophobic probe 
This method was an adaptation of Uchegbu’s method [125]. A stock solution of methyl 
orange (25 µM) was prepared with sodium tetraborate buffer (0.02 M, pH 9.4) in deionised 
water. The solution was placed in a sonic bath for 3h. Twenty two concentrations of 
modified polymers (0.00145 - 3 mgmL-1) were made up using the methyl orange solution 
as the diluent. Each sample was probe sonicated for 5 min and allowed to cool to room 
temperature. The polymer solutions were placed in a UV-visible spectrophotometer 
(Agilent 8453) and their maximum absorbance was recorded (350-600 nm). The methyl 
orange stock solution was used as the control. The presence of hypsochromic shift was 
determined by comparing the polymer solution wavelength maxima with the λmax of methyl 
orange stock solution. 
3.2.2.2.2. Surface tension  
The polymers were made up in aqueous solution (twenty two solutions, 0.00145 - 3 
mgmL-1) and sonicated for 5 min before cooling to room temperature. The surface tension 
of polymer solutions were measured at 25 °C using a torsion balance (OS, White 
Electrical Instrument Co, London). The platinum ring and platform were cleaned with 
ethanol and doubly distilled water prior to analysis of each sample. The measurement was 
conducted in triplicate for each polymer solution to obtain an average value. The surface 
tension of deionised water was determined between each concentration to ensure no 
cross contamination of samples had occurred. 
3.2.2.2.3. Fluorescent spectra of Fmoc5 
Fmoc5 was dissolved in doubly distilled water and sonicated for 10 min. After cooling to 
room temperature eight samples of 0.023 - 3 mgmL-1 concentration were run on the 
Luminescence Spectrometer (Perkin Elmer LS55, USA) with excitation wavelength set at 
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259 nm. The samples were scanned between 200 - 500 nm at 400 nmsec-1, excitation slit 
width of 15 nm and emission slit width of 3 nm. Emission spectra were collected and 
analysed using the supplied software. 
3.2.2.3. Transition electron microscopy 
All samples were visualised at The University of Glasgow, Division of Infection & 
Immunity, IBLS, Integrated Microscopy Facility. Formvar/carbon-coated 200 mesh nickel 
grids were glow discharged. Polymer solutions made up in doubly distilled water were 
dried onto the hydrophilic support film.  1 % aqueous methylamine vanadate (20 µL) 
(Nanovan;  Nanoprobes , Stony Brook, NY, USA) stain solution was applied and the 
mixture dried down immediately with filter paper to remove excess liquid. The dried 
samples were imaged with a LEO 912 energy filtering transmission electron microscope at 
120 kV. Contrast enhanced, zero-loss energy filtered digital images were recorded with a 
14 bit /2 K Proscan CCD camera. 
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3.3. Results 
3.3.1. Photon correlation spectroscopy 
Characterisation was carried out on the nano aggregates in aqueous solution. The 
hydrodynamic size of 5 % mole grafted polymer aggregates (1 mgmL-1) formed in 
aqueous solution ranged from 99 nm (QDansyl10) to 284 nm (QFmoc5) (Table 10). The 
low polydispersity index indicated that fairly uniform single sized populations were 
produced [226].  
Table 10.Size analysis for 1 mgmL-1 aqueous polymer solutions n=3, ave (SD). 
Modified Polymer Size (nm) P.D.I 
Ch5 183 (2) 0.167 (0.101) 
QCh5 272 (33) 0.303 (0.025) 
Fmoc5 199 (2) 0.140 (0.053) 
QFmoc5 284 (2) 0.142 (0.001) 
Fmoc10 128 (3) 0.163 (0.015) 
QFmoc10 169 (15) 0.136 (0.102) 
Dansyl5 120 (6) 0.285 (0.025) 
QDansyl5 215 (29) 0.337 (0.041) 
Dansyl10 99 (29) 0.367 (0.153) 
QDansyl10 138 (22) 0.125 (0.102) 
Naphth5 188 (3) 0.127 (0.001) 
QNaphth5 128 (4) 0.268 (0.201) 
Naphth10 156 (5) 0.258 (0.002) 
QNaphth10 172 (12) 0.135 (0.013) 
 
On increasing the molar grafting level from 5 % to 10 %, a trend was witnessed whereby 
the size of the self assemblies formed decrease from 199 to 128 nm (Fmoc), 120 to 99 nm 
(Dansyl) and 188 to 156 nm (Naphth) (Table 10). This suggests that increased 
hydrophobicity of the amphiphile resulted in stronger hydrophobic interactions with the 
aqueous environment forming more compact aggregates, however these were not 
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statistically significant. The PDI values increased slightly with higher hydrophobic grafting, 
perhaps due to the random nature of the grafting allowing the formation of both intra and 
intermolecular aggregates.  
Figure 45 shows the size distribution report for Dansyl5. The chart shows that all the 
aggregates formed are within the size range of 50  - 300nm. Although this is a relatively 
large range, only one type of aggregation is present as only one peak is observed.  
 
Figure 45.Photon correlation spectroscopy size correlation chart for 1 mgmL-1 Dansyl5 in 
doubly distilled water (n=3, ave). 
The size correlation chart for Dansyl10 (Fig. 46) shows the self assemblies formed are not 
all of uniform size and that two size populations are present in solution. The larger peak 
between 45 - 150 nm indicates that the majority of the aggregates in solution exist within 
this size range. This peak can be attributed to intermolecular aggregation whereby more 
than one polymer strand comes together to form the self-assembly. The smaller peak at 5 
– 15 nm perhaps is due to intramolecular aggregation, whereby one lone polymer strand 
can spontaneously self aggregate forming a self-assembly. The presence of these two 
peaks means the aggregates formed are poly disperse.  
 
Figure 46.Photon correlation spectroscopy size correlation chart for 1 mgmL-1 Dansyl10 in 
doubly distilled water (n=3, ave). 
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Addition of hydrophilic moieties generally increased the self-assembly size was witnessed 
for all quaternized polymers with exception to QNaphth5 (however this was not statistically 
significant)(Table 10). Upon quaternization Ch5 (183 nm) increased to 272 nm (QCh5). 
The increase in hydrodynamic size is possibly due to a higher level of solvation with the 
presence of the quaternary ammonium ions on the shell of the polymeric self-assemblies. 
 
In general all the 5 % modified polymers experienced a higher degree of polydispersity 
upon quaternization while for the 10 % quaternized polymers, although their size did 
increase, the polydispersity index decreased slightly (Table 10). 
Size correlation charts for all the polymers can be viewed in Appendix 3.0 
3.3.2. Determination of CAC 
3.3.2.1. Surface Tension 
Surface tension measurements were used to estimate the CAC values of the self-
assemblies formed. The CAC values for the modified polymers were measured at the 
point in the graph where the surface tension comes to a plateau. The appearance of the 
surface tension graphs changed dramatically depending on the hydrophobic group. From 
the surface tension graph (Fig. 47) the CAC values for Ch5 and Dansyl5 were determined 
as 0.093 and 0.5 mgmL-1 respectively. The appearance of the Fmoc5 and Naphth5 surface 
tension graphs differed greatly from the Ch5 and Dansyl5. Both these polymer solutions 
showed two areas of plateau in the graph suggesting the presence of two CAC values at 
0.4 and 1.5 mgmL-1 (Fmoc5) and 0.187 and 0.5 mgmL-1 (Naphth5).  
 
Figure 47.Surface Tension results for ♦ Ch5, ■ Fmoc5, ▲Dansyl5 and X Naphth5 carried 
out on a torsion balance at 25 ⁰C, (n=3, ave ± SD). 
The Fmoc5, Dansyl5 and Naphth5 had much lower surface tension values than the Ch5, 
this can be attributed to the presence of aromatic rings within the pendant groups. The 
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aromatic rings are more hydrophobic than the alkyl chain or ring system present in the 
cholesteryl moiety of Ch5 [227].  Dansyl5 showed the greatest decrease in surface tension 
from 0.072 Nm-1 of water to 0.045 Nm-1. This indicted that the dansyl moiety was the most 
hydrophobic, with stronger aggregation interactions in aqueous phase [227]. 
Fig. 48 shows that addition of a hydrophilic moiety decreases the CAC value from 0.25 
and 1 mgmL-1 (Fmoc5) to 0.125 and 0.5 mgmL-1 (QFmoc5). This reduction was also 
observed for the Ch5 (0.093 mgmL-1) and QCh5 (0.023 mgmL-1) (Table 11). However 
addition of hydrophilic moieties to all other polymers resulted in the presence of no CAC 
value. At higher hydrophobic grafting levels the CAC appeared to be lowered. The CAC 
value of the Fmoc self-assemblies decreased from 0.4 and 1.5 mgmL-1 (Fmoc5) to 0.187 
and 0.75 mgmL-1 (Fmoc10) (Fig. 48). 
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Figure 48.Surface Tension results for ♦ Fmoc5, ■ QFmoc5 and ▲ Fmoc10 carried out on a 
torsion balance at 25 ⁰C (n=3, ave). 
For the quaternized polymers excluding QCh5 and QFmoc5, no CAC was observed over 
the concentration range tested (0.0145 – 3 mgmL-1). The surface tension for QDansyl5 
(Fig. 49) shows the surface tension remained at the surface tension value for water (0.072 
Nm-1). The surface tension plots for all other modified polymers are in Appendix 4.0. Table 
11 shows the CAC values for all the modified polymers determined using surface tension 
measurements. 
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Figure 49.Surface Tension results for QDansyl5 carried out on a torsion balance at 25 ⁰C 
(n=3, ave). 
Table 11.CAC values for modified polymers in aqueous solutions and appearance in 
solution above CAC value (n=3, ave). 
Modified Polymer CAC value (mgmL-1) Appearance in solution 
above CAC 
Ch5 0.093 White cloudy solution 
QCh5 0.023 Colourless clear solution 
Fmoc5 0.4 and 1.5 Colourless clear solution 
QFmoc5 0.125 and 0.75 Colourless clear solution 
Fmoc10 0.187 and 0.75 Colourless clear solution 
QFmoc10 No CAC observed Colourless clear solution 
Dansyl5 0.5 Yellow clear solution 
QDansyl5 No CAC observed Yellow clear solution 
Dansyl10 0.25 Yellow clear solution 
QDansyl10 No CAC observed Yellow clear solution 
Naphth5 0.187 and 0.5 Colourless clear solution 
QNaphth5 No CAC observed Colourless clear solution 
Naphth10 0.125 and 0.75 Colourless clear solution 
QNaphth10 No CAC observed Colourless clear solution 
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3.3.2.2. UV hydrophobic probe 
Methyl orange studies were carried out in order to observe a hypsochromic shift allowing 
determination of the CAC value of the modified polymer. Methyl orange has a λmax of 464 
nm. When an amphiphile is diluted in a methyl orange solution, a hypsochromic shift 
occurs in the UV spectra [76]. This is due to the methyl orange favouring the hydrophobic 
core of the surfactant micelles. The CAC is identified as the point where the wavelength 
remains constant and a plateau is observed on the graph.  
 
For Ch5 (Fig. 50) the shift occurred at 0.0313 mgmL-1. After this concentration the 
wavelength, (and thus the gradient of the graph) reached a plateau indicating the 
occurance of complete aggregation [3]. After the plateau the values started to rise up to 
450 nm, this may be due to the high polymer concentration (0.5 mgmL-1) making the 
solution cloudy, thus giving inaccurate UV reading. A hypsochromic shift was observed at 
2 mgmL-1 for Fmoc5 (Fig. 51). 
 
Figure 50.Effect of Ch5 on the peak absorbance of methyl orange at 464 nm (n=3, ave ± 
SD). 
 
Figure 51.Effect of Fmoc5 on the peak absorbance of methyl orange at 464 nm (n=3, ave 
± SD). 
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The formation of aggregates at lower concentrations of Fmoc5 were not detectable in the 
methyl orange study indicating surface tension measurements were more sensitive in 
determining CAC values. All the other polymers tested did not show any noticeable shift in 
λmax (Fig. 52) perhaps due to the method being insensitive or the aromatic nature of the 
hydrophobic groups, fmoc, dansyl and naphthalene groups (normally used as 
fluorophores) interfering with or quenching the methyl orange readings [228]. 
 
Figure 52.Effect of ◊ Dansyl5, □ Naphth5, ▲ Fmoc10, ♦ Dansyl10 and ■ Naphth10 on the 
peak absorbance of methyl orange at 464 nm (n=3, ave ± SD). 
Consistent with the unquaternized results, the QCh5 showed hypsochromic shifts upon 
aggregation of methyl orange (Fig. 53). The CAC value for QCh5 (0.0313 mgmL-1) was 
identical to its corresponding unquaternized polymer. QFmoc5 (Fig. 53) together with the 
rest of the quaternized polymers showed no hypsochromic shift, resulting in no CAC 
value. 
  
Figure 53.Effect of ◊ QCh5 and ■ QFmoc5 on the peak absorbance of methyl orange at 
464 nm (n=3, ave ± SD). 
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3.3.2.3. Fluorescent spectra of Fmoc5 
A possible explanation for the two CAC values obtained by surface tension measurement 
of Fmoc and Naphth modified polymers could be due the formation of excimers. To further 
investigate the theory of excimer formation at higher concentrations of Fmoc5, its 
fluorescent emission spectra was studied (Fig. 54). 
 
Figure 54.Fluorescent emission spectra of Fmoc5         0.02 mgmL-1,      0.4 mgmL-1 and                    
……..1.5mgmL-1, excited at 315 nm.  
As the concentration increases (0.02 – 1.5 mgmL-1), the emission peak shifts from 440 nm 
across the range of wavelengths to 525 nm. At 1.5 mgmL-1 a large peak is observed at 
525 nm, however as the concentration decreases to 0.4 mgmL-1 this peak diminishes until 
it completely disappears at 0.02 mgmL-1. The spectra produced gives a good indication 
that excimer formation has occurred as peak shift is a common occurrence [229,230,231]. 
It was therefore also assumed that excimer formation was occurring with Naphth-PAA 
polymers since they have similar structures and also exhibited two CAC values when 
surface tension measurements were carried out. 
3.3.3. Transition electron microscopy 
The Ch5 micrograph (Fig. 55) showed the nano particles to be less than 100 nm in size. 
Traditionally at this size it would be expected to see polymeric micelles, however the 
particles appeared to be much more dense in structure suggesting the formation of nano-
particles. 
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Figure 55.TEM analysis of Ch5 in doubly distilled water (1 mgmL-1).  
The Fmoc5-PAA TEM showed that self assemblies formed both at the lower (0.3 mgmL-1) 
(Fig. 56 a) and the higher (2 mgmL-1) concentrations (Fig. 56 b). The concentrations 
tested were significant due to the two CAC values observed from the surface tension 
measurement (0.4 and 1.5 mgmL-1). The self-assemblies at the higher concentration 
appear to be of larger size (50 nm) than that of the lower concentration sample (25 nm). 
The TEM of the 0.3 mgmL-1 sample suggests that self assemblies are formed at this lower 
concentration and therefore the first CAC value obtained from the surface tension 
measurement is a true CAC measurement.  
 
                              
           a)                                       b) 
Figure 56.TEM analysis of Fmoc5 in doubly distilled water a) 0.3 mgmL-1, b) 2 mgmL-1. 
 
Photon correlation spectroscopy of the Fmoc5 at varied concentration was carried out 
(Table 12). Table 12 shows that at 0.3 mgmL-1 the self-assemblies formed were 247 nm 
which was much bigger than the TEM result. Perhaps, the large difference in size could 
be due to the aggregated formed clustering together resulting in a large hydrodynamic 
radius when analysed by photon correlation spectroscopy.  
 
200nm                    100nm 
300nm 
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Table 12. Photon correlation spectroscopy results for increasing polymer concentrations 
of Fmoc5 in aqueous solution n=3, ave (SD). 
Polymer concentration 
mgmL-1 
Size (nm)  (n=3, ave± SD). PDI 
0.3 247 (1) 0.142 (0.018) 
1.0 
 
199 (2) 
 
0.140 (0.053) 
 
2.0 295 (4) 0.169 (0.013) 
 
The self-assemblies decrease in size at higher concentration of 1 mgmL-1 (199 nm), the 
reason for the size decrease can be attributed to the higher hydrophobic content in 
solution forming stronger hydrophobic interactions with the water thus resulting in more 
compact aggregation. However at further polymer concentration increase up to 2 mgmL-1 
the self-assemblies increased in size up to 295 nm. This size increase indicates that as 
more polymer strands aggregate together at higher concentrations, larger self-assemblies 
are formed.  
3.4. Discussion 
The formation of self-assemblies of modified polymers in aqueous environments were 
characterised and their critical aggregation concentration (CAC) determined.  
The hydrophobic pendant group had a direct impact on self-assembly size. This may be 
due to pendant group exhibiting differing level of hydrophobic interactions [76]. Thus, the 
higher the level of hydrophobic grafting encourages stronger hydrophobic interaction and 
hence the formation of smaller self-assemblies occurred [76]. This trend was observed for 
the 10 % mole grafted polymers in comparison with the 5 % mole grafted (Table 10). 
Addition of hydrophilic moieties onto the polymer backbone also affected the self-
assembly size (Table 10). Apart from QNaphth5, quaternization of the polymers led to 
larger self-assemblies formed in aqueous environments (however no statistical 
significance was observed). Perhaps this could be attributed to the permanent positive 
charge on the polymer backbone decreasing the hydrophobic interaction between the 
hydrophobic pendant groups and thus forming less compact self-assemblies [76].  
Appearance of a hypsochromic shift in the UV absorption of methyl orange allows 
successful CAC determination. Methyl orange is a well established hydrophobic probe for 
CAC measurement [3,123,125,203]. However in this case accurate determination was not 
possible for all the polymers. This was due to the method not being sensitive enough to 
detect the CAC values or to the aromatic pendant groups possessing an inherent 
fluorescent nature and therefore masking of the hypsochromic shift occurred [228]. It was 
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therefore necessary to find a more appropriate method for determination of CAC value for 
those polymers. 
Surface tension measurement is a commonly used technique for the determination of 
surfactant CMC [117,232,233,234]. PAA substituted with 5% mole hydrophobic groups 
exhibit different trends in the surface tension confirming the choice of hydrophobic group 
had a major impact on aggregate formation. Both Fmoc and Naphth polymers appeared to 
have two CAC values according to the surface tension data (Fig. 47). This is unusual and 
to the best of my knowledge has not been reported before. The first CAC value observed 
may be a attributed to intermolecular aggregation as the polymer strands come together 
to shield the hydrophobic groups from the aqueous environment. The second CAC value 
observed is thought to be due to excimer formation occurring as more polymer strands 
come closer together resulting in the stacking of the molecules.  
To further investigate the theory of excimer formation at higher concentrations of Fmoc5-
PAA, a fluorescent spectrum was run on (Fig. 54). The resultant spectrum showed clearly 
that as the polymer concentration is increased, the emission peak shifts from 440 nm to 
525 nm with increased intensity [235]. The spectral changes resulting upon excimer 
formation showed the appearance of a new, broader and strongly shifted band to higher 
wavelengths in the emission spectra. This is due to the charge transfer interaction and 
stabilisation occurring especially in polar solvents [236]. 
This phenomenon was unique to these two polymers as they possess a flat 
stereochemistry, thus tight stacking could occur at higher concentrations. However the 
cholesterol moiety lacking planarity was too bulky for such stacking to occur. The dansyl 
group looks similar to the fmoc and naphthalene moieties. However, the sulphur – oxygen 
double bonds (sulphoxide) give a 3D structure, thus preventing any stacking.  
The addition of the hydrophilic groups onto the PAA backbone enhances the solubility of 
the modified polymer due to the presence of a permanent charge. This phenomenon has 
previously been reported for both PAA and chitosan quaternary derivatives [76,237]. This 
helps to increase the aggregation of the modified polymers at lower concentrations due to 
an increased solvation layer, thus lowering the CAC value.  
Measurement of surface tension of QDansyl5, QNaphth5, QFmoc10, QDansyl10 and 
QNaphth10 yielded unexpected results. Upon quaternization, the compounds showed no 
change in surface tension from water (0.072 Nm-1). Thus no CAC occurred within the 
range of concentrations tested (0.0145 - 3 mgmL-1). The CAC could either be lower than 
0.0145 mgmL-1 or the phenomenon was due to the formation of intramolecular aggregates 
(Fig. 57) [238,239,240]. 
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Figure 57. Schematic representation of intramolecular formation of quaternized polymers 
in aqueous solution. 
Intramolecular aggregates are formed when one lone polymer strand aggregates with 
itself to form a self-assembly. The positive charge of the quaternary ammonium moiety 
could be enough to initiate intramolecular aggregation at very low polymer concentrations 
therefore the surface tension of the solutions are unaffected (Fig. 49). Interestingly, the 
addition of the quaternary ammonium ion, eliminated the two types of aggregation 
formation observed between the Ch and Dansyl and the Fmoc and Naphth polymers. The 
aggregation differed due to the formation of excimers within the self-assemblies of the 
Fmoc and Naphth polymers due to the planar nature of the hydrophobic pendant groups. 
However with formation of intramolecular aggregates in the quaternary polymers no CAC 
values were observed and it was assumed the aggregation formation was consistent for 
all quaternized10 % grafted polymers whereby no excimer formation occurred. 
In general the CAC values achieved in this work were higher than others quoted in the 
literature for polymeric micelles [215, 241,242, 243]. This may be attributed to charge 
repulsion forces due to the ammonium ion preventing the polymer strands coming 
Hydrophobic drug 
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together. In addition, this could be due to increased steric repulsion forces between the 
bulky nature of the hydrophobic pendant groups compared to the straight chain alkyl 
molecules traditionally used [244].  
The electron micrograph of Ch5 TEM (Fig. 55) and Fmoc5 (Fig. 56) both show that the self 
assemblies formed in aqueous solution are nano aggregates. The size estimation from the 
TEM micrographs (Ch5, <100 nm) were lower than the size found using PCS (Ch5, 183 
nm). This is due to the fact that PCS measures the hydration layer around the particles 
giving rise to the larger size. Therefore PCS may give more accurate size estimation. 
Overall, the size varied little between the modified polymers formed. However the greatest 
factor affected was the CAC value. This was particularly apparent when conducting the 
surface tension measurements. The polymers with planar aromatic groups (Fmoc and 
Naphth), showed two CAC values, whereas the polymers with cholesteryl and Dansyl 
group only showed one. Interestingly this indicated that the planar aromatic pendant 
groups and the bulkier pendant groups resulted in the formation of self-assemblies in two 
very different manners in the aqueous environment. 
The surface tension graph for the Ch5 and for the Dansyl5 showed the presence of only 
one CAC value (0.093 and 0.5 mgmL-1, respectively) (Fig. 47). Below the CAC values, no 
self-assemblies formed, while above the CAC values, the surface tension measurement 
remained constant, even at concentrations of up to 3 mgmL-1. This suggested that only 
one aggregation mechanism was present, i.e. intermolecular aggregation. The surface 
tension value varied with hydrophobic pendant group, Ch5 exhibited a much lower CAC 
value than the Dansyl5 . Lower CAC values often indicated a higher degree of 
hydrophobicity of the pendant groups, however as previously discussed the dansyl moiety 
was more hydrophobic than the cholesteryl resulting in greater decrease in surface 
tension values [227]. Therefore the reason Ch5 had lowered CAC value can perhaps be 
attributed to the larger bulky groups coming in closer contact at lower concentrations in 
solution driving aggregation formation. This aggregation phenomenon was consistent with 
low molecular weight surfactants which assemble via intermolecular aggregation which 
possess one CAC value. Intermolecular aggregation, where more than one polymer 
strand was coming together to shield their hydrophobic groups in a larger self-assembly 
(Fig. 58).  
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Figure 58. Polymer aggregation model for Ch-PAA and Dansyl-PAA. 
 
The TEM of the Fmoc5 (Fig. 56) showed that at polymer concentrations of 0.3 mgmL-1 self 
assemblies formed, which corresponded with the CAC determination from the surface 
tension measurement (Fig. 47). Self-assemblies produced at this concentration may be 
due to intermolecular aggregation of the polymer (Fig. 59). At higher concentrations of 
Fmoc5 (1 mgmL-1), the self assemblies had decreased in size from 247 nm to 199 nm 
respectively. This was due to polymer intermolecular aggregation forming excimer 
stacking of the hydrophobic pendants, making the self assemblies more compact and 
stable, this was confirmed with the shift of emission on the fluorescent spectra (Fig. 54). 
The larger size observed at 2 mgmL-1 (295 nm) using photon correlation spectroscopy can 
be attributed to a higher number of polymer strands aggregating together with excimer 
formation forming more layered and larger self assemblies. 
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3.5. Conclusion 
Novel comb shaped amphiphilic polymers have been successfully synthesised which are 
able to form nano self-assemblies in aqueous solution. The results showed that the 
presence of different hydrophobic groups gave rise to significant differences in properties 
both with the polymer and their self-assemblies. The presence of a permanent positive 
charge on the polymer backbone due to quaternization also had an impact on the self-
assemblies and their properties in the aqueous solution. Further work needs to be carried 
out to determine the solubilisation capacities of all the modified polymers synthesised. 
 
 
Figure 59. Polymer aggregation model for Fmoc-PAA and Naphth-PAA. 
 86 
 
 
 
 
 
Chapter Four 
Drug Loading of Polymeric self-assemblies 
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4.1. Introduction 
In aqueous environments amphiphilic polymers form polymeric self-assemblies. It has 
been well documented that hydrophobic drugs can become physically encapsulated inside 
the lipophilic core of these self-assemblies [70,75,91,158]. The driving force behind such 
encapsulation can be attributed to hydrophobic interaction forces, whereby the 
hydrophobic drug favours the lipophilic core of the polymeric self-assemblies. 
Traditionally two methods of drug loading in self-assemblies were employed. The first 
method used was called solvent evaporation [245,246], were both the polymer and drug 
were dissolved in organic solvents [245]. The solvents were then removed and the 
resulting residue was reconstituted with water. On the addition of water, self-assembly 
formation was initiated. The second method involves dialysis [218,247]. The polymer and 
drug were again both dissolved in organic solvents and placed inside a dialysis membrane 
and exhaustively dialysed against water [218]. The diffusion of the solvent out of the 
membrane and water into the membrane drives the formation of self-assemblies. The 
excess free drug was also removed via diffusion gradient out of the dialysis membrane. 
However, the self-assemblies were too large and remained inside the dialysis tubing. 
These methods were effective. However, the use of organic solvents in drug loading is not 
favourable. This is due to the possibility that residual organic solvents could remain inside 
the formulation. Organic solvents are toxic and this would lead to problems on 
administration in vivo. 
More recently a much simpler and safer technique has been reported using probe 
sonication [3,76]. Sonication of the amphiphilic polymers in aqueous phase encourages 
aggregation formation. Upon sonication of the nano-aggregates with the desired 
hydrophobic drug, easy and efficient drug loading of the self-assemblies occurs. The lack 
of organic solvents in this drug loading method eliminates the safety concerns associated 
with the previous methods. 
The release of drug from any delivery system is extremely important as it gives an 
estimation of the in vivo fate of the drug [245]. The desired drug release profile is 
dependent upon both the route of delivery and the therapeutic effect required. In oral 
delivery of drugs, it is imperative that the drug is not prematurely released in the upper 
gastrointestinal regions however, it is also essential that the drug is quickly and effectively 
released and not retained in the carrier vehicle [248]. 
Polymeric nano-particles have been extensively investigated for their ability to deliver 
anticancer agents to tumour sites [70,156,249]. Their ability to accumulate in tumour 
tissues due to the enhanced permeability and retention effect (EPR) gives rise to their 
huge popularity in this field. Generally drug release from polymeric self-assemblies occurs 
quicker than from larger micro sized systems [250]. This is due to the increased surface 
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area of the nano-particles giving rise to higher diffusion rates [250]. These polymeric 
systems needs to be stable in the blood and should not release the drug prematurely 
before it reaches its target site. Also it is desirable to achieve controlled release for 
anticancer drug delivery. This would decrease the likelihood of under or over dosing and 
the number of administrations and hence increase patient compliance [251]. In order to 
determine the time taken to release a drug from its carrier system an in vitro release study 
is often performed.  
Consistency of drug release and administration dose depends upon the stability of the 
initial formulation [252]. Every formulation has its unique stability, this is determined by 
assessing the quality of the formulation under various conditions over periods of time i.e. 
temperature, light etc [253]. Although nano-particulate formulations have shown 
widespread potential in drug and gene delivery, their major disadvantage is their poor 
stability in aqueous form [252,253,254]. These systems may exhibit good short term 
stability, however particle aggregation and loss of payload may occur over longer periods 
[254].  
Freeze drying has been considered a good technique to improve stability of nano 
particulate formulations [253]. Freeze drying (or lyophilisation) is a process which removes 
water from the formulations by deep freezing them followed by sublimation of the ice 
crystals under lowered pressure [18]. The freeze dried formulations can then be 
reconstituted with exact amounts of water before administration. 
4.1.1. Model Hydrophobic Drugs 
The model hydrophobic drugs propofol (2,6-diisopropylphenol), prednisolone (1-
dehydrocortisone), griseofulvin ((2S)-trans-7-chloro-2’,4,6-trimethoxy 6’-
methylspiro(benzofuran-2[3H],1’-[2] cyclohexene)3,4’-dione), etoposide (VP-16-213, 4′-
Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside) and  BNIPDaoct 
(Bisnahthalimidopropyldiamino octane) were used in drug solubilisation studies. 
Propofol (Fig. 60) is a commonly used short acting anaesthetic agent with favourable 
pharmacokinetic abilities [255, 256,257,258]. Propofol has an aqueous solubility of 100 
µgmL-1 at 25 ⁰C. Due to its low water solubility it is formulated as oil in water emulsion for 
intravenous administration (10 mgmL-1). However, intravenous administration of the 
emulsion proves very painful to patients and often has to be preceded by an initial 
injection of painkillers [259]. Another problem associated with this formulation is its high 
number of infections within patients [256,258]. It is therefore desirable to develop an 
aqueous based formulation for intravenous administration.  
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CH(CH3)2(H3C)2HC
 
Figure 60.Chemical structure of propofol, molecular weight (MW) = 178 gmol-1, log P = 
4.16 [260]. 
Prednisolone (Fig. 61) is a steroid drug prescribed for the treatment of inflammatory 
conditions for example arthritis, asthma etc. Prednisolone is slightly soluble in water (215 
µgmL-1 at 25 ºC), which results in reduced oral bioavailability [4,261,262]. In order for a 
drug to be administered orally, it must first dissolve in the aqueous GI fluid before drug 
absorption can occur. Prednisolone is currently administered as coated tablets or more 
commonly in a suspension formulation (3 mgmL-1) [263]. The large dose concentration 
needed for therapeutic effect leaves an undesirable taste and many side effects resulting 
in poor patient compliance [263,264]. A formulation is required to increase aqueous 
solubility and oral bioavailability, thereby reducing administration dosage and 
unfavourable taste. 
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Figure 61.Chemical structure of prednisolone, MW = 360 gmol-1, log P = 1.8 [265]. 
Griseofulvin (Fig. 62) is a lipophilic drug with an aqueous solubility of 30 µgmL-1 at 25 ºC 
[266]. The antifungal properties of griseofulvin are used in both animals and humans for 
the treatment of dermatophyte infections [267,268,269].  
C
O
O
CH3Cl
H3CO
OCH3 OCH3O
 
Figure 62.Chemical structure of griseofulvin, MW = 353 gmol-1, log P = 2.2 [272]. 
The hydrophobic nature of the drug results in low solubility in GI tract resulting in poor oral 
bioavailability [265,270]. Currently griseofulvin is administered orally in microcrystalline 
preparations with 500-1000 mgday-1 doses prescribed [269]. However, a great deal of 
intersubject and intrasubject variation is experienced, perhaps due to erratic and 
incomplete absorption of the drug in the GI tract [271].  This results in poor patient dosing 
which may lead to some patients being under dosed while others may be over dosed. A 
formulation used to improve the aqueous solubility of griseofulvin could potentially 
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increase its bioavailability [271]. This would result in lower dosages and a higher dose 
consistency compared to the current market formulations. 
Etoposide (Fig. 63) is one of the most efficient antineoplastic chemotherapeutics used 
today [273,274]. The drug acts as a topoisomerase II inhibitor [274]. DNA topoisomerases 
are enzymes found in the cell nucleus which allow rearrangement of its DNA by making 
transient breaks in the DNA strand [274]. The inhibition of topoisomerase II results in the 
death of cancerous cells [274]. Clinically etoposide is used for treatment of lung, ovarian 
and testicular cancer [273,275,276]. Etoposide has a low aqueous solubility of 148-153 
µgmL-1 [276]. The drug is currently formulated in a cosolvent formulation for parenteral 
routes. However, its poor aqueous solubility has led to precipitation upon dilution in vivo 
[274,276]. 
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Figure 63.Chemical structure of etoposide, MW = 589 gmol-1, log P = 0.698 [277]. 
BNIPDaoct (Fig. 64) is a novel anticancer agent from the bisnaphthalamidopropyl series 
designed by Oliveira and colleagues [278]. Bis-naphthalimide derivatives have been 
reported to possess great potential as cytotoxic drugs for treatment of cancer 
[278,279,280,281,282]. However the compounds exhibited poor solubility in aqueous 
solutions [282]. BNIPDaoct showed negligible aqueous solubility and as a result harsh 
solvents such as DMSO have been needed in order to get the drug into solution [278]. A 
formulation is required to enhance aqueous solubility of BNIPDaoct thus improving its 
antitumor activity and making it more efficient. BNIPDaoct had to be synthesised for this 
study as the novel nature of the drug means it is not commercially available (Appendix 
5.0). 
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Figure 64.Chemical structure of BNIPDaoct, MW= 780.58. 
 
2HBr 
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4.1.2. High performance Liquid Chromatography 
High performance liquid chromatography (HPLC) is perhaps one of the most important 
analytical tools used in the pharmaceutical industry today. Its uses span across a range of 
applications from drug discovery to formulation development and beyond. HPLC allows 
the separation of compounds on the basis of transport of molecules by a mobile phase 
through a stationary phase known as a column [283]. 
Reverse phased (RP) HPLC employs a non polar stationary phase such as carbon or 
silica and a polar mobile phase. Separation of compounds occurs dependant on the 
hydrophobicity of the molecules [283]. Hydrophobicity is governed by polarity and size of 
the molecule. The larger and less polar compounds are retained on the column for longer 
with the smaller polar molecules being eluted first. The versatility of this technique allows 
the separation of polar, non-polar and ionisable compounds, whereby increasing the 
polarity of the mobile phase increases the retention time of non-polar molecules in the 
column. 
 
4.1.3. Aims and Objectives 
The aim of this study focuses on the ability of amphiphilic poly(allylamine) (PAA) comb 
shaped polymers to form polymeric self-assemblies capable of solubilising hydrophobic 
compounds. HPLC analysis will be carried out to determine the maximum drug loading 
capacity of the polymers for each of the 5 drugs (propofol, prednisolone, griseofulvin, 
etoposide and BNIPDaoct). The optimal formulations will be characterised using photon 
correlation spectroscopy (PCS), fourier transform infrared spectroscopy (FTIR) and 
transmission electron microscopy (TEM). In vitro drug release profiles will be determined 
by HPLC. The formulations will be freeze dried. A stability study over one month will be 
carried out to determine optimal storage conditions for the freeze dried and solution 
formulations. 
 
 
 
 
 
 
 
 92 
4.2. Materials and Methods 
4.2.1. Materials used 
Material Supplier 
Modified PAA polymers Synthesised in Chapter Two 
Propofol Sigma-Aldrich Co., UK 
Prednisolone Sigma-Aldrich Co., UK 
Griseofulvin Sigma-Aldrich Co., UK 
Etoposide Sigma-Aldrich Co., UK 
BNIPDaoct Synthesised in section 4.3.1 
0.45µm GDX PVDF filters Whatman, UK 
HPLC grade methanol Fisher Scientific, UK 
HPLC Grade acetonitrile Fisher Scientific, UK 
Highly purified water MillexQ system (UK) 
Orthophosphoric acid Sigma-Aldrich Co., UK 
Potassium dihydrogen phosphate Sigma-Aldrich Co., UK 
Octane sulfonic acid  Sigma-Aldrich Co., UK 
Anhydrous sodium acetate Sigma-Aldrich Co., UK 
Phosphate buffered saline Fisher Scientific, UK 
 
4.2.2. Methods 
4.2.2.1. Synthesis and Characterisation of BNIPDaoct (Bisnaphthalimido propyl 
diaminooctane) 
Fig. 65 shows the reaction pathway for the synthesis of BNIPDaoct. The reactions were 
carried out stepwise with the product from each step being fully characterised to ensure 
completion of the reactions and the purity of the compound.  For synthesis method see 
Appendix 5.0. 
 
 
 93 
 
Naphthalic Anhydride                       Polyamine 
 
  Naphthalimidoalcohol 
 
o-Tosylated napthalimide        +   Protected polyamine 
 
    Protected bisnaphthalimido derivative 
 
   Bisnaphthalimidopropyldiaminooctane (BNIPDaoct) 
 
Figure 65. Synthetic pathway for BNIPDaoct. 
4.2.2.2. Drug Loading of Nano-particles 
Polymer solutions of 1 mgmL-1, 3 mgmL-1 and 6mgmL-1 were made up in deionised water 
and probe sonicated for 10 min to ensure aggregation of the self-assemblies was 
achieved. The hydrophobic drug was added in 1:1, 5:1 and 10:1 initial drug:excipient 
weight ratios and the drug-polymer solutions were probe sonicated for a further 10 min to 
ensure maximum encapsulation was achieved. After cooling to room temperature, the 
solutions were filtered using 0.45 µm syringe filters (with prefilters) to ensure any excess 
unencapsulated drugs were removed.  
4.2.2.3. Determination of Drug Loading Capacity 
4.2.2.3.1. Solubilisation of Propofol 
The drug loading capacity of the self-assemblies was determined using high performance 
liquid chromatography (HPLC) (Shimadzu prominence UFLC, UK), as previously reported 
by Qu and colleagues [203]. A RP Zorbax ODS 250 mm x 46 mm x 5 µm HPLC column 
(Hichrom, UK) was used with flow rate of 1 mLmin-1 (80:20 v/v methanol:water) in an 
isocratic mode. The samples were diluted with mobile phase and 20 µL was injected onto 
the column. The resultant peak at 7 min was analysed at 229 nm (Shimadzu prominence 
UFLC, UK). The amount of propofol present in the samples was determined by comparing 
to a standard calibration carried out previously with propofol dissolved in methanol (4 
µgmL-1 – 250 µgmL-1), R2 = 0.999.  
(i) 
(ii) 
(iii) 
(iv) 
(v) 
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4.2.2.3.2. Solubilisation of Prednisolone 
The content analysis of prednisolone in the formulation was carried out using an HPLC 
consisting of a RP Phenomenex C18 150 mm x 4.6 mm x 3.5 µm column with the mobile 
phase at 1 mLmin-1 in an isocratic mode. A UV detector (Shimadzu prominence UFLC, 
UK) was set at 243 nm. A mobile phase of 36:64 (v/v) acetonitrile:water was run through 
the column and 20 µL of sample was injected each time. The retention of the peak was 3 
min. Prednisolone content in the samples was quantified by comparing to a standard 
calibration of prednisolone dissolved in acetonitrile:water 36:64 (v/v)  (6 µgmL-1 – 25 
µgmL-1), R2 = 0.999. 
4.2.2.3.3. Solubilisation of Griseofulvin 
This method was an adaptation of Trimaille’s method [284]. The samples were passed 
through a RP Phenomenex C18 250 mm x 46 mm x 5 µm HPLC column and detected at 
293 nm (Shimadzu prominence UFLC, UK). The mobile phase (45:55 v/v) acetonitrile:45 
mM potassium dihydrogen phosphate made up in water and pH adjusted to pH3 with 
orthophosphoric acid) ran at a rate of 1 mLmin-1. The samples were diluted with mobile 
phase and 20 µL was injected onto the column, the resultant peak at 9.5 min was 
analysed. The quantification of griseofulvin present in the samples was determined from a 
standard calibration of griseofulvin in mobile phase (0.6 µgmL-1 – 10 µgmL-1), R2 = 0.999.  
4.2.2.3.4. Solubilisation of Etoposide 
Etoposide content was carried using an adaptation of Dandaundi’s method [285]. The 
formulations were passed through a RP Zorbax ODS 250 mm x 46 mm x 5 µm HPLC 
column was used with flow rate of 1 mLmin-1 of the mobile phase (40:3:57 v/v/v) 
methanol:acetonitrile:water). The column eluent was monitored at 229 nm (Shimadzu 
prominence UFLC, UK). The samples were diluted with mobile phase and 20 µL was 
injected onto the column, the resultant peak at 20 min was analysed for peak area using 
the HPLC software (Shimadzu prominence UFLC, UK). The drug content was determined 
using a calibration graph of etoposide in methanol (31 µgmL-1 - 500 µgmL-1), R2 = 0.999. 
4.2.2.3.5. Solubilisation of BNIPDaoct 
BNIPDaoct concentration in self-assemblies was analysed using a RP Zorbax ODS 250 
mm x 46 mm x 5 µm HPLC column. The mobile phase consisted of 55:45 (v/v) 
buffer:acteonitrile with a flow rate of 1 mLmin-1. The buffer for the mobile phase was made 
up of octane sulfonic acid (0.432 g) and anhydrous sodium acetate (1.64 g) in 200 mL 
with deionised water with the pH adjusted to pH 4.5. The column eluent was monitored at 
234 nm excitation and 394 nm emission, using a fluorescent detector (Shimadzu 
prominence UFLC, UK). The samples were diluted with the mobile phase and 20 µL was 
injected onto the column, the resultant peak at 10 min was analysed. A calibration was 
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carried out by dissolving BNIPDaoct in DMSO:water (50:50 (v/v)) (39 - 625 µgmL-1), R2 = 
0.999. 
4.2.2.4. Sizing of Nano-aggregates 
Size measurements were determined for drug formulations using photon correlation 
spectroscopy (PCS). This was carried out as previously reported in section 3.2.2.1. 
4.2.2.5. Transition Electron Microscopy 
The optimal formulations were viewed under the transmission electron microscope (TEM) 
as described in section 3.2.2.3. 
4.2.2.6. FTIR analysis of freeze dried Formulations 
The optimal freshly prepared formulations (as described in 2.2.2.2.3) were freeze-dried. 
The freeze-dried preparation was run on the fourier transform infrared (FTIR) with a 
diamond tip and the peaks identified and compared to the spectra obtained for the freeze-
dried free drug and unloaded polymer separately. 
4.2.2.7. In vitro drug release 
The formulation (2 mL) was pipetted inside dialysis tubing (MW cut off = 12-14 kDa) and 
dialysed against PBS in sink (200 mL, 0.2 M) at 37 ºC with stirring. At various time points 
1 mL of the external PBS was extracted and replaced with 1 mL of fresh PBS. The 
presence of drug in the collected PBS was determined using HPLC (see sections 
4.2.2.3.1 - 4.2.2.3.5), according to the method of Lee et al. [286]. 
4.2.2.8. Stability of Formulations 
The formulation for each drug was prepared as described in 4.2.2.2. were stored in both 
their freeze dried and solution forms, in air tight desiccators (55 % humidity) at room 
temperature and in dark conditions. After set time periods, the formulations were 
examined by HPLC analysis to quantify the amount of drug encapsulated by the polymeric 
nano-aggregates. The formulation stability testing was carried out both in solution and in 
freeze-dried formulations which were reconstituted with water before testing. 
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4.3. Results  
4.3.1. Synthesis of BNIPDaoct 
BNIPDaoct was successfully synthesised. Characterisation confirmed the pure product 
was produced and its 1H, 13C and Dept NMR data correlated well with the published data 
(Appendix 5.0) [278]. 
4.3.2. Drug Loading of Nano-particles 
4.3.2.1. Solubilisation of Propofol 
All polymeric nano-aggregates (1, 3 and 6 mgmL-1) were loaded with propofol in 1:1, 5:1 
and 10:1 drug:polymer mass ratio. HPLC was used to determine the maximum loading 
concentration for each polymer. Fig. 66 shows a typical HPLC spectra for propofol. The 
retention time for this drug was around 7 min. 
Figure 66.Reverse phase HPLC chromatogram of propofol detected at 229 nm.  
The amount of solubilised propofol ranged from 0.19 to 22.4 mgmL-1 (QDansyl5 and 
Dansyl10 respectively). The maximum concentration solubilised by each of the amphiphilic 
polymers is shown in Figure 67. Both Ch5 and Dansyl10 (6 mgmL-1, at initial drug:polymer 
loading ratio of 10:1) proved excellent in the solubilisation of propofol. These polymers 
improved the aqueous solubility up to 78-fold and 223-fold respectively (Fig. 67). These 
formulations possessed excipient to drug levels as low as 0.77 and 0.13 respectively. 
However, the quaternized counterparts of all the modified polymers were not as effective 
with a maximum of 1.05 mgmL-1 propofol solubilised by Ch5. 
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Figure 67.Maximum propofol concentration   solubilised by each modified polymer (6 
mgmL-1) at 1:1, 5:1 or 10:1 initial drug:polymer loading ratios determined by HPLC, 
compared to the intrinsic solubility (n=3, ave ± SD).  
 
Figure 68 shows the relationship between the initial mass feed ratio of drug:polymer. For 
the cholesteryl self-assemblies (Fig. 68a) a trend is observed whereby the higher the 
initial drug:polymer loading ratio the greater the concentration of propofol solubilised. Also 
it is apparent that the higher the polymer concentration, the higher the concentration of 
propofol in formulation. For Ch5 and QCh5 the optimal level of drug loading was observed 
with 6 mgmL-1 polymer and with 10:1 drug:polymer ratio, however the QCh5 loading was 
notably poor compared with the Ch5.  
 
 
 
 
 
 
 
 
 
  1:1   1:1  10:1 
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Figure 68. Propofol solubilisation capacity in a) cholesteryl, b) fmoc and c) dansyl self-
assemblies in aqueous solution at 1, 3 and 6 mgmL-1 with 1:1, 5:1 and 10:1 drug:polymer 
initial mass loading ratio (n=3, ave ± SD). 
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Fmoc modified self-assemblies showed a much different trend to the cholesteryl polymers 
(Fig. 68b). At lower polymer concentrations both the Fmoc5 and Fmoc10 appeared to load 
the maximum concentration of propofol at 5:1 drug:polymer initial feed ratio. However at 
higher polymer concentration this was not true. At 6mgmL-1, the optimal propofol loading 
was achieved at 1:1 drug:polymer ratio. This could be due to a number of reasons. 
Perhaps this phenomenon was due to the expansion of the self-assembly to 
accommodate larger quantities of propofol resulting in large aggregates which may have 
been removed during the filtration process [117]. It was also observed that at higher 
grafting levels of fmoc, greater propofol solubilisation occurred. This perhaps was due to 
higher hydrophobic content of polymer allowing greater hydrophobic interaction between 
the drug and the core without destabilisation of the aggregates. The optimal propofol 
formulations with Fmoc5 and Fmoc10 were at 6mgmL-1 and 1:1 drug:polymer ratio with 
0.46 and 0.69 mgmL-1 of drug being solubilised respectively. 
 
The dansyl modified self-assemblies showed an interesting change in drug loading profile 
with the addition of more hydrophobic content on the polymer (Fig. 68c). At 5 % molar 
grafting the self-assemblies encapsulated the highest propofol concentration at 5:1 
drug:polymer ratio. This was witnessed for all polymer concentrations (1,3 and 6 mgmL-1). 
This could be attributed to the aromatic dansyl groups not being hydrophobic enough to 
cope with the ‘bombardment’ of excess drug entering their core causing collapse of their 
aggregates as witnessed with the fmoc polymers or simply that no more drug could 
physically fit inside the core. However, at 10 % molar grafting of the dansyl nano-
aggregates, the trend observed was similar to that of the cholesteryl polymers. The 
highest solubilisation of propofol using Dansyl10 (22.4 mgmL-1) occurred at 6 mgmL-1 
polymer concentration at 10:1 drug:polymer initial feed ratio. This formulation improved 
the aqueous solubility of propofol 223-fold. 
 
The excipient:drug ratio is the relative amount of polymer needed to solubilise 1mgmL-1 of 
drug. For cholesteryl and dansyl PAA self-assemblies, the excipient:drug ratio decreases 
with increasing polymer concentration and increasing drug:polymer initial feed ratio of 
hydrophobic drug (Fig. 69). However, the excipient:drug ratios were independent of the 
initial drug:polymer loading ratio, whereby the amount of drug initially loaded did not 
directly affect the actual concentration of drug solubilised. The Fmoc formulations did not 
seem to follow the solubilisation trend. Whereby, at higher polymer concentrations, lower 
excipient:drug ratios were observed and increasing the initial drug loading ratio resulted in 
lower excipient:drug ratios. Higher levels of grafting in fmoc modified self-assemblies 
show lower excipient:drug ratios due to more drug being encapsulated at higher degrees 
of grafting as previously discussed. 
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The quaternized counterparts possess higher excipient:drug ratios, confirming that these 
polymers were less effective than the non-quaternized polymers, therefore more polymer 
was needed to solubilise a smaller amount of the drug. This relationship is an inverse 
relation of the solubilisation data (Fig. 68).  
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Figure 69. Excipient:drug ratio of propofol formulations in a) cholesteryl, b) fmoc and c) 
dansyl self-assemblies at increasing drug:polymer loading ratios. 
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The propofol solubilisation study could not be carried out using the Naphth polymers as 
their inherent fluorescent excitation was around the same wavelength as the propofol and 
thus interference was observed on the HPLC spectra (Fig.70). An attempt was made to 
separate the peaks using a range of techniques including altering the mobile phase and 
flow rates, however, no peak separation was achieved. Therefore it was decided not to 
carry out any further solubilisation studies on the Naphth polymers. 
 
Figure 70. HPLC spectra of Naphth5 and propofol formulation showing overlapping peaks. 
 
4.3.2.2. Solubilisation of Prednisolone 
The propofol drug loading study helped to deduce which polymers were good at drug 
loading. This was useful as it helped to narrow the range of polymers used for the 
prednisolone drug loading. As all the previous quaternized compounds seemed to be 
inefficient at drug loading, only one quaternized polymer was used for the prednisolone 
study (QCh5). No Naphth polymers were tested as no previous data could be gained. The 
polymers were tested at 1, 3 and 6 mgmL-1 and using 1:1, 5:1 and 10:1 drug:polymer 
mass loading ratios. 
 
Figure 71. Reverse phase HPLC chromatogram of prednisolone detected at 243 nm.  
 
The retention time for prednisolone was around 3 mins (Fig. 71). Maximum solubilisation 
achieved ranged from 2.05 to 31.82 mgmL-1 (QCh5 and Dansyl10 respectively) (Fig. 72). 
Dansyl10 was the most effective system as 31.82 mgmL-1 of drug was solubilised which 
was 100-fold improvement of its aqueous solubility giving and excipient:drug ratio of only 
0.19. The solubilisation capacity QCh5 (2.05 mgmL-1) was significantly lower than Ch5 
(7.05 mgmL-1) consistent with propofol; therefore no further analysis was carried out on 
the quaternized compounds.  
Naphth polymer  
peaks 
Propofol peak 
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Figure 72. Maximum prednisolone concentration solubilised by each modified polymer (6 
mgmL-1) at different 1:1, 5:1 or 10:1 initial drug:polymer loading ratios, determined by 
HPLC, compared to the intrinsic solubility (n=3, ave ± SD). (Fmoc5 and Dansyl5 polymer 
concentration 3 mgmL-1). 
 
Figure 73 shows the concentration of prednisolone solubilised at each concentration (1,3 
and 6 mgmL-1) and drug:polymer ratio. In general the prednisolone loading of the self-
assemblies generally increased with increasing polymer concentration except Fmoc5 and 
Dansyl5. Increasing initial drug:polymer mass loading ratio, resulted in lower  
excipient:drug ratio’s as total drug encapsulated increased (Fig. 74). This trend correlated 
well with the trend observed for the propofol solubilisation study. Fmoc5 proved an 
exception to the trend as its maximum drug loading was at 3 mgmL-1 and at 5:1 initial 
drug:polymer loading ratio. Perhaps as previously discussed for the propofol solubilisation 
the Fmoc5 hindered drug solubilisation at higher concentrations due to excimer formation 
or excess drug entering the hydrophobic core resulted in core destabilisation and 
ultimately collapse of the self-assembly. 
 
The excipient:drug ratios for prednisolone formulations (Fig. 74) formed unique patterns. 
For Ch5 (Fig. 74a) at the highest polymer concentration of 6 mgmL-1 the excipient:drug 
ratio appeared to be dependent on the initial drug:polymer mass loading ratio. This meant 
that the higher the initial feed of the hydrophobic drug to the polymer self-assemblies, the 
more efficient the aggregates became at encapsulating the drug within their lipophilic 
core. This phenomenon was also witnessed for 1 mgmL-1 QCh5. The rationale behind this 
dependant drug loading is that with increasing drug content a greater driving force for 
hydrophobic interactions is experienced and ultimately drug encapsulation is increased 
thus decreasing the excipient:drug ratio. For all other Ch5 and QCh5 polymer 
concentrations the excipient:drug ratio appeared independent whereby the initial feed of 
drugs did not influence the encapsulation efficiency of the self-assemblies. This 
phenomenon is not well understood however it may be due to external forces determining 
the drug loading ability of the self-assemblies such as steric hindrance, core stability etc. 
10:1 
10:1 
10:1 
10:1 
5:1 
10:1 
 103 
 
For all the concentrations of Fmoc5 and Fmoc10 the excipient:drug ratio was independent 
of the initial drug:polymer mass loading ratio (Fig. 74b). However, at 1 mgmL-1 Fmoc5 the 
graph showed an interesting trend. The excipient:drug ratio appeared to be dependant up 
to 5:1 mass loading ratio. However with further increase of the loading ratio to 10:1 the 
efficiency of the system remained constant (and the graph plateaued). A similar trend was 
observed for 6 mgmL-1 Dansyl5 however at the increased 10:1 loading ratio the efficiency 
decreased i.e. Higher excipient:drug ratio. The reason for this trend is unknown, however, 
it could be attributed to the previously discussed ‘limiting factors’ in the drug loading of 
these self-assemblies. Whereby, the formation of excimers by the Fmoc10 or steric 
hindrance of the prednisolone within the self-assemblies or destabilisation of the core 
occurred at increased drug loading ratio. All other concentrations of Fmoc5 and Fmoc10 
appeared to be independent. 
 
At 3 mgmL-1 Dansyl5 and 6 mgmL-1 Dansyl10 the excipient:drug ratio for prednisolone 
loading appeared to be dependant upon concentration and initial loading ratio (Fig. 74c). 
Interestingly for Ch5 and Dansyl10 the polymer concentrations for which a dependant trend 
was observed, were the concentrations were maximum drug solubilisation occurred (6 
mgmL-1). This would suggest in order to achieve an efficient system, it is desirable to have 
a inverse linear relationship between the excipient:drug ratio and the initial drug:polymer 
mass loading ratio. Whereby, at higher drug loading concentrations, higher drug 
encapsulation is achieved, thus, lowering the excipient:drug ratio (QCh5 is an exception to 
this theory as all of the solubilisation studies showed low drug encapsulation). Not 
surprisingly the Ch5 and Dansyl10 achieved the lowest excipient:drug ratio, Fmoc5, Fmoc10 
and QCh5 were least efficient, this data correlated well with the drug solubilisation data 
(Fig. 73). 
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Figure 73. Prednisolone solubilisation capacity in a) cholesteryl, b) fmoc and c) dansyl 
self-assemblies in aqueous solution at 1, 3 and 6 mgmL-1 with 1:1, 5:1 and 10:1 
drug:polymer initial mass loading ratio (n=3, ave ± SD). 
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Figure 74. Excipient:drug ratio of prednisolone formulations in a) cholesteryl, b) fmoc and 
c) dansyl self-assemblies at increasing drug:polymer loading ratios. 
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4.3.2.3. Solubilisation of Griseofulvin 
When comparing the solubilisation data for propofol and prednisolone, two polymers 
consistently stood out as excellent solubilising agents, these were Ch5 and Dansyl10. The 
optimal initial drug loading ratio and the most effective polymer concentration were chosen 
based on the previous model hydrophobic drugs. Therefore all subsequent experiments 
will use these ratios and concentrations for the Ch5 and Dansyl10 polymers. 
 
Figure 75. Reverse phase HPLC chromatogram of griseofulvin detected at 293 nm.  
The retention time for griseofulvin detection on the HPLC was around 9 min (Fig. 75). Ch5 
and Dansyl10 were capable of solubilising 1.2 and 16.7 mgmL-1 griseofulvin (Table 13).  
This was an increase in the aqueous solubility (0.03 mgmL-1) by 40-fold and 557-fold 
respectively. The Dansyl10 had an extremely low excipient:drug ratio of 0.34, this result 
was consistent with the low ratios obtained for the prednisolone and propofol formulations. 
 
Table 13.Griseofulvin loading capacity in modified polymers determined using reverse 
phase HPLC n=3, ave (SD). 
Polymer Polymer 
Conc. 
(mgmL-1) 
Initial 
Drug:Polymer 
Mass Ratio 
Concentration 
of Griseofulvin 
solubilised 
(mgmL-1) 
Excipient:Drug 
Ratio after 
solubilisation 
Increment 
from 
griseofulvin 
aqueous 
solubility 
Ch5 6 10:1 
 
1.200 (0.017) 5.00 40 Fold 
Dansyl10 6 10:1 16.710 (4.121) 0.34 557 Fold 
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4.3.2.4. Solubilisation of Etoposide 
 
 
Figure 76. Reverse phase HPLC chromatogram of etoposide detected at 229 nm.  
 
 
Etoposide was detected at around 5 min (229 nm) (Fig. 76). Table 14 shows that Ch5 and 
Dansyl10 were capable of solubilising up to 1.0 and 1.9 mgmL-1 of etoposide respectively. 
Consistent with the previous solubilisations studies, Dansyl10 was the most efficient with a 
13-fold increase from the aqueous solubility of the drug (0.15 mgmL-1). However, 
etoposide solubilisation was relatively lower compared to all the other model drugs 
(excipient:drug ratio of 3.17 for Dansyl10). 
 
 
 
Table 14.Etoposide loading capacity in modified polymers determined using reverse 
phase HPLC for each drug:polymer ratio n=3, ave (SD). 
Polymer Polymer 
Conc. 
(mgmL-1) 
Initial 
Drug:Polymer 
Mass Ratio 
Concentration 
of Etoposide 
solubilised 
(mgmL-1) 
Excipient:Drug 
Ratio after 
solubilisation 
Increment 
from 
etoposide 
aqueous 
solubility 
Ch5 6 
 
10:1 1.020 (0.040) 5.88 7 Fold 
Dansyl10 6 10:1 1.890 (0.011) 3.17 13 Fold 
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4.3.2.5. Solubilisation of BNIPDaoct 
The solubilisation study for BNIPDaoct yielded some strange results. Fig. 77 shows an 
HPLC spectrum for the drug at low concentration (0.039 mgmL-1 in DMSO:Water (50:50 
v/v)). A signal peak is observed at around 7 min. 
Figure 77. Reverse phase HPLC chromatogram of BNIPDaoct detected at 394 nm 
emission. 
At polymer concentration of 1 mgmL-1, Ch5 was capable of solubilising 0.3 mgmL-1 of the 
drug using 1:1 initial drug:polymer mass ratio (Table 15). Previously all studies to find an 
aqueous solubility of BNIPDaoct yielded no results as the aqueous solubility was 
negligible. Therefore the increment increase from aqueous solubility could not be 
determined. The excipient:drug ratio was 3.33. However on loading the drug at higher 
polymer concentrations using higher initial drug:polymer mass ratios, the HPLC spectra 
changed dramatically. Fig. 78 shows the HPLC spectra of 1 mgmL-1 Ch5 at 1:1, 5:1 and 
10:1 initial drug:polymer mass ratios. 
 
Table 15.BNIPDaoct loading capacity in modified polymers determined using reverse 
phase HPLC for each drug:polymer ratio n=3, ave (SD). 
Polymer Polymer 
Conc. 
(mgmL-1) 
Initial 
Drug:Polym
er Mass 
Ratio 
Concentration 
of BNIPDaoct 
solubilised 
(mgmL-1) ±SD 
Excipient:Drug 
Ratio after 
solubilisation 
Increase 
from 
BNIPDaoct 
aqueous 
solubility 
Ch5-PAA 1 1:1 0.3 (0.01) 3.33 - 
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Figure 78.HPLC spectra of BNIPDaoct using 1 mgmL-1 of Ch5 at a) 1:1 b) 5:1 c) 10:1 
initial drug:polymer mass ratios. 
 
a) 
b) 
c) 
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Previous Ch5 solubilisation studies demonstrated that increased initial drug:polymer mass 
ratio resulted in increased drug solubilisation capacity. It was therefore assumed that by 
increasing the initial drug:polymer mass ratio (Fig. 78) of BNIPDaoct, the actual 
concentration solubilised would also be increased. As the concentration of solubilised 
drug increased (even upon extensive dilution) additional peaks were observed on the 
spectra making it inaccurate for determination of drug loading concentration. These extra 
peaks were observed when using the Dansyl10 polymer also. Therefore no further 
solubilisation data for Ch5 or Dansyl10 could be obtained. However, the assumption made 
could be visually confirmed as at higher initial drug:polymer mass ratios the formulations 
appearance changed from translucent white and yellow (Ch5 and Dansyl10 polymer alone 
respectively) to orange. This change in colour can be attributed to the solubilisation of 
drug as it was an orange solid compound. The orange colour appeared sequentially 
darker from 1:1 to 5:1 to 10:1 ratios suggesting more drug had been solubilised. 
The reason for this phenomenon is unknown. However, one possible explanation is that 
higher drug concentrations may result in the formation of drug conformers. Conformers 
are different structural configurations of the same molecule. These may have been 
retained at different times on the HPLC column, giving rise to extra peaks. However, since 
these peaks were not found in the calibration, addition of the peak areas of the 
hypothesised isomer peaks would be inaccurate. 
 
4.3.3. Photon correlation spectroscopy 
The hydrodynamic size of optimal formulations for each drug was determined by a photon 
correlation spectrometer (Table 16).  
The Ch5 alone had a size of 295 nm. Interestingly the pattern of the size measurements 
seemed to follow the pattern of the drug loading capability. The propofol loaded self-
assemblies had the largest amount of propofol solubilised (7.80 mgmL-1) and size (666 
nm), followed by the prednisolone with solubilisation of 7.05 mgmL-1 and a size of 304 nm. 
The Ch5 self-assemblies containing griseofulvin were only capable of solubilising 1.2 
mgmL-1 of drug and the size measurement also followed this trend with a size of only 284 
nm. This indicated that the larger the particle size of the loaded self-assemblies, the 
higher concentration of hydrophobic drug encapsulated. The size of the griseofulvin 
loaded micelles appeared to be smaller than the unloaded self-assemblies; this possibly 
suggests a strong interaction was being experienced in the core of the micelle, resulting in 
a compact formation of the assemblies. 
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Table 16.Photon correlation spectrometry size analysis of optimal Ch5 and Dansyl10 
formulations at 6 mgmL-1 with initial drug:polymer mass ratio of 10:1, (n=3, ave). 
Polymer / Formulation Size (nm) 
mean (SD) 
PDI 
mean ±SD 
Ch5 alone 296 (4) 0.285 (0.004) 
Ch5,propofol 666 (79) 0.376 (0.025) 
Ch5, prednisolone 304 (4) 0.318 (0.014) 
Ch5, griseofulvin 284 (6) 0.209 (0.012) 
Ch5, etoposide 654 (24) 0.392 (0.011) 
Ch5,BNIPDaoct 183 (2) 0.167 (0.001) 
Dansyl10 alone 126 (8) 0.465 (0.022) 
Dansyl10, propofol 608 (49) 0.385 (0.009) 
Dansyl10, prednisolone 350 (4) 0.369 (0.007) 
Dansyl10, griseofulvin 305 (7) 0.254 (0.007) 
Dansyl10,etoposide 886 (115) 0.425 (0.012) 
 
The size of the Dansyl10 polymer was 126 nm; this was significantly smaller than the drug 
loaded self-assemblies. The inner hydrophobic core possessed the ability to expand to a 
higher degree and therefore encapsulate a high drug concentration. The propofol loaded 
system had the greatest size of 608 nm, followed by the prednisolone loaded system with 
350 nm, and with griseofulvin having the smallest size of 305 nm. The size trend observed 
for the Dansyl10 formulations were similar to the trends for the size of the Ch5 formulations. 
The formulations loaded with griseofulvin were consistently smaller than for the propofol 
and prednisolone formulations; however the Dansyl10, griseofulvin still has a larger size 
compared to Dansyl10 unloaded self-assemblies which is different from the Ch5, 
griseofulvin formulation. 
On loading the Ch5 and Dansyl10 self-assemblies with etoposide, both the self-assemblies 
appeared to experience a large increase in size (Table 16). The Ch5  (296 nm) increased 
to 654 nm whilst the Dansyl10 (126 nm) increased to 886 nm upon encapsulation of the 
drug. This appeared to be a large increase considering the low concentration of etoposide 
encapsulated within the formulations (1.02 mgmL-1 and 1.89 mgmL-1 Ch5, etoposide and 
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Dansyl10, etoposide respectively). However, the large size of the self-assemblies size can 
be attributed to the large molecular size of the etoposide drug physically expanding the 
inner core of the aggregates. 
4.3.4. Negative staining transmission electron microscopy 
Optimal formulations were sent for TEM imaging. The TEM micrographs of the Ch5 and 
Ch5 formulations (Figure 79) show clearly the formation of aggregates. The Ch5 alone and 
all the Ch5 formulations appear to form solid nano-particles at 6 mgmL-1.  The sizes 
observed on the micrographs follow a similar trend to the PCS, however, the size of the 
nano-aggregates observed in the TEM micrographs appear smaller than the results 
obtained by PCS (Table 16). This may be due to the fact that PCS measures the 
hydrodynamic size around the particle (including its hydration layer) and thus results in a 
higher size estimation. 
The TEM micrographs of Dansyl10 and Dansyl10 formulations (Fig. 80) show that nano-
particles are formed at 6 mgmL-1 of the polymer in solution and the resultant formulations. 
However, the sizes observed on the micrographs do not follow the same trend as the 
previous PCS results. The Dansyl10, propofol and Dansyl10, prednisolone formulation 
appear to be smaller in size when compared with the Dansyl10, griseofulvin formulation. 
The reason for the change in trend is unknown; however, it may be possible that as a 
result of sample preparation the nanoparticle collapsed appearing to form smaller 
particles.  The Dansyl10, etoposide (Fig. 80 e) appears to have formed clusters, which 
perhaps accounts for its large size on the PCS. 
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        a)        b) 
               
        c)         d) 
 
e) 
Figure 79. a) Negative-stained TEM of a filtered (0.45 µm) aqueous dispersion of Ch5 on 
probe sonication in water (bar=500 nm), b) Ch5, propofol (bar= 1 µm), c) Ch5, prednisolone 
nano-particles, d) Ch5, griseofulvin  (bar=200 nm)  and e) Ch5,  etoposide (bar= 500nm). 
All the formulations consisted of 6 mgmL-1 polymer and 10:1 initial drug:polymer mass 
ratio. Arrows show drug loaded self-assemblies. 
  500nm 
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    a)            b) 
              
    c)        d) 
 
      e) 
Figure 80. a) Negative-stained TEM of a filtered (0.45 µm) aqueous dispersion of 
Dansyl10 on probe sonication in water (bar=200 nm), b) Dansyl10, propofol (bar= 200 nm), 
c) Dansyl10, prednisolone nano-particles (bar=200 nm), d) Dansyl10, griseofulvin (bar=200 
nm)  and e) Dansyl10, etoposide  (bar= 500 nm). All the formulations consisted of 6 mgmL-
1 polymer and 10:1 initial drug:polymer mass ratio. Arros show drug loaded self-
assemblies formed. 
  500nm 
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4.3.5. FTIR Analysis of freeze dried formulations 
The FTIR spectrum of the freeze dried preparations were obtained in order to confirm the 
presence of functional groups of the drug and polymer.  
4.3.5.1. FTIR of Ch5 formulations 
4.3.5.1.1. FTIR of Ch5, propofol formulation 
Figure 81 c) shows the FTIR spectra obtained from the Ch5, propofol formulation. The 
presence of the O-H peak at 3600 cm-1 and the ortho substituted aromatic benzene peaks 
at 748 cm-1 were the functional groups present on the propofol moiety. This indicated that 
propofol had been successfully encapsulated in the formulation. All peak assignments can 
be seen in Table 17. 
Table 17.Peak bandwidth assignment occurring on FTIR spectra of Ch5, propofol 
formulation using diamond powder tip (20scans). 
Formulation Bandwidth (cm-1) Bond type Functional Group 
3600 
 
O-H Stretch Hydroxyl  (propofol) 
3300 
1640-1560 
 
N-H Stretch 
 2⁰ Amine (Ch5) 
3100 
748 
 
C-H Stretch Aromatic (propofol) 
Ortho subs benzene 
2962 
1460 
 
C-H Stretch Alkyl (Ch5) 
1600 
 
C=O Bend Carbonyl (Ch5) 
1311 C-C Bend  
 
Alkyl (Ch5) 
Ch5, propofol 
 
815 C-O Bend   (Ch5) 
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Figure 81. FTIR spectra of a)Ch5, b) propofol and c) Ch5, propofol formulation.  
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c) 
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Propofol 
Ch5, propofol 
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4.3.5.1.2. FTIR of Ch5, prednisolone formulation 
Peak assignment of the FTIR spectra obtained for the Ch5, prednisolone formulation (Fig. 
82 c) confirmed the presence of the drug in formulation. This was due to the presence of 
the hydroxyl band at O-H (3404 cm-1) and the C=O (1720 cm-1) of the 6 membered 
carbonyl ring, these groups were not present in the spectra for Ch5 alone and therefore 
can be attributed to the drug molecule. Full peak assignment can be viewed in Table 18. 
The large negative peak observed at 2350 cm-1 was due to changes in the background 
CO2. 
 
Table 18. Peak bandwidth assignment occurring on FTIR spectra of Ch5, prednisolone 
formulation using diamond powder tip (20scans). 
Formulation Bandwidth (cm-1) Bond type Functional Group 
3404 O-H Stretch 
 
Hydroxyl (prednisolone) 
1656 
 
N-H Stretch 
 2⁰ Amine (Ch5) 
900-850 
 
C-H Bend Aromatic  (prednisolone) 
Subs benzene 
2923 
1460 
 
C-H Stretch Alkyl  (Ch5) 
1720 C=O Bend Carbonyl 6 membered 
ring    (prednisolone) 
 
1311 C-C Bend  
 
Alkyl (Ch5) 
Ch5, prednisolone 
 
950 C-O Bend (Ch5) 
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Figure 82. FTIR spectra of a) Ch5, b) prednisolone and c) Ch5, prednisolone formulation. 
 
1720.01254 
1720.01254 
3404 
a) 
b) 
c) 
Ch5 
Prednisolone 
Ch5, prednisolone 
 119 
4.3.5.1.3. FTIR of Ch5, griseofulvin formulation 
Fig. 83c) gives confirmation of the successful encapsulation of griseofulvin within the self-
assemblies. This can be deduced due to extra peaks being present at 3359 cm-1 (O-H), 
1750 cm-1 (C=O), 800 cm-1 (Aromatic substituted benzene) and a weak peak at 550 cm-1. 
These extra peaks correlate well with the functional groups present on the griseofulvin 
moiety. For all peak assignments see Table 19. As previously mentioned the peak or 
trough witnessed at 2350 cm-1 was due to changes in background CO2. 
Table 19.Peak bandwidth assignment occurring on FTIR spectra of Ch5, griseofulvin 
formulation using diamond powder tip (20scans). 
Formulation Bandwidth (cm-1) Bond type Functional Group 
3359 
 
O-H Stretch Hydroxyl (griseofulvin) 
1620  
 
N-H Stretch 
 2⁰ Amine (Ch5) 
800  
 
C-H Bend Aromatic (griseofulvin) 
Subs benzene 
2941  
1460 
 
C-H Stretch Alkyl (Ch5) 
1750 C=O Stretch Carbonyl 5 membered ring  
(griseofulvin) 
 
1600 
 
C=O Stretch Carbonyl (griseofulvin) 
1500 C-C Bend  
 
Alkyl (Ch5) 
950 C-O Bend 
 
(Ch5) 
Ch5, griseofulvin 
 
550 C-Cl Bend Chloro alkane (griseofulvin) 
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Figure 83.FTIR spectra of a) Ch5 ,b) griseofulvin and c) Ch5, griseofulvin. 
3359 
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1750 
a) 
b) 
c) 
        Ch5 
       Griseofulvin 
        Ch5, griseofulvin 
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4.3.5.2. FTIR of Dansyl10 formulations 
4.3.5.2.1. FTIR of Dansyl10, propofol formulation 
Figure 84c) shows the FTIR spectrum obtained from the Dansyl10, propofol formulation. 
As with the Ch5, propofol spectra, the presence of the O-H peak at 3419 cm-1 and the 
ortho substituted aromatic benzene peaks at 750 cm-1 were resultant from the functional 
groups present on the propofol moiety. This indicated that propofol had been successfully 
encapsulated in the formulation. All peak assignments can be seen in Table 20.  
 
Table 20.Peak bandwidth assignment occurring on FTIR spectra of Dansyl10, propofol 
formulation using diamond powder tip (20scans). 
Polymer Bandwidth (cm-
1) 
Bond type Functional Group 
3419 O-H Stretch Hydroxyl (propofol) 
1640-1560 
 
N-H Stretch 
 1⁰ Amine (Dansyl10) 
750 
 
C-H Bend 
 
Aromatic (propofol) 
Ortho Subs. benzene 
2960 
 
C-H Stretch Alkyl (Dansyl10) 
1450 C=C Bend Aromatic (Dansyl10) 
1095 C-N Bend Aliphatic amine (Dansyl10) 
Dansyl10, propofol 
 
950 C-O Bend (Dansyl10) 
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Figure 84. FTIR spectra of a) Dansyl10, b) propofol and c) Dansyl10, propofol formulation. 
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4.3.5.2.2. FTIR of Dansyl10, prednisolone formulation 
Peak assignment of the FTIR spectra obtained for the Dansyl10, prednisolone formulation 
(Fig. 85) showed similar peaks to the Ch5, prednisolone spectra indicating the presence of 
the drug in the formulation. This was due to the presence of the hydroxyl band at O-H 
(3413 cm-1) and the C=O (1720 cm-1) of the 6 membered carbonyl ring, these groups were 
not present in the spectra for Dansyl10 alone and therefore can be attributed to the drug 
molecule. Full peak assignment can be viewed in Table 21. 
 
Table 21.Peak bandwidth assignment occurring on FTIR spectra of Dansyl10 , 
prednisolone formulation using diamond powder tip (20scans). 
Polymer Bandwidth (cm-
1) 
Bond type Functional Group 
3413 O-H Stretch Hydroxyl (prednisolone) 
1656 
 
N-H Stretch 
 1⁰ Amine (Dansyl10) 
900-850 
 
C-H Bend 
 
Aromatic (prednisolone) 
Subs. benzene 
2927 
 
C-H Stretch Alkyl (Dansyl10) 
1720 C=O Stretch Carbonyl 6 – membered 
ring (prednisolone) 
1450 C=C Bend Aromatic (Dansyl10) 
Dansyl10, 
prednisolone 
 
950 C-O Bend (Dansyl10) 
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Figure 85. FTIR spectra of a) Dansyl10, prednisolone and c) Dansyl10, prednisolone 
formulation. 
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a) 
b) 
c) 
Dansyl10 
      Prednisolone 
Dansyl10, prednisolone 
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4.3.5.2.3. FTIR of Dansyl10, griseofulvin formulation 
Fig. 86 gives confirmation of the successful encapsulation of griseofulvin within the self-
assemblies. This can be deduced due to extra peaks being present at 3377 cm-1 (O-H), 
1750 cm-1 (C=O of aromatic substituted benzene) and a weak peak at 750 cm-1. These 
extra peaks correlate well with the functional groups present on the griseofulvin moiety 
and the Ch5, griseofulvin formulation. For all peak assignments see Table 22. 
 
 
Table 22.Peak bandwidth assignment occurring on FTIR spectra of Dansyl10, griseofulvin 
formulation using diamond powder tip (20 scans). 
Polymer Bandwidth (cm-
1) 
Bond type Functional Group 
3377 O-H Stretch Hydroxyl (griseofulvin) 
1587 
 
N-H Stretch 
 1⁰ Amine (Dansyl10) 
900-850 
 
C-H Bend 
 
Aromatic (griseofulvin) 
Subs. benzene 
2921 
1585 
 
C-H Stretch Alkyl (Dansyl10) 
1750 C=O Stretch Carbonyl 6 – membered 
ring (griseofulvin) 
1500 C-C Bend  
 
Alkyl (Dansyl10) 
1450 C=C Bend Aromatic (Dansyl10) 
1150 C-N Bend Aliphatic amine (Dansyl10) 
Dansyl10, 
griseofulvin 
 
750 C-Cl Bend Chloroalkane (griseofulvin) 
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Figure 86. FTIR spectra of a) Dansyl10, b) griseofulvin and c) Dansyl10, griseofulvin 
formulation. 
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4.3.6. In vitro Drug Release 
The release of the drugs from the optimal formulations was carried out in sink conditions 
over 96 h at 37 ⁰C in phosphate buffer saline (PBS). Fig. 87 and 88 show the drug release 
from the Ch5 and Dansyl10 formulations. The Ch5 formulations were able to achieve 
sustained drug release over 48 to 72 h, whilst the Dansyl10 formulations achieved 
sustained release over 72 to 96 h. 
 
Figure 87. In vitro release of propofol, prednisolone and griseofulvin from Ch5 
formulations in PBS at 37 ºC (n=3, ave ± SD). 
 
 
Figure 88. In vitro release of propofol, prednisolone and griseofulvin from Dansyl10 
formulations in PBS at 37 ºC (n=3, ave ± SD). 
 
Propofol release from Ch5 and Dansyl10 showed different release profiles over 72 h. The 
release was almost constant upon initial drug release. For Ch5 50 % of propofol (7.8 mg) 
In vitro drug release of Ch5 formulations 
In vitro drug release of Dansyl10 formulations 
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was released in the first 7 h, after 48 h the drug had been completely released, the 
release profile showed a consistent release over the 48 h period. The Dansyl10 showed a 
slower release pattern with only 20 % of propofol (8.95 mg) being released after 7 h and 
after 48 h less than 80 % of the propofol drug content had been released. The release 
continued steadily until after 72 h the drug was completely released. The release profile 
for Dansyl10 resembled a zero order release profile; however when a linear trend line was 
fit to the data the R2 value was 0.9733. This meant the drug release could not be 
described as perfectly zero order. 
Prednisolone release for both formulations measured over 96 h showed a triphasic 
release profile. This is normally exhibited by biodegradable polymers [287,288]. An initial 
burst is followed by a lag phase and then a secondary lag phase (Fig. 87 & 88). For Ch5, 
the initial burst occurs in the first 6 h and accounts for 53 % of the total drug content (7.47 
mg), the after initial lag phase between 6 - 48 h only 60 % of the drug has been released. 
After 72 h the drug had been completely released. The Dansyl10 had only released 20 % 
(12.73 mg) of prednisolone in its initial burst phase in the first 7 h. After 48 h less than 40 
% of the drug was released. In the final lag phase the drug was steadily released until 100 
% of the drug (63.64 mg) was released at 96 h. The Dansyl10 showed a more sustained 
release profile for prednisolone. 
The release profile of griseofulvin was also triphasic (Fig. 87). 20 % of the Ch5 was 
released within the first 7 h, the release appeared to plateau at this time, after 20 h, it 
appeared that no more griseofulvin was released. After 24 h, the drug was consistently 
released until after 72 h 100 % release had been achieved. The Dansyl10 showed a similar 
pattern, however after 7 h less than 10 % of the griseofulvin was released. A plateau was 
also observed but, after 24 h the drug was constantly released up to 100 % at 72 h.  
4.3.7. Stability of formulations 
The formulations were stored in a dark airtight container for 4 weeks. Over this time the 
formulations were analysed for total drug content and the hydrodynamic size was 
determined using photon correlation spectroscopy. The formulations were initially stored 
in two forms; as liquid formulations and as freeze dried ‘cakes’ (reconstituted with water 
and sonicated). However, on initial testing of the freeze dried ‘cakes’, it was deduced 
using HPLC that all the propofol in the formulations had been lost in the freeze drying 
process, perhaps due to the volatile nature of this drug [289]. 
At the commencement of testing it was apparent that prednisolone and griseofulvin liquid 
preparations were forming viscous gels over time. Those gels were too thick to be 
analysed. The stability data shown (Fig. 89 & 90, Table 23-24) are therefore of liquid 
propofol preparations and freeze dried prednisolone and griseofulvin preparations. 
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Figure 89. % of drug lost from nano-aggregates of Ch5 over 4 weeks. Propofol stored in 
solution, prednisolone and griseofulvin formulations stored as freeze dried ‘cakes’ and 
reconstituted with water. The formulations were stored in 55 % humidity, at room 
temperature and protected from light (n=3, ave ± SD). 
Over the 4 week period propofol appeared to be gradually lost from the Ch5 formulation 
(Fig. 89) from 0 to 30 % (0 to 4 weeks). The size data for the propofol formulation 
correlates well with the drug loss. The size of the self-assemblies are reduced from 666 
nm to 239 nm as the drug content decreases (0 to 4 weeks) (Table 23). The initial loss of 
prednisolone and griseofulvin (15 % and 10 % respectively) experienced from the Ch5 
formulation is possibly due to the freeze drying process. However no further notable loss 
is apparent over the 4 wk period. The self assembly sizes of prednisolone and griseofulvin 
formulation notably increased after the freeze-drying process. The absorbance 
wavelength of the freshly prepared Ch5, prednisolone and Ch5, griseofulvin liquid 
formulations had increased from 304 nm and 284 nm to 907 nm and 658 nm respectively 
after freeze drying and reconstitution. The reason for this is unknown; however it may be 
due to disruption of the polymer structure during the freeze-drying process resulting in 
different aggregation formation. Over the 4 week period it appeared that the longer the 
freeze-dried formulations were stored, the more stable they became as no drug loss had 
occurred but the size and PDI decreased. 
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Table 23.Size data for Ch5 formulations over a 4 week period.  
Photon correlation spectroscopy Formulation Time (wks) 
Size (nm) 
mean (SD) 
PDI 
mean (SD) 
6 mgmL-1    
Ch5  1:10 
propofol 
0 
1 
2 
3 
4 
 
666 (79.418) 
394 (49.048) 
367 (79.811) 
264    (5.356) 
239    (3.804) 
0.376 (0.025) 
0.340 (0.066) 
0.282 (0.104) 
0.285 (0.025) 
0.237 (0.023) 
6 mgmL-1 Ch5  
1:10 
prednisolone 
0 
1 
2 
3 
4 
 
907 (37.470) 
881  (52.818) 
1006 (14.962) 
809 (18.540) 
883 (37.906) 
0.560 (0.044) 
0.477 (0.069) 
0.584 (0.093) 
0.375 (0.009) 
0.399 (0.038) 
6 mgmL-1 Ch5  
1:10 
griseofulvin 
0 
1 
2 
3 
4 
658 (20.932) 
437 (34.453) 
536 (24.278) 
464  (10.313) 
424    (5.352) 
0.694 (0.027) 
0.674 (0.156) 
0.593 (0.089) 
0.433 (0.035) 
0.382 (0.006) 
Propofol samples stored as solution, prednisolone and griseofulvin samples stored as 
freeze dried ‘cakes’ and reconstituted with water. All samples stored at 55 % humidity, 
room temperature and protected from light n=3, ave (SD). 
 
The stability profiles from the Dansyl10 formulations (Fig. 90) show similar patterns to the 
Ch5 formulations. The propofol had a cumulative loss over the 4 week period, however 
only 10 % was lost (in comparison with Ch5, propofol formulation, 30 %). The size of the 
aggregates in the formulations remained consistent across the 4 wk period (Table 24). 
The initial loss of prednisolone and griseofulvin (10 % and 20 %) from the freeze drying 
process was also observed and was consistent with the Ch5 formulations. However the 
griseofulvin content did decrease over the 4 wk period with 40 % being lost after wk 4. 
Consistent with the Ch5 formulations, the freshly prepared Dansyl10, prednisolone and 
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Dansyl10, griseofulvin liquid formulations increased from 350 nm and 305 nm to 462 nm 
and 545 nm after freeze drying. Both the prednisolone and griseofulvin self-assemblies 
increased in size across the 4 wk period from 462 to 829 nm and from 545 to 1055 nm 
respectively. The polydispersity index’s also varied greatly, this indicated that the Dansyl10 
formulations were less stable than the Ch5 formulations. 
 
 
Figure 90. % of drug lost from nano-aggregates of Dansyl10 over 4 weeks. Propofol stored 
in solution, prednisolone and griseofulvin formulations stored as freeze dried ‘cakes’ and 
reconstituted with water. The formulations were stored in air tight containers, at room 
temperature in darkened conditions (n=3, ave ± SD). 
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Table 24.Size data for Dansyl10 formulations over a 4 week period.  
Photon correlation spectroscopy Formulation Time (wks) 
Size (nm) 
mean (SD) 
PDI 
mean (SD) 
6 mgmL-1    
Dansyl10 1:10 
propofol 
0 
1 
2 
3 
4 
 
608     (49.37) 
631 (140.922) 
585   (90.113) 
741 (133.671) 
677 (124.107) 
0.385 (0.009) 
0.300 (0.083) 
0.349 (0.059) 
0.386 (0.009) 
0.324 (0.063) 
6 mgmL-1 
Dansyl10 1:10 
prednisolone 
0 
1 
2 
3 
4 
 
462   (29.441) 
703     (4.561) 
715   (43.736) 
618   (87.825) 
829 (134.476) 
0.422 (0.111) 
0.499 (0.235) 
0.646 (0.254) 
0.552 (0.102) 
0.970 (0.541) 
6 mgmL-1 
Dansyl10  1:10 
griseofulvin 
0 
1 
2 
3 
4 
545 (18.785) 
687 (84.742) 
806 (20.731) 
1090 (83.781) 
1055 (75.434) 
0.586 (0.022) 
0.131 (0.105) 
0.247 (0.087) 
0.541 (0.101) 
0.513 (0.029) 
Propofol samples stored as solution, prednisolone and griseofulvin samples stored as 
freeze dried ‘cakes’ and reconstituted with water. All samples stored at 55 % humidity, at 
room temperature and protected from light n=3, ave (SD). 
 
 
 
 
 
 
 133 
4.4. Discussion 
The driving force behind the encapsulation of hydrophobic drugs inside the core of 
polymeric self-assemblies is a basic energetic principle. It is energetically favourable for 
hydrophobic drugs to shield themselves from aqueous environments. As the polymeric 
self-assemblies spontaneously formed the core – shell structures, the smaller lipophilic 
drug molecules accumulate within the hydrophobic region where they remain physically 
entrapped. These self-assemblies continuously and spontaneously break and reform in 
dynamic equilibrium above their critical aggregation concentration (CAC) [72,249,290]. 
Model hydrophobic drugs were encapsulated inside the modified PAA polymers and their 
drug content was analysed. In general drug loading capacities of drugs are affected by a 
number of factors. Previously it has been reported that by changing the polymer 
architecture and hydrophobic content, the drug loading capacity varied [72,137]. Sezgin 
and colleagues fabricated block copolymer poly(ethylene glycol)–distearoyl phosphatidyl 
ethanolamine (PEG2000-DPSE) polymers for solubilisation of poorly soluble and insoluble 
drugs. However they found that the hydrophobic core acted in a drug specific manner, 
whereby only certain drugs were capable of encapsulation [291]. The polymeric nano-
aggregates were loaded with anticancer drugs camptothecin (CPT), octaethylporphine 
(OEP) and  meso-tetraphenyl porphine (mTPP) [291]. Sezgin found that the polymer had 
very low loading capacities for CPT and OEP (0.15 % and 4.7 % w/v of drug incorporated 
respectively), whilst the mTPP achieved up to 93.3 % drug loading [291]. Furthermore, 
they also reported that as the chain length of the PEG group was increased, so too did 
drug solubilisation, thus concluding that for specific drugs and applications, the self-
assemblies could be tailor made by varying polymer structure and hydrophobic block 
length to allow solubilisation of specific molecules [291]. Zhang reported that by varying 
the poly(DL-lactide)-block-methoxy polyethylene glycol (PDLLA-MePEG) monomer weight 
ratio, the concentration of anticancer drug Taxol® was modified [292]. The drug loading 
concentration of Taxol® was increased with increasing the PDLLA monomer of the block 
copolymer, thus resulting in higher lipophilic content causing stronger hydrophobic 
interactions with the drug molecules [292].  Although this principle has been extensively 
studied using amphiphilic polymers [137], the use of hydrophobic aromatic groups and the 
differences in drug loading on comb shaped polymers is seldom reported. 
The modified PAA’s described in this work all possessed the ability to encapsulate 
practically insoluble drugs within their hydrophobic core. The results confirm that varying 
the hydrophobic group directly impacts the self-assembly loading capacity. This is 
perhaps due to the chemical structure of the hydrophobic pendant group. The small planar 
structure of fmoc enabled excimer formation to occur, where stacking of the molecules 
occurred. This was also witnessed in the naphthalene modified polymer. The close 
stacking of these molecules may limit the number of drug molecules entering the 
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hydrophobic core, thus making them less effective. However, this may differ with differing 
drug architecture. The more bulky hydrophobic molecules such as cholesterol or dansyl 
may experience some steric hindrance when in close proximity to each other, and hence 
small drug molecules may be able to ‘slot’ into such spaces and maximise their loading 
concentration (Fig. 67 & 72). 
At higher hydrophobic grafting, increased  concentrations of drugs were solubilised (Fig. 
91). This can be attributed to greater hydrophobicity of the polymer forming polymeric self-
assemblies with greater hydrophobic interactions with the lipophilic drug molecules [293]. 
The higher extent of hydrophobic interactions results in greater driving force for 
hydrophobic drug solubilisation and hence a higher drug loading capacity is experienced. 
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Figure 91. Solubilisation of propofol and prednisolone and 5 % and 10 % molar grafting 
levels using fmoc and dansyl modified polymers. 
 
Hydrophilic modification of the polymer backbone appeared to decrease the maximum 
concentration of propofol solubilised. However, visual examination of the formulations 
before filtration would suggest otherwise. Clear solutions before filtration were formed 
upon sonication suggesting complete drug solubilisation. This could be due to the positive 
charge forming less hydrophobic or larger self-assemblies encapsulating the propofol 
which were removed during the filtration process.  
Ch5 and Dansyl10 proved to be the best solubilising polymers across the library of 
polymers synthesised. The solubilising potential of these amphiphilic polymers was 
consistent across the range of model drugs used (Fig.92). This indicates that the polymers 
are non-drug selective i.e. they are capable of solubilising any hydrophobic drug and are 
not specific to one molecular type. This is an excellent property to possess in a drug 
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delivery system indicating its potential as a universal solubiliser and can be used across a 
broad range of applications.  
 
Figure 92. Solubilisation capacities of Ch5 and Dansyl10 polymers of propofol, 
prednisolone, griseofulvin and etoposide. 
Overall it was observed that for the Ch5 and Dansyl10 formulations, higher polymer 
concentration achieved greatest solubility of the hydrophobic drugs. This was due to the 
fact that more micelles would have been present in solution, resulting in higher degree of 
solubilisation. At increased initial drug:polymer mass loading ratios increased solubility 
was achieved for these polymers (Fig. 68 & 73). With increased drug loading there was a 
larger driving force for hydrophobic encapsulation within the lipophilic core of the self-
assemblies and thus more drug was solubilised [294]. The excipient:drug ratios of the 
filtered formulations were calculated. Solubilisation was achieved at excipient:drug ratios 
as small as 0.13 (Fig. 69). These ratios were considerable less than the values needed 
with traditional low molecular weight surfactants or liposomes which often require 
excipient:drug ratios ranging from 15:1 to as high as 1000:1 [3]. It is desirable to use low 
excipient:drug ratios when solubilising a drug, the system is not only more efficient and 
cost effective, but it also minimises any harmful or uncomfortable side effects to the 
patient. 
 
The ability of one polymer to load different drugs with differing efficiency was observed. 
This was also due to a number of factors. The structural properties of drugs being loaded 
has an impact on drug loading capacity [295]. Planar drugs (consisting of aromatic ring 
systems) have the ability to stack closely together, allowing higher concentrations to 
become encapsulated within the hydrophobic core. Bulkier or more rigid molecules with 
Ch5   Dansyl10 
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higher molecular weight (e.g. etoposide) find it more difficult to accumulate together in 
high concentration as steric hindrance prevents this occurring, meaning the encapsulation 
efficiency is decreased.  
In the case of propofol, its low molecular weight (MW = 178) (Fig. 60), allows the 
molecules to fit closely together without much steric hindrance thus maximising the 
concentrations being encapsulated (Fig. 67). The chemical structures of prednisolone and 
griseofulvin (Fig. 61 & 62), are more bulky and inflexible thus hindering close proximity of 
the molecules by stacking. Perhaps the low solubilisation capacity for etoposide in both 
Ch5 (1.02 mgmL-1) and Dansyl10  (1.89 mgmL-1) can be attributed to its large molecular 
weight and complicated structure (Fig. 63). 
The aqueous solubility of lipophilic drugs also impacts on solubility inside self-assembly 
cores. The more lipophilic the drug molecule, the greater affinity it will have for the 
hydrophobic core of the polymeric self-assembly. Prednisolone was solubilised by 
Dansyl10 (31.82 mgmL-1) achieving a 100-fold improvement of its aqueous solubility. 
Griseofulvin was solubilised by Dansyl10 (16.71 mgmL-1) 400-fold better than the aqueous 
solubility (Table 13). Griseofulvin possesses very low aqueous solubility (0.03 mgmL-1). 
Perhaps the highly lipophilic nature of the drug resulted in a greater driving force for 
hydrophobic interactions between the griseofulvin and the self-assemblies, thus 
increasing the amount of drug solubilised. However when griseofulvin is compared with 
propofol and prednisolone, a much lower concentration of drug was encapsulated (Table 
13). 
Log P is another parameter which affects the solubility of drugs in solutions. Log P values 
are often used to compare the hydrophobicity of molecules [295]. Drugs with high log P 
values indicate that the drugs would rather partition into lipophilic than aqueous media 
[296]. This phenomenon results in drugs with higher log P values having higher affinity for 
the hydrophobic core of the polymeric nano-aggregates and thus higher concentrations 
are solubilised. Looking at the model drug solubilisation, this trend is witnessed. The 
propofol had the highest log P value of 4.16 and a high degree of drug loading was 
achieved. Prednisolone and griseofulvin have similar log P values (1.8 and 2.2 
respectively) and thus would be expected to have similar drug loading capabilities; 
however this is not the case. As mentioned previously the griseofulvin loading was notably 
less than the prednisolone loading, this perhaps due to other factors such as steric 
hindrance being present. The etoposide has the lowest log P value (0.698) this would 
indicate that it is the most hydrophilic molecule of all the drugs. In our study, this was not 
the case, etoposide achieved the lowest drug loading within all the formulations (Table 
14). However as previously mentioned etoposide was the largest drug molecule which 
appears to be the limiting factor as regards to its encapsulation inside Ch5 and Dansyl10. 
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Propofol has for many years been the focus of solubilisation studies [94, 258,297,298]. Its 
highly lipophilic nature makes it an ideal drug for researchers to incorporate within their 
novel drug delivery systems. Previously propofol has been formulated by complexation 
with hydroxypropyl and sulfobutyl-β-cyclodextrin [298,258]. Other technologies to improve 
propofol solubility were the synthesis of water soluble prodrugs and the use of other 
chemical delivery systems [257,297,299,300,301]. In 1996 Trapani reported achieving a 
266 fold increase on the aqueous solubility of propofol using 2-Hydroxypropyl-β-
cyclodextrin [258]. In this study he recorded a solubility of 39.73 mgmL-1 of propofol. 
However other solubility studies have failed to reach this concentration [94,203,257]. In 
this study we reported that Dansyl10 achieved a 223-fold increase from the aqueous 
solubility. Although this is not as high as previously reported by Trapani and colleague’s 
[258], cyclodextrins can be very drug selective, whereas the Dansyl10 and Ch5 have 
demonstrated good solubilising potential across all the drugs tested in this study. 
In 2007 Seedher and Sharma reported that combination of prednisolone with other 
common soluble drugs such as caffeine, paracetamol and ibuprofen could enhance its 
solubility [302]. They reported that combination of prednisolone with soluble paracetamol 
enhanced the solubility 2.14-fold [302]. In comparison with previous work, the Ch5 and 
Dansyl10 polymer show excellent results greatly exceeding this data with solubilities up to 
7.05 mgmL-1 (Ch5) and 31.82 mgmL-1 (Dansyl10) and without the addition of a secondary 
drug substance. 
Balakrishnan reported a 105-fold increase in the aqueous solubility of griseofulvin using 
sodium dodecyl sulphate (SDS) [303]. SDS is a commonly used surfactant within the 
pharmaceutical field, it is frequently used as an excipient to solubilise hydrophobic drugs. 
Ch5 and Dansyl10 achieved 40-fold and 557-fold enhancement of griseofulvin solubility. 
Although the SDS achieved higher loading than the Ch5 polymer, polymeric nano-
aggregates possess lower excipient:drug ratios making them more efficient for drug 
solubilisation. 
Etoposide has previously been used by many research groups for solubility studies 
[276,285,304,305]. Its anticancer potential has been hindered its by poor aqueous 
solubility. Recently Shin and colleagues have reported achieving 3.31 mgmL-1 solubility of 
etoposide within poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG—B-PLA). This is a 
22-fold increase from the aqueous solubility of the drug [304]. Ch5 (1.02 mgmL-1) and 
Dansyl10 (1.89 mgmL-1) were capable of increasing the aqueous solubility of etoposide by 
7-fold and 13-fold respectively.  
The difference in release profiles between polymeric self-assemblies can be attributed to 
the variation in hydrophobic group attached to the polymer backbone [306]. The higher 
hydrophobicity of the 10 % molar grafted dansyl self-assemblies made water penetration 
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of the nano aggregate difficult thus slowing drug release [307]. Therefore higher 
hydrophobicity of the Dansyl10 can lead to a more controlled release of the drugs. 
The variation of drug release between the types of drugs can be explained by the 
aqueous solubility of these drugs. The lower aqueous solubility of the drugs, the higher 
their affinity for the hydrophobic core of the nano aggregate [296,308].  This high affinity 
results in the ‘reluctance’ of the drug to become released into solution [308]. This trend is 
observed predominantly within the first 7 h for all the drugs. Griseofulvin has the lowest 
aqueous solubility (0.03 mgmL-1) followed by propofol (0.1 mgmL-1) with prednisolone 
having the highest solubility (0.2 mgmL-1). Figure 87 shows for the initial 7 h period, the 
fastest drug is released from the Ch5 self-assemblies was prednisolone followed by the 
propofol, the griseofulvin releases the lowest concentration over this time period. This 
trend was also observed in the release from the Dansyl10 nano-aggregates in the first 7 h 
of the study (Fig. 88).  
Lin and colleagues reported the in vitro release of naproxen from poly(β-benzyl-L-
aspartate)-graft-poly(ethylene glycol) (PBLG-g-PEG) [113]. They reported that by varying 
the polyethylene glycol content of the polymer, varied drug release profiles occurred. After 
7 h 25 – 40 % of total naproxen release had occurred (PBLG-g-PEG1 and PBLG-g-PEG2 
respectively) [113]. After the initial burst the drug release slowed down, at the end of their 
80 h study 40 – 90 % of drug release had occurred (PBLG-g-PEG1 and PBLG-g-PEG2 
respectively) [113]. San Miguel and colleagues loaded amphiphilic triblock copolymer 
poly(2-N,N-dimethylamino) ethyl methacrylate)-block-poly(caprolactone)-block-poly(2-
N,N-dimethylamino) ethyl methacrylate) (PDMAEMAco) with anticancer agent 
chlorambucil [160]. They found that PDMAEMAcoCL20 micelles were capable of sustained 
release of chlorambucil over more than 100 h. In the first 24 h of the study only 22 % of 
drug release had occurred [160]. Only after 130 h total drug release was achieved [130]. 
When compared with other amphiphilic polymer formulations the Ch5 and Dansyl10 
formulations release the drug notably quicker. Perhaps further modification of the polymer 
backbone such as higher grafting or use of secondary hydrophobic groups could be used 
to achieve a more sustained drug release in vitro. 
The stability of a formulation is one of the most important aspects for pharmaceutical 
application. Liquid and freeze dried formulations were tested for drug content over a 4 
week period in dark conditions and at room temperature with 55 % humidity. The results 
reinforce the fact that different formulations using the same excipient do not all require the 
same storage conditions, i.e. Propofol could not be freeze-dried due to high level of drug 
loss and prednisolone and griseofulvin samples could not be stored as liquids as they 
formed viscous gels. The stability of each formulation differed, the propofol formulations 
stored as liquids appeared to slowly lose drug content over the 4 week period up to a 
maximum of 30 % (Ch5) and 10 % (Dansyl10) (Fig. 89 & 90). The prednisolone and 
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griseofulvin formulations on the whole appeared to be stable across the 4 week period. 
The major drug loss for these formulations occurred at the initial freeze drying process, 
however with careful optimization and perhaps the use of cryoprotectants could minimise 
drug loss [253]. Interestingly the sizes of the self-assemblies were larger after freeze 
drying and reconstitution at week 0, the reason for this is unknown and needs to be further 
investigated [309]. 
 
4.5. Conclusion 
The varied size, solubilisation potential of the drug loaded polymers reinforced the theory 
that the structural features of the hydrophobic drug hugely affects its ability to load within 
the micelle core. Ch5 and Dansyl10 have shown excellent drug loading capacities over a 
range of hydrophobic drugs, indicating that they were not drug specific and could be used 
as universal drug solubilisers. In vitro release profiles showed that all the Ch5 and 
Dansyl10 formulations achieved sustained release between 48 – 96 h. Biological 
characterisation is necessary for the amphiphiles and formulations to indicate their 
potential as drug solubilisers in vitro and in vivo. 
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5.1. Introduction 
Novel drugs and novel drug delivery systems go through rigorous testing both in preclinial 
and clinical stages before they are mass produced and marketed. After initial 
characterisation of the compounds, in vitro testing is carried out. In vitro analysis is an 
important process, in which mammalian cells are tested outside the body. This is the most 
accurate estimation of the in vivo fate of the compounds. In vitro work or tissue culture 
allows the study of cells without the variations occurring in vivo [310]. The physiochemical 
environment, homogeneity of the sample and scale can be controlled by the user [310]. 
However, it is important to mention, that although in vitro analysis is beneficial, it cannot 
give a true representative of in vivo conditions.  
5.1.1. Bioavailability Investigation 
It is important to determine the biocompatibility of a formulation in vitro before it can be 
used in vivo. In order to do so, a number of assays are carried out. There is no set type or 
number of assays for this type of evaluation. The most common tests used are simple 
haemolysis assays and cytotoxicity assays. These tests are simple, quick, relatively cheap 
and most importantly reproducible.   
5.1.1.1. Haemolysis Assay 
Haemolysis assays are carried out on red blood cells to determine whether a compound 
has a haemolytic effect towards the red blood cells resulting in cell lysis. This is a 
particularly beneficial assay for formulations which are to be administered via intravenous 
injection. Intravenously administered formulations are injected directly into the 
bloodstream and therefore must not cause any haemolytic or adverse effect on blood cells 
for their safe use. The assay is carried out with a Tween 80 standard. Tween 80 is a low 
molecular weight surfactant that has been approved in the UK for intravenous 
administration and oral consumption [311]. 
5.1.1.2. Cytotoxicity Assay 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay is a standard 
assay for determining the cytotoxic effect of a compound or formulation when exposed to 
cells. The assay is carried out by treating cells in the exponential growth phase to a 
formulation for a set period of time [288]. The formulation is removed and the cells are 
allowed a set amount of time to recover or to die from the effect of exposure to the 
formulation. After this the % cell viability can be determined by referring to the IC50 value 
produced; this is the polymer concentration at which only 50 % of the cells are still viable.  
MTT is a soluble tetrazolium dye with a distinctive yellow appearance. However, in the 
presence of viable cells, the MTT is reduced to an insoluble purple formazan crystal. By 
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dissolving the formazan crystal in dimethyl sulfoxide (DMSO) the viability of cells can be 
measured on a microplate reader. The optimal time for cells to be incubated with MTT to 
achieved accurate viability determination has been reported to be 4 h. 
5.1.1.3. Cellular Localisation of Formulations 
It is essential to track a formulation on its cellular journey in order to fully understand how 
the formulation enters the cell and to confirm that the target site for payload release is 
reached. Cellular localisation studies are carried out on successful formulations usually 
via the attachment of fluorescent tags to the polymer backbone [312]. It is quite common 
for the drug molecules to fluoresce as many drug molecules consist of aromatic ring 
systems exhibiting inherent fluorescence. However, in order for distinction between the 
delivery vehicle and the drug, it is imperative that they emit fluorescence at different 
wavelengths and in different colours. 
Commonly used fluorescent tags include rhodamine and fluoroisothiocyanate (FITC) 
[152,313]. However, recently advancement in polymer chemistry has led to the fabrication 
of fluorescent polymers such as poly(N-isopropyl-acrylamide-co-N-vinyl carbazole-block-
poly(dimethylamino) ethyl acryate (PNIPPAm-co-PNVC)-b-PDMAEA) and galactose-
polycaprolactone-g-dextran-fluorescein isothiocyanate (Gal-PCL-g-Dex-FTIC) where no 
tag is needed for fluorescent emission [174,176]. 
5.1.2. In vivo analysis 
In vivo analysis uses animal models to determine the pharmacokinetic effects of drugs 
and formulations after administration i.e. the drug plasma levels to determine drug half life 
(T1/2) and the area under the curve (AUC) to determine the bioavailability of a drug. In vivo 
studies are the most effective and valuable method of determining the fate of drugs after 
administration to the body. Mice and rats are the most common animals used for in vivo 
studies as their immune system is comparable to humans, they are also more economical 
as they cost less and small amounts of drug are used in the studies compared with larger 
animals such as rabbits, guinea pigs and dogs [314]. 
Drugs can be administered through various routes, the most common are through 
intravenous injection and oral dosage. Analysis can be carried out on healthy or diseased 
animal models depending on the desired therapeutic effect. The pharmacokinetic 
properties of the drugs can be analysed using simple assays or HPLC analysis to 
determine drug concentration in the blood. Other inspection methods can also be carried 
out, for example the time taken for the animal to fall asleep in the delivery of anaesthetics, 
or the time taken for loss of reflex in legs [203]. In anticancer therapeutics tumour growth 
delay is measured in diseased models [315]. 
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5.1.2. Aims and Objectives 
The modified polymers will be tested in vitro. Their safety profile will be characterised 
using haemolysis assay and their cytotoxic effect on human colorectal carcinoma (Caco-
2) and human smooth muscle kidney (HEK) cells will be determined using MTT assay. 
The cytotoxic effect and cellular localisation of optimal formulations of Ch5 and Dansyl10 
using etoposide and BNIPDaoct will be determined. In vivo absorption of griseofulvin 
through oral gavage of sprague dawley rats will be carried out. The effect of a novel 
anticancer drug Bisnahthalimidopropyldiamino octane (BNIPDaoct) in the presence of Ch5 
on tumour bearing nude mice will also be undertaken to determine the antitumoral activity 
after repeated dosing. 
5.2. Materials and Methods 
5.2.1. Materials used 
Material Supplier 
Modified PAA polymers Synthesised in Chapter Two 
Formulations of modified PAA Formulated in Chapter Four 
BNIPDaoct Synthesised in section 4.3.1 
Etoposide Sigma-Aldrich Co., UK 
Griseofulvin Sigma-Aldrich Co., UK 
Bovine blood samples McIntosh Abattoir, (UK) 
HPLC Grade methanol Fisher Scientific, UK 
HPLC Grade acetonitrile Fisher Scientific, UK 
Highly purified water MillexQ system (UK) 
Phosphate buffered saline Fisher Scientific, UK 
DMSO Fisher Scientific, UK 
Sodium chloride Fisher Scientific, UK 
Hydrochloric acid Fisher Scientific, UK 
Rhodamine B isothiocyanate Sigma-Aldrich Co., UK 
HEK cell lines Kindly donated by the University of 
Hertfordshire 
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Material Supplier 
Caco-2 cell lines ECCAC 
Minimal essential media (MEM) Sigma-Aldrich Co., UK 
Dulbecco’s minimal essential media 
(DMEM) 
Sigma-Aldrich Co., UK 
Foetal bovine serum Fisher Scientific, UK 
Trypsin in EDTA Fisher Scientific, UK 
Penicillin streptomycin Fisher Scientific, UK 
L-Glutamine Sigma-Aldrich Co., UK 
Non essential amino acids Sigma-Aldrich Co., UK 
Glycerol  Sigma-Aldrich Co., UK 
Triton X Sigma-Aldrich Co., UK 
3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich Co., UK 
L-Glycine Sigma-Aldrich Co., UK 
Microvette®CB300 Vet Tech Solutions, UK 
Sprague Dawley rats Charles River, UK 
Female NMRI Nu/Nu mice le Genest-St.-Isle, France 
Amphotericin B Sigma, St. Louis, MO 
Gemcitabine Sigma, St. Louis, MO 
RPMI 1640 media BioWhitaker, Belgium 
10 % heat activated foetal bovine serum BioWhitaker, Belgium 
Non-enzymatic cell-dissociation solution Sigma, St. Louis, MO 
Thiopental  Sigma, St. Louis, MO 
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5.2.2. Methods 
5.2.2.1. Haemolysis Assay 
Fresh bovine blood was washed with phosphate buffered saline (PBS buffer) (0.1 M) and 
centrifuged (2500 rpm) for 10 min at 4 ºC. The supernatant was discarded. This process 
was repeated until the supernatant was clear. The erythrocyte was isolated and weighed 
and a 3 % (w / v) dilution in PBS solution was carried out. The red blood cell solution (80 
µL) was pipetted into the wells of a 96 well round bottom plate.  
A 10 mgmL-1 stock solution of polymer was made up in deionised water and pH adjusted 
to pH 7.4 with NaOH / HCl. Various concentrations (1 - 0.05 mgmL-1) of polymer solution 
were prepared from the stock solution using PBS as the diluent. The wells of the plate 
were then treated with 80 µl of increasing polymer concentrations. PBS and Triton X (80 
µL each) were used as the negative and positive controls respectively. The plates were 
incubated at 37 ºC for 4 h before being centrifuged at 2500 rpm for 10 min at 4 ºC. The 
supernatant (100 µL) was transferred to a flat bottomed 96 well plate for analysis. The 
absorbance of the plate was read at 570 nm on a microplate reader (Ascend Lab-
Systems, UK). The % haemolysis was calculated in relation to the positive and negative 
controls. 
The remaining pellets were viewed under the light microscope (Leica DM3000B, Leica 
UK) and observations were recorded. 
5.2.2.2. Cytotoxicity Assay  
5.2.2.2.1. Cytotoxicity of Modified Polymers 
The cytotoxicity of the modified PAA polymers was determined using the MTT assay 
model. Caco-2 cells were cultured in minimum essential medium (MEM) containing 10 % 
foetal bovine serum (FBS), 1 % L- glutamine and 1 % non essential amino acids (NEAA). 
A 10 mgmL-1 polymer solution was prepared using sterile water as the diluent. The 
solution was further diluted with media to form a 0.5 mgmL-1 stock solution. From the 
stock solution nine dilutions (0.2 - 1x10-4 mgmL-1) were made using media as the diluent 
(Table 25).  
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Table 25. Polymer dilutions for MTT assay 0.5 – 1 x 10-4 mgmL-1. 
Polymer 
concentration  
(mgmL-1) 
Volume of 0.5 mgmL-1 
polymer stock  solution (mL) 
Volume of media (mL) 
0.5 - - 
0.2 1.400 2.100 
0.1 0.700 2.800 
0.08 0.560 2.910 
0.05 0.350 3.150 
0.025 0.175 3.325 
0.01 0.070 3.430 
0.005 0.050 4.950 
0.001* 0.700 2.800 
0.0001* 0.070 3.430 
*Prepared using 0.005 mgmL-1 polymer stock solution 
Caco-2 cells (200µL, 10000 cells/well) in exponential growth phases were seeded into a 
96-well flat bottomed plate and incubated for 24 h at 37 ºC with 5 % CO2. The media was 
replaced with increasing polymer concentrations (0.5 – 1 x 10-4 mgmL-1) as prepared 
above. Media and Triton X (1:5 PBS) were the negative and positive controls respectively. 
The plate was incubated as before. After 24 h the polymer solutions were removed and 
replaced with fresh media. The plate was further incubated for 24h before the media was 
removed and replaced once more. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
(MTT) (50 µL, 5 mgmL-1) was added to the wells and the plate was incubated (37 °C with 
5 % CO2) in the dark for 4 h. After this time the MTT solution was removed from the wells. 
The remaining purple formazan complexes were dissolved in DMSO (200 µL) and L-
glycine buffer (25 mL, made up of 3.75 g glycine and2.93 g NaCl made up in 500 mL and 
pH adjusted to pH 10.5) and the absorbance of the plates was read at 570 nm using a 
microplate reader (Ascend Lab-Systems, UK). Percentage cell viability was calculated 
relative to the positive and negative controls.  
5.2.2.2.2. Cytotoxicity of anticancer drug formulations 
An MTT assay was carried out (5.2.2.2.1.) using Caco-2 and HEK cells. Caco-2 cells were 
cultured as previously described (5.2.2.2.1.). HEK cells were cultured in Dulbecco’s 
minimum essential medium (DMEM) containing 10 % FBS and 1 % penicillin streptomycin 
(Penstrep). Cytotoxicity assays for anticancer drugs etoposide and BNIPDaoct alone (0.5 
– 1x10-6 mgmL-1) and formulations of the anticancer drugs using Ch5 and Dansyl10 
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polymers were carried out. The polymers were fixed at a concentration of 0.005 mgmL-1 
were the cell viability is  90 % (IC90) based on the MTT assay. 
Polymeric self-assemblies were formed by probe sonicating the polymers in sterile water 
(5 mgmL-1). The polymer stock solutions were diluted to 0.005 mgmL-1 with media. 
Etoposide and BNIPDaoct stock solution (20 mgmL-1) was prepared by diluting the drug in 
DMSO. The formulations were prepared by addition of drug into 0.005 mgmL-1 polymer 
solution (Table 26). 
Table 26. Preparation of anticancer drug formulations for MTT assay (1 x 10-6 – 0.5 
mgmL-1). 
Drug concentration 
(mgmL-1) 
Volume of 20 mgmL-1 drug 
stock solution (µL) 
Volume of 0.005 mgmL-1 
polymer stock solution (mL) 
0.5 112.500 4.5 
0.2 45.000 4.5 
0.1 22.500 4.5 
0.05 11.500 4.5 
0.025 5.600 4.5 
0.01 2.250 4.5 
0.005 1.125 4.5 
0.001* 90.000 4.5 
0.0001* 9.000 4.5 
0.000001* 1.000 4.5 
*Prepared using 0.05 mgmL-1 drug stock solution 
5.2.2.3. Cellular localisation of BNIPDaoct formulations 
In order to visualise the cells using the confocal microscope, a fluorescent tag was 
attached to the Ch5 polymer. The Dansyl10 and BNIPDaoct possessed inherent 
fluorescence and therefore no tagging was required. 
5.2.2.3.1. Grafting of rhodamine to primary amines of Ch5 
Ch5 (50 mg) was dissolved in 100 mL water with stirring. A solution of rhodamine B 
isothiocyanate (1 mgmL-1, 10 mL) was prepared in DMSO and added dropwise to the 
polymer solution over 0.5 h at room temperature. The reaction was stirred for 1 h in dark 
conditions before exhaustive dialysis against water using dialysis membrane, molecular 
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cut off 12 – 14 KDa. At least six 5 L water changes were made over a 24 h period until the 
water turned from pink to colourless to ensure all the free rhodamine was removed. The 
dialysate was freeze dried and the product recovered. Successful attachment of 
rhodamine was confirmed by the polymer product displaying a distinctive pink colour. 
5.2.2.3.2. Confocal imaging of cells 
Caco-2 and HEK cells were cultured in exponential growth phase in 6-well plates 
containing glass cover slips (5 x 104 cell/mL). The cells were allowed to grow for 2 days in 
a CO2 incubator at 37 ºC. After this time the media was removed and replaced with 3 mL 
of polymer, drug or polymer-drug formulation over various time intervals. The polymer 
concentrations were fixed at 0.005 mgmL-1 and the BNIPDaoct was tested at 
0.0001mgmL-1. Both concentrations were the IC90 value determined from the MTT data. 
BNIPDaoct stock solution (0.05mgmL-1) was prepared by dissolving the drug in DMSO. 
The formulations were prepared by the addition of stock BNIPDaoct (40 µL) in polymer 
solution (20 mL, 0.005 mgmL-1). 
The polymers were incubated with the cells for 0.5, 1, 2 and 4 h after which the solutions 
were removed and the cells were washed with media ( X 3) and allowed to recover in 3 
mL of media at 37 ºC in a CO2 incubator.   
After 0.5 h the media was removed and the cells were quickly exposed to icy 
paraformaldehyde (2 %) for a couple of seconds before being washed and allowed to 
rehydrate in PBS for 10 min. The cover slips were then removed from the wells and air 
dried before being mounted with glycerol onto slides. The slides were viewed using the 
confocal microscope (Nikon D-Eclipse C1, Nikon UK) using the appropriate filters (green 
for Dansyl10, red for Ch5 and blue for BNIPDaoct). 
5.2.2.4. In vivo oral absorption of griseofulvin 
5.2.2.4.1. Preparation of griseofulvin formulations 
All solutions were made immediately prior to in vivo administration. 
5.2.2.4.1.1. Preparation of griseofulvin in water 
Griseofulvin (2 mgmL-1) was added to doubly distilled water and sonicated for 10 min to 
ensure maximum solubilisation of the drug had occurred. The solution was filtered using 
0.45 µm syringe filters with prefilters to remove any excess undissolved drug.  
5.2.2.4.1.2. Preparation of Ch5 and Dansyl10 griseofulvin formulations 
Ch5 polymer solution (6 mgmL-1) was prepared by dissolving the polymer in water followed 
by probe sonication (10 min). Griseofulvin (60 mgmL-1) was added to the Ch5 solution and 
sonicated for a further 10 min to ensure maximum drug solubilisation had occurred. The 
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solution was filtered using 0.45 µm syringe filters with prefilters to remove any excess 
undissolved drug. The amount of solubilised griseofulvin was 1.2 mgmL-1 (Table 15, pg 
108). The Dansyl10, griseofulvin formulation was prepared as described above (16.71 
mgmL-1) except a 1 in 5 dilution was then performed of the polymer-drug formulation, to 
adjust the dosage and enable direct comparison of the results with the Ch5, griseofulvin 
formulation.  
5.2.2.4.2. In vivo oral administration and evaluation of griseofulvin absorption 
18 male sprague dawley rats (280 g) were separated into four groups (n=4 groups or n=3, 
ave controls) (Table 27) and their food was withdrawn over night (18 h), the rats had free 
access to water at all times. The rats were orally dosed with a griseofulvin suspension in 
water and two griseofulvin formulations (11.8 mgKg-1) via oral gavage. The formulations 
were prepared as previously described (5.2.2.4.1.). The rats were monitored to evaluate 
their behaviour immediately after administration and throughout the investigation. Blood 
samples (approximately 100 µL) were collected using 300µL microvettes 
(Microvette®CB300, Vet Tech Solutions, UK) at various time points (1, 4 and 7 h) via tail 
vein venesection. After the first time point (1 h) food was given to the rats. After 24 h the 
rats were sacrificed using a carbon dioxide chamber and an immediate heart puncture 
was carried out to retrieve the blood. All blood samples were centrifuged at 2000 rpm for 
10 min and the plasma was pipetted off into separate eppendorf tubes. The plasma 
samples were frozen until ready for analysis. Polymers alone were used as the controls.  
Plasma (100 µL) was diluted with 250 µL acetonitrile and vortexed for 30 sec. The mixture 
was then centrifuged at 3000 rpm for 10 min. The supernatant was collected and 50 µL 
was injected onto the column. The griseofulvin content of the plasma was determined by 
HPLC analysis reported by Ahmed [271]. A RP Zorbax ODS 250 mm x 46 mm x 5 µm 
HPLC column (Hichrom, UK) was used with a flow rate of 2 mLmin-1 (50:50 v/v 
acetonitrile:water) in an isocratic mode (Varian LC, Varian UK). The resultant peak at 3 
min was analysed at 260 nm (excitation) and 389 nm (emission) using a fluorescent 
detector (Varian LC, Varian UK). The amount of griseofulvin present in the samples was 
determined by comparing to a standard calibration carried out previously with griseofulvin 
spiked blank plasma samples (1.9 µgmL-1 – 10 µgmL-1), R2 = 0.992 .  
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Table 27. Group labels and numbers of griseofulvin formulations administered to male 
Sprague dawley rats by oral gavage. 
Group label Number of rats Formulation 
PC 3 Ch5 alone 
PD 3 Dansyl10 alone 
G 4 Griseofulvin in water 
C 4 Ch5, griseofulvin 
D 4 Dansyl10, griseofulvin 
 
The statistical significance of the results was assessed using two-way analysis on 
variance ANOVA and Dunnett multiple comparison t-test via SPSS 13.0 for Windows. 
5.2.2.5. In vivo therapeutic effect of BNIPDaoct 
5.2.2.5.1. Preparation of Ch5, BNIPDaoct formulation 
Ch5 polymer solution (1 mgmL-1) was prepared by probe sonicating the polymer in distilled 
water (10 min). BNIPDaoct (1 mgmL-1) was added to the Ch5 solution and sonicated for a 
further 10 min to ensure maximum drug solubilisation had occurred. The solution was 
filtered using 0.45 µm syringe filters with prefilters to remove any excess undissolved 
drug. The final drug content in the formulation is 0.3 mgmL-1 (Table15, pg105). 
5.2.2.5.2. In vivo Effect of CH5, BNIPDaoct formulation on xenograff tumour (BxPC3 
cell line implanted) 
The method was carried out as described by Aubert and colleagues [316].Female NMRI 
Nu/Nu mice (24 – 30 g) were kept in pathogen-free conditions. All surgical procedures and 
animal care were carried out according to accreditation number 04333 given by the 
French ministry of agriculture. Human pancreatic cancer cells (BxPC-3) were cultured in 
RPMI 1640 media which was supplemented with 10% heat inactivated fetal bovine serum, 
L-glutamine (2 mM), penicillin streptomycin and amphotericin B (100 µgmL-1 of each).The 
cells were washed twice with cold PBS followed by cell harvesting with non-enzymatic 
cell-dissociation solution for 10 min at 37°C. The cells were washed with PBS (X 3) and 
kept on ice until ready for injection. The mice were transiently anesthetised (<30 s) with a 
low dose (2.5 mg) of thiopental and placed into a restraining tube. The tumor cell 
suspension (1.8x106 cells in 100 µL of PBS) was injected subcutaneously into the right 
flank of the mice. When the tumor became palpable (2 weeks),  2 dimensional 
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measurements were taken using Vernier calipers once a week, the volume of the tumors 
was calculated using  the formula: (pi/6) x (a x b2), where a is the largest and b the 
smallest diameter of the tumor. 
Two treatments were performed per week over 4 weeks. Four groups of mice were 
treated with 1 mgKg-1 of the Ch5 polymer and Ch5, BNIPDaoct formulation via 
interperitoneal injection (Table 28). Gemcitabine, one of the current treatments of 
pancreatic cancer was used as a control (2.5 mgmKg-1) to compare with the novel 
formulation. The efficacy of the treatment was evaluated by the change in the tumor 
volume during the 4 week period. The tumour volume was measured twice a week over 
the 4 week study. The mice were sacrificed after 5 weeks.  Statistical analysis was carried 
out using the Mann Whitney test and the results were considered to be statistically 
different when P<0.05. 
Table 28. Groups of BNIPDaoct formulations administered to nude tumour bearing mice 
via intravenous injection. 
Number of mice Formulation 
6 Ch5 alone 
11 Gemcitabine 
13 Ch5, BNIPDaoct 
 
 
 
5.3. Results 
5.3.1. Haemolysis Assay 
The modified PAA polymers were tested for their haemolytic activity against red blood 
cells. Figure 93 shows the haemolysis results for the 5 and 10 % hydrophobic grafted 
polymers. Ch5 could not be tested within the 0.5 – 1 mgmL-1 concentration range as the 
polymer precipitated out of PBS solution, however at below 0.1 mgmL-1 the assay could 
be carried out. At the low concentration range of 0.005 – 0.1 mgmL-1 the Ch5 showed 
negligible haemolytic activity with the % haemolysis below 0.5 % (Fig. 94). 
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Figure 93. % Haemolytic activity of hydrophobic modified polymers on bovine red blood 
cells with polymer solutions of   0.5 – 1 mgmL-1 (n=3, ave ± SD). 
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Figure 94. % Haemolytic activity of Ch5 on bovine red blood cells with polymer solutions 
of   0.1 – 0.005 mgmL-1 (n=3, ave ± SD). 
Introduction of hydrophobic groups onto the PAA backbone increased the haemolytic 
effect of the PAA (Fig. 93). However, most of the amphiphiles caused no haemolytic effect 
on the red blood cells with (% haemolysis ≤ 10 % from polymer concentration from 0.05 to 
1 mgmL-1) with exception to Dansyl5, Naphth5 and Naphth10. The haemolytic activity varied 
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with different hydrophobic pendant group on the amphiphiles. The Naphth5 and Dansyl10 
polymers resulted in notably higher haemolytic activity than the other groups. 
As a general trend, higher levels of hydrophobic grafting lowers the haemolytic activity 
(Fig. 93). Lower levels of haemolytic activity was also experience upon quaternization of 
the amphiphiles (Fig. 95). The reduction in haemolytic activity results in greater 
biocompatibility. 
Most of the PAA amphiphiles showed an independent haemolytic trend, whereby, 
increase in polymer concentration did not have an effect on haemolytic activity. However, 
Dansyl5 and Naphth5 appeared to be concentration dependant (Fig. 95). This possibly 
explained their unusually high haemolytic activity at the higher concentration ranges. 
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Figure 95. % Haemolytic activity of quaternized polymers on bovine red blood cells with 
polymer solutions of   0.5 – 1 mgmL-1 (n=3, ave ± SD). 
The red blood cells where imaged under the light microscope to identify any changes in 
the appearance of red blood cells. In Figure 96(a) the red blood cells where incubated 
with PBS which mimics the conditions naturally occurring in the body. The biconcave disc 
shape can clearly be identified. The cells exist individually and not in clusters.  In Fig. 
96(b) the cells have been incubated with Triton X, no healthy red blood cells remained, 
only broken fragments of the cells were visualised. This was due to the surface active 
Triton X lysing all the cells.  
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Figure 96. Bovine red blood cells incubated with a) PBS b) Triton X (x 100 magnification). 
The morphology of the red blood cells did not change in the presence of the 5 or 10 % 
hydrophobic grafted polymers (Fig 97 a&b). The type of hydrophobic group and level of 
grafting did not appear to alter or disrupt the red blood cell structure. However, at higher 
concentrations of Dansyl5, Naphth5 and Naphth10 cell lysis occurred resulting in reduced 
population of blood cells (Fig. 98). 
                                          
     
Figure 97. Bovine red blood cells incubated with a) 0.75 mgmL-1 Fmoc5 b) 0.75 mgmL-1 
Fmoc10 and c) 0.75 mgmL-1 QFmoc5 (x 40 magnification). 
a) b) 
b) a) 
c) 
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The red blood cells formed large clusters in the presence of all the quaternized polymers. 
Fig. 97 c) shows the clumping of red blood cells in the presence of QFmoc5 when 
compared with Fmoc5. This trend was observed for all the quaternized amphiphiles. 
Perhaps this phenomenon may be due to the positive charge on the hydrophilic modified 
polymer causing haemagglutination to occur. However, the shape of the red blood cells 
was not altered in the presence of the positively charged polymers; they still retained their 
round appearance until the point when cell lysis occurred. 
 
                                                                                             
Figure 98. Bovine red blood cells incubated with a) 0.75 mgmL-1 Dansyl5 b) 0.75 mgmL-1 
QNaphth5 (x 40 magnification). 
 
5.3.2. Cytotoxicity Assay 
5.3.2.1. Cytotoxicity of modified polymers 
The MTT assay was carried out to determine the polymer concentration at which only 50 
% (IC50) of the cells population were viable. Polymers with lower IC50 values, have a 
greater cytotoxic effect. No notable difference was observed between the IC50 of the 
modified polymer and the unmodified PAA backbone (Table 29). The different 
hydrophobic groups had only a slight impact on the IC50 values. The IC50 of the unmodified 
PAA backbone was 23.3 µgmL-1 and the presence of the hydrophobic pendants did not 
significantly change the IC50 value of the backbone. Ch5 had a higher IC50 value (37.4 
µgmL-1) indicating that the presence of the cholesteryl group improved the safety profile of 
the polymer. The presence of Dansyl had the adverse effect reducing the IC50 to 17.4 
µgmL-1 (Dansyl5).  
 
 
a) b) 
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Table 29. IC50 values for Caco-2 cells treated with modified PAA polymers (1 x 10-4 – 0.5 
mgmL-1) for 24 h n=3, ave (SD). 
Polymer IC50 value on Caco-2 cells 
(µgmL-1) 
Number fold more cytotoxic 
compared to  IC50 of PAA 
PAA 23.3 (20.1) - 
Ch5 37.4 (3.7) -1.61 
QCh5 55.8 (13.9) -2.39 
Fmoc5 22.9 (3.61) 0.98 
QFmoc5 28.1 (2.0) -1.21 
Fmoc10 27.9 (9.62) -1.19 
QFmoc10 18.4 (4.23) 1.26 
Dansyl5 17.4 (3.5) 1.39 
QDansyl5 51.3 (5.1) -2.20 
Dansyl10 24.6 (0.9) -1.06 
QDansyl10 34.3 (1.2) -1.47 
 
The addition of hydrophilic groups to the polymer backbone in general increase the IC50 
value. The IC50 of Ch5 (37.4 µgmL-1) was increased to 55.8 µgmL-1 upon quaternization 
(Fig. 99). This can be attributed to the conversion of the primary amines on the polymer 
backbone to their less toxic quaternary ammonium status [317]. Furthermore this trend 
was exhibited by all quaternized polymers with the exception to Fmoc10. Upon 
quaternization the IC50 of Fmoc10 reduced from 27.9 µgmL-1 to 18.4 µgmL-1 (QFmoc10), the 
reason for this observation is unknown (Table 29). 
The degree of grafting also had an impact on the cytotoxicity of the polymers. At higher 
levels of grafting a decrease in cytotoxicity was observed (Fig. 100 & 101). Fmoc10 and 
Dansyl10 appeared safer than their 5 % counterparts (27.9 and 24.6 µgmL-1 respectively), 
this perhaps was due to the reduced number of primary amine groups present, thus 
reducing the cytotoxicity of the polymer. 
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Figure 99. MTT results for % cell viability of Caco-2 cells exposed to  ■ Ch5  □ and    QCh5  
(1.0 – 1.0 x 10-4 mgmL-1) (n=3, ave ± SD). 
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Figure 100. MTT results for % cell viability of Caco-2 cells exposed to ■  Fmoc,  □    
QFmoc5,   ●     Fmoc10    and ○  QFmoc10  (1.0 – 1.0 x 10-4 mgmL-1) (n=3, ave ± SD). 
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Figure 101. MTT results for % cell viability of Caco-2 cells exposed to    ■  Dansyl5 ,   □    
QDansyl5,     ●     Dansyl10   and  ○  QDansyl10   (1.0 – 1.0 x 10-4 mgmL-1) (n=3, ave ± SD). 
 
5.3.2.2. Cytotoxicity of anticancer formulations 
MTT assays were carried out on Ch5 and Dansyl10 formulations of etoposide and 
BNIPDaoct to determine whether the polymeric self-assemblies were capable of delivering 
cytotoxic drugs into the cells and enhancing the therapeutic effect of the drugs.  
In order for an anticancer agent to be successful, it requires a cytotoxic effect when in 
contact with cancer cells. This requires a low IC50 value. To determine whether our 
formulation enhanced the therapeutic effect of the anticancer agent, they were formulated 
at the polymer IC90 concentration (the concentration at which 90 % of cells where viable 
determined via MTT assay). Since the polymers were tested using their IC90 values, it is 
assumed that they have negligible cytotoxic effect on cells, and any change in IC50 value 
when treated with anticancer formulations when compared to the free drug is as a result of 
increased uptake of the drug or due to the enhanced therapeutic effect. 
When Caco-2 and HEK293 cells were treated with etoposide, it appeared that the 
HEK293 cells had a much lower IC50 values than the Caco-2 cells, 2.5  µgmL-1 and 189.9 
µgmL-1 respectively, indicating etoposide is more cytotoxic on HEK cells (Table 30). 
Perhaps the slower rate of proliferation on healthy HEK cells compared to the carcinoma 
Caco-2 cells made them more susceptible to the cytotoxic effect in vitro.  
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Table 30. MTT assay of polymers and formulations on HEK 293 cells.  
Polymer/Drug/Formulation IC50 value on 
Caco-2 cells 
(µgmL-1) 
Increase in 
cytotoxicity 
IC50 value on 
HEK cells  
(µgmL-1) 
Increase in 
cytotoxicity 
Ch5 37.4 - 51.4 - 
Dansyl10 24.6 - 19.3 - 
Etoposide  189.9 - 2.5 - 
Ch5, etoposide 86.3 2.2 fold 1.4 1.8 fold 
Dansyl10,  etoposide 13.6 14 fold 0.2 10 fold 
BNIPDaoct 6.4 - 5.0 - 
Ch5, BNIPDaoct 5.1 1.3 fold 0.2 30 fold 
Dansyl10, BNIPDaoct 0.4 16 fold 0.2 30 fold 
IC90 of the polymer was used in the formulations (5 µgmL-1). 
When Ch5, etoposide formulation was exposed to the two cell lines, an equal increase in 
cytotoxicity was experienced by both cell lines (Table 30). This indicates that Ch5 was able 
to enhance the therapeutic effect of the drug compared with the free etoposide. A similar 
effect was observed for the Dansyl10, etoposide formulation. However the Dansyl10, 
etoposide formulation achieved the largest decrease in IC50 values for both cell lines (14-
fold and 10-fold respectively), suggesting that the Dansyl10 was a more effective delivery 
vehicle for the delivery of etoposide to Caco-2 and HEK cells. 
When both cell lines were exposed to BNIPDaoct, the IC50 value with the HEK cells was 
slightly lower than Caco-2 cells (Table 30). The presence of the Ch5, BNIPDaoct 
formulation have similar cytotoxic effect as the free drug on Caco-2 cells, with only  1.3-
fold increase in cytotoxicity experienced. However, when the formulation was exposed to 
the HEK293 cells, a larger increase in cytotoxicity was observed (30-fold). Again the 
Dansyl10, BNIPDaoct formulation increased the cytotoxic effect on both cell lines with 
higher cytotoxic properties on HEK293 than that of Caco-2 cells. 
5.3.3. Cellular localisation of BNIPDaoct formulations 
Cellular localisation studies of the Ch5, BNIPDaoct formulation in Caco-2 and HEK293 cell 
lines. Both the polymer and drug were formulated at the non toxic concentrations, their 
IC90 values were used which were previously determined from the MTT assay (5.3.2.2.). 
The Ch5 polymer was tagged with rhodamine as a fluorophore to allow intracellular 
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visualisation. Rhodamine is a commonly used tag and exhibits red emission fluorescence. 
Dansyl10 possessed its own inherent fluorescence and hence a tag was not required. The 
dansyl moiety on the polymer emits a green flourescence. The BNIPDaoct drug also 
possessed its own inherent fluorescence and appears as a blue colour on the confocal 
microscope when inside the cells. It is important to note that if no polymer or drug entered 
the cells, the images from the confocal microscope would appear black as no fluorescent 
moieties are present. 
Fig. 102 (A4) shows the confocal images for the Ch5, BNIPDaoct formulation on Caco-2 
cells over 4 h. It was observed that polymer alone, free drug and formulation only 
appeared within the cells after 4 h. The polymer and the drug appear to co-localise within 
the cell cytoplasm. The polymer does not appear to enhance the uptake of the drug. This 
observation correlates well with the cytotoxicity assay. The small bright dots on A4 are 
due to cell debris remaining from dead cells stained with Ch5. The cells also appear to be 
clustered, however, this might not be a true representation of the in vitro condition after 
sample treatment. Cells were 90 % confluent before cell fixation, and during this process 
some of the less adherent cells have been removed during the washing steps.  
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Figure 102. Confocal images (X 400 magnification) of A) Ch5, B) BNIPDaoct and C) Ch5, 
BNIPDaoct formulation at 1) 1 h, 2) 2 h and 4) 4h on Caco-2 cells. Red- polymer, blue- 
BNIPDaoct. 
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The confocal images showed the Ch5 formulation also did not enhance the cellular uptake 
in HEK cells (Fig. 103). The free drug, polymer alone and formulation were co-localised in 
the cytoplasm after 4 h. This result does not correlate with the cytotoxicty assay as a 30-
fold increase in cytotoxicty was observed with the presence of Ch5. 
 
     
 
     
 
     
 
Figure 103. Confocal images (x 400 magnification) of A) Ch5, B) BNIPDaoct and C) Ch5, 
BNIPDaoct formulation at 1) 1 h, 2) 2 h and 4) 4h on HEK cells. Red- polymer, blue- 
BNIPDaoct. 
 
 
 
C1 B1 A1 
 C2 B2 A2 
  C4 B4 A4 
 163 
The Dansyl10 formulations showed similar uptake in both Caco-2 and HEK cell lines (Fig. 
104 & 105). The drug and polymer separately were taken up by the cells after 4 h, 
however when formulated together they appeared to be co-localised within the cellular 
cytoplasm after 2 h. This suggests that the Dansyl10 formulations (green) appeared to 
have a synergistic effect on the HEK cell and Caco-2 cell lines. This result correlates well 
with the cytotoxicty assay (Table 30). The Caco-2 cells treated with the formulation, the 
drug fluorescence was more evident as a deeper blue colour was observed, however in 
the HEK cells the green fluorescence of the polymer was predominant. This observation 
correlates well with the cytotoxicity assay, whereby the formulation achieved a 30-fold 
increase in cytotoxicty on the HEK cells but only a 16-fold increase on the Caco-2 cells. 
 
     
 
     
 
     
 
Figure 104. Confocal images (x 400 magnification) of A) Dansyl10, B) BNIPDaoct and C) 
Dansyl10, BNIPDaoct formulation at 1) 1 h, 2) 2 h and 4) 4h on Caco-2 cells. Green- 
polymer, blue- BNIPDaoct. 
A1 B1 C1 
A2 B2 C2 
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Figure 105. Confocal images (x 400 magnification) of A) Dansyl10, B) BNIPDaoct and C) 
Dansyl10, BNIPDaoct formulation at 1) 1 h, 2) 2 h and 4) 4h on HEK cells. Green- polymer, 
blue- BNIPDaoct. 
 
5.3.4. In vivo oral absorption of griseofulvin 
Griseofulvin in water and two griseofulvin formulations (using Ch5 and Dansyl10) were 
administered to male Sprague dawley rats via oral gavage. The rats were constantly 
monitored visually to ensure that no gross toxicity was experienced, causing pain or 
discomfort to the animals. The rats were fully alert and appeared comfortable after the 
dosing with the exception to one. After administration of the formulation, one of the Ch5, 
griseofulvin group had to be euthanised due to suspected oesophageal puncture, a known 
possible adverse event of oral gavage. The level of griseofulvin present in plasma 
A1 B1 C1 
A2 B2 C2 
A4 B4 C4 
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samples of the rats was determined by HPLC analysis. The griseofulvin peak had a 
retention time of approximately 3 min (Fig. 106).  
             
Figure 106. Reverse phase HPLC chromatogram of griseofulvin detected in plasma at 
260 nm (excitation) and 239 nm (emission) of a) Ch5, griseofulvin after 4 h and b) Ch5, 
griseofulvin after 7 h. 
 
The plasma concentration level was determined at 1, 4, 7 and 24 h time points, a graph of 
griseofulvin concentration vs. time was plotted (Fig. 107).  
 
 
Figure 107. Mean plasma griseofulvin concentration (µgmL-1) following administration of 
griseofulvin by oral gavage to male Sprague dalwey rats under fasted conditions over 24 
h,       griseofulvin in water (n=4),        Ch5, griseofulvin (n=3, ave) and         Dansyl10, 
griseofulvin (n=4). Error bars = SD. * p<0.001 formulations vs. griseofulvin in water, ¤ 
p,0.001 Dansyl10, griseofulvin vs. Ch5, griseofulvin, and ^ p,0.001 Ch5, griseofulvin vs. 
Dansyl10, griseofulvin. 
 
 
   ^ 
 
a) 
    b) 
* 
* 
* * 
* 
 * 
 * 
 * 
   ¤ 
 
   ¤ 
 
   ^ 
 
  ¤ 
 
   ^ 
 
  ¤     ^ 
 
 166 
At all time points the griseofulvin formulation appeared to have higher plasma drug levels 
than the griseofulvin in water. The griseofulvin concentration at each time point was found 
to be significantly higher than the griseofulvin in water control (p<0.001).The CMax 
(concentration at which the maximum level of drug was absorbed) of the griseofulvin in 
water was at 1 h, after this time no more drug was absorbed. The Ch5, griseofulvin 
showed the greatest absorption, with as much as 17.059 µgmL-1 found in the plasma. The 
tMax (time at which the maximum concentration was observed) occurred at 4 h for this 
formulation. This indicated that the formulation was stable within the stomach enabling 
absorption possibly in the small intestine and into the blood plasma. In contrast, the tMax of 
Dansyl10, griseofulvin formulation was after 1 h with a CMax of 9.752 µgmL-1. The lower 
absorption of the Dansyl10 formulation could be due to the dilution carried out in the 
preparation stages resulting in lower polymer concentration leading to instability within the 
stomach, whereby, the formulation prematurely released its payload hindering efficient 
absorption across the GI tract over sustained periods of time. This observation correlates 
well with the larger critical association concentration (CAC) of Dansyl10 (0.25 mgmL-1) 
compared to Ch5 (0.093 mgmL-1) (Table 11, pg 75). 
 
5.3.5. In vivo therapeutic effect of BNIPDaoct 
A Ch5, BNIPDaoct formulation was administered weekly to tumour bearing nude mice and 
the effect on tumour volume was measured over a 4 week period. After 4 weeks the mice 
were sacrificed and the final tumour volume was determined (Fig. 108). 
 
Figure 108. Mean tumour volume in mice implanted with BxPC3 cell line and treated with      
….CH5,     CH5, BNIPDaoct formulation, and  ▼ gemcitabine. Treatment was started after 
two weeks when tumour was palpable. Error bars are SD. (* P < 0.05, CH5,BNIPDaoct 
formulation vs. CH5; ** P < 0.05, CH5, BNIPDaoct formulation vs. gemcitabine). Arrow 
indicate the first (¤) and the last injection (¤¤).  
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The tumour volume after treatment with Ch5 alone grew from 0.03 cm3 on day 0 up to 0.25 
cm3 on day 26. The tumour volume after administration with the Ch5, BNIPDaoct 
formulation was quite remarkable, the growth of the tumour was significantly  reduced with 
the tumour volume on day 26 being only 0.1 cm3 (after 6,9,12,16 days, p values= 
0.028,0.01, 0.003, 0.028 respectively when compared to the Ch5 alone). The decrease in 
tumour size was similar with the gemcitabine formulation with the tumour volume being 
0.125 cm3 after the 26 days. When compared to gemcitabine there is a slight decrease in 
size, however this was only significant after the third injection (p=0.006). The results 
strongly suggested that the Ch5, BNIPDaoct was as efficient as gemcitabine as an 
anticancer therapeutic agent. 
Fig. 109 shows photographs of tumours extracted from the nude tumour bearing mice 
after 4 weeks. The tumour treated with Ch5 is the largest in size at 10 mm, as expected 
since Ch5 was the control. The tumour treated using the Ch5, BNIPDaoct formulation, the 
tumour size is notably smaller at approximately 6 mm in comparison with the Ch5 control. 
The tumour treated with commercially available anticancer drug gemcitabine which 
appears to have been impeded the tumour growth resulting in a final tumour size of 
approximately 8 mm. These images highlight the potential of Ch5, BNIPDaoct formulations 
in anticancer therapeutics.  
 
 
Figure 109. Representative example of each tumour recovered at the end of each drug 
treatment. 
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5.4. Discussion 
Haemocompatibility is an essential characteristic of any drug or formulation being 
administered intravenously into the body. We observed that most of the modified PAA 
polymers had no notable haemolytic effect over the concentration range tested (0.005 - 1 
mgmL-1) with less than 10 % haemolytic activity observed (Fig. 93). Hydrophobic 
modification of the parent PAA backbone resulted in increased haemolytic activity. This 
finding was not consistent with other reports of cationic polymers [317].  Aravindan and 
colleagues reported that acyl grafting of poly(ethylenimne) (PEI) decreased the haemolytic 
effect as the positive charge density on the cationic polymer was reduced hence reducing 
interactions with negatively charged red blood cell membranes [317]. However, we found 
that higher grafting levels of hydrophobic modification generally reduced the haemolytic 
effect.  
On the other hand, it has also been hypothesised that hydrophobic alkyl pendant groups 
are able to anchor into the phospholipid bilayer of the red blood cells and hence disrupting 
their structure and forming polymer-lipid aggregates [318].  Our study suggests that the 
aromatic pendant groups also possess the ability to disrupt the lipid bilayer causing 
rupture of the cell, however this phenomenon only occurs at high polymer concentrations.  
Numerous research groups have published work on addition of hydrophilic moieties onto 
polymer backbones such as quaternization [3,76,125,319]. It has been reported that 
quaternization results in an increase in haemocompatibility [122]. We found that upon 
quaternization of the PAA amphiphiles, a decrease in haemolytic activity was observed 
consistent with the previous findings. The decrease in haemocompatibility can be 
attributed to the reduced number of 1º amine groups on the polymer, as 1º amines are 
known to exert haemolytic effects on erythrocyte membranes, while tertiary amines 
reduce the haemolytic effect [316,320]. It was observed however, that the presence of the 
permanent positive charge resulted in the formation of heamagglutination, whereby the 
cells had not deviated from their original shape, but had aggregated together into groups, 
possibly due to electrostatic interactions [321]. This phenomenon was not observed for 
the corresponding unquaternized amphiphile counterparts.  
Hydrophobic modification of the PAA backbone had little impact on the cytotoxicity of the 
polymer. The hydrophobic pendant group had an impact on the cytotoxicity experienced 
by the cells, with Ch5 having the highest IC50 value (37.4 µgmL-1) and Dansyl10 having the 
lowest (17.4 µgmL-1) on Caco-2 cells (Table 29). Addition of hydrophobic groups to the 
backbone resulted in slight decrease in cytotoxicity. Higher grafting levels and 
quaternization of the polymer resulted in a lower 1º amine levels in the polymer. It has 
previously been reported that 1º amines are highly cytotoxic and by reducing their 
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presence on a polymer will result in an increased safety profile of that polymer [317]. 
These findings are in agreement with both the haemolysis and cytotoxic assay results. 
The IC50 values for the polymers were lower than the CMC values (Table 11, pg 75). 
However it is important to remember that in vitro conditions are not exactly the same as 
the conditions found in vivo. For example the cell line is only a representative of one or 
two cell types in the body, the cells were seeded onto a flat surface and therefore have 
lost their 3D geometry, they are also treated with a high concentration/cell number which 
would not happen in vivo. All these conditions need to be taken into consideration when 
analysing the cells as they may not be affected by much higher dosages than suggested 
in vivo. 
Polymeric self-assemblies have been previously shown to enhance the in vitro cellular 
uptake of therapeutic agents such as anticancer drugs [70,98]. Danhier and colleagues 
loaded poly(ethyleneglycol)750-block-poly(ε-caprolactone-co-trimethylenecarbonate) with 
anticancer paclitaxel and exposed the formulation to human cervix epithelial carcinoma 
cells [98]. They reported that the polymer loaded paclitaxel had a lower IC50 (12.5 µgmL-1) 
than the free drug (17.6 µgmL-1) after only 24 h exposure [98]. The polymer concentration 
was fixed at 82 % cell viability and therefore the decrease in IC50 value could be solely 
attributed to the cytotoxic effect of the paclitaxel [98]. These results do not show a notable 
difference between the cytotoxic effect of the free drug and the formulation. In comparison 
the Ch5 and Dansyl10 formulations achieved much larger increment of increased 
cytotoxicity. 
Consistent with these results we observed that in both Caco-2 and HEK cell lines the 
cytotoxic effect of both etoposide and BNIPDaoct was enhanced as much as 2.2-fold and 
14-fold on Caco-2 cells (Ch5, etoposide and Dansyl10, etoposide respectively) and 30-fold  
on HEK cells (Ch5, BNIPDaoct and Dansyl10, BNIPDaoct respectively) (Table 30). The 
Dansyl10 appeared to be the more effective anticancer drug carrier as it showed the 
highest reduction of IC50 value. These findings could be attributed to the synergistic effect 
observed by confocal imaging of the BNIPDaoct formulations over time. The synergistic 
effect experienced with the Dansyl10 formulation resulted in the polymer, drug formulations 
becoming co-localised in the cytoplasm after only 2 h whereas, separately they were only 
apparent after a 4 h period.  
Oral absorption of griseofulvin through the gastrointestinal (GI) tract is very low and 
commonly varied amongst individual patients [265,271]. To achieve the desired 
therapeutic effect various formulations have been attempted in vivo including aqueous 
suspensions, emulsions etc. [270,271]. The absorption of griseofulvin in vivo is affected by 
a number of factors such as low aqueous solubility of drug, patients stomach and the type 
of formulation [270]. In clinics, patients who are prescribed with griseofulvin are advised to 
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eat a high fat content meal immediately following oral administration of the drug in order to 
increase drug solubility and to aid absorption across the GI tract [271]. 
Fujioka and colleagues administered griseofulvin orally in a gelatine capsule to male 
Wistar rats (20 mgKg-1). They analysed the plasma drug levels over a 10 h period 
achieving a CMax of 1.37 µgmL-1 after 7 h with the bioavailability of 1.04 [270]. However, 
the results from the study widely varied with inter-patient variation being evident [270]. 
Ahmed and colleagues have recently formulated griseofulvin in fast dissolving freeze dried 
emulsion tablets [271]. The tablets were administered in a single dose (125 mg) to healthy 
human volunteers. The maximum concentration of griseofulvin reported in the blood 
plasma was 2.42 µgmL-1 which occurred after 1 h [271]. They compared their formulation 
to the commercially available Fulvin which only resulted in a Cmax of 1.10 µgmL-1 and with 
a much longer tMax of 6 h [271]. This indicated that the current marketed formulation of 
griseofulvin was inefficient, taking a longer time to achieve Cmax concentration. 
Using our formulations we have demonstrated oral absorption of griseofulvin as high as 
17.059 µgmL-1 for Ch5, griseofulvin, this was a 8.89-fold increase compared to the 
aqueous griseofulvin formulation (for total concentration absorbed over 24 h period). 
Dansyl10 achieved its tmax after only 1 h, whereas Ch5 achieved tmax after 4 h. Perhaps the 
earlier tmax experienced by the Dansyl10 formulation and reduced absorption can be 
attributed to destabilisation of the self-assemblies in the stomach, prematurely releasing 
their payload and thus hindering efficient absorption and sustained release of the drug. 
The shorter tmax of Dansyl10 would suggest that Cmax was observed after griseofulvin had 
been absorbed through the stomach wall, whereas, the longer tmax of the Ch5, suggests 
that after 4 h the griseofulvin should have been absorbed through the intestine. The Ch5 
appears to be more efficient for oral delivery of the drug than Dansyl10 (8.89-fold increase 
compared with 5.20-fold increase in total griseofulvin absorption respectively). 
When compared with previous studies by other groups both the Ch5 and Dansyl10 
formulations resulted in excellent drug absorption in vivo. A 50-fold (Ch5, griseofulvin) and 
28-fold (Dansyl10, griseofulvin) increase of griseofulvin absorption compared to previously 
reported figures by Ahmed when comparing the CMax, these were a 110-fold and 63-fold 
increase compared to the Fulvin formulation [271]. The effects of inter-individual variation 
did not appear evident using the Dansyl10 formulation as all the subjects had drug plasma 
levels with a small standard deviation. This would suggest that the nano carriers were less 
susceptible to factors affecting the drug absorption among patients. The large 
concentrations of drugs absorbed together with the small standard deviations observed 
indicated that the PAA amphiphiles were capable of significantly enhancing the absorption 
of griseofulvin in vivo (p<0.0001 when compared to griseofulvin in water). The large 
increase in drug plasma levels experienced after oral administration of Ch5 and Dansyl10 
griseofulvin formulations compared to others work. However this could be due to two 
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factors. Firstly, the increased aqueous solubility of griseofulvin experienced when in 
formulation could aid in greater absorption through the stomach wall and into the blood 
stream. However, the polymeric nano-carriers may also facilitate transport across the GI 
tract enabling a higher concentration of drug to become absorbed. The later of which 
could possibly explain the reduced inter-subject variations which have been previously 
reported [271].  
In vivo delivery of anticancer drugs using polymeric self-assemblies has been reported not 
only facilitate the uptake of the drugs but also to enhance the therapeutic effect observed 
[322]. Le Garrec and colleague loaded anticancer agent paclitaxel into novel polymeric 
poly(N-vinyl pyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) self-assemblies [97]. 
Female Balb/C mice with C26 colon adenocarcinoma were treated intravenously with the 
formulation over 20 days.They observed a 13-fold decrease in relative tumour size over 
20 days of treatment, this was 2-fold better than Taxol® [97]. However, they concluded that 
this could be improved by the manipulation of polymer structure [97]. 
Recently, Xu and colleagues loaded methoxypolyethylene glycol –poly (D,L-lactic acid) 
with anti tumour drug triptolide with 66.7 % encapsulation efficiency [322]. They 
administered the drug (0.15 mgKg-1) intravenously to S-180 tumour bearing mice and 
observed reduction in tumour weight from 2.58 g using free drug to 1.23 g using polymer 
formulation [322]. The rational for such activity is the tendency of the nano sized 
aggregates to accumulate within the tumour vasculature due to the enhanced permeability 
and retention effect [70]. 
A Ch5, BNIPDaoct formulation (1 mgmL-1, 0.3 mgmL-1) was administered to nude tumour 
bearing mice over a 4 week period. The study found that the Ch5, BNIPDaoct formulation 
was capable of reducing tumour growth rate when compared to Ch5 alone. The reduction 
in tumour growth was comparable to the current commercially available drug gemcitabine 
for anticancer treatment. When compared with other studies, the reduction in tumour size 
is not as large. This could be due to the anticancer drug BNIPDaoct not being as effective 
or due to the polymer delivery system being less efficient. Nevertheless, this study 
indicates the reduction in tumour size was significant (p< 0.05) compared to the polymer 
alone control. 
5.5. Conclusion 
The polymers showed no haemolytic effect on red blood cells over the concentrations 
tested. The Ch5 and Dansyl10 polymeric self-assemblies were capable of increasing 
cytotoxic effect of etoposide and BNIPDaoct in two cell lines. The Dansyl10 exhibited a 
synergistic effect on the drugs enhancing their uptake into cells after only 2 h (compared 
with 4 h for the free drug and polymer alone). Both polymers increased oral absorption of 
griseofulvin in vivo without gross toxicity observed in rats. Ch5 was shown to decreased 
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tumour size when encapsulating BNIPDaoct. In general the Ch5 and Dansyl10 show 
excellent potential as hydrophobic drug solubilisers. 
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Chapter Six 
General Conclusions and Future Work 
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6.1 General conclusions 
Homopolymer poly(allylamine) (PAA) has been successfully modified to produce novel 
PAA polymers different levels of hydrophobic (cholesteryl, fmoc, dansyl and naphthalene) 
modification and some amphiphilic PAA’s were further modified with hydrophilic 
(quaternary ammonium) groups. Fourteen novel comb shaped amphiphilic PAA polymers 
were synthesised with high yield and good reproducibility. 
In the aqueous environment all the PAA amphiphiles were capable of forming 
spontaneous nano self-assemblies comprising of a hydrophobic inner core. At 25 °C the 
PAA amphiphiles formed self-assemblies which were shown to have a hydrodynamic 
diameter of 120 – 199 nm. At low concentrations they all formed clear aqueous solutions 
upon sonication, the solutions formed were cloudy at higher concentrations. The 5 % 
grafted hydrophobic modified polymers formed intermolecular aggregates in solution. At 
higher concentration of fmoc and naphthalene modified polymers, excimer formation was 
observed whereby, the planar aromatic pendant groups began stacking in an ordered 
arrangement resulting in a second point of inflection on the surface tension 
measurements. The Ch5 polymer had the lowest CAC with the aromatic pendant groups 
resulting in relatively larger CAC values. At higher levels of hydrophobic grafting (10 %) 
and upon hydrophilic modification some of the polymers formed intramolecular 
aggregates. It is thought that the presence of the permanent positive charge encouraged 
aggregation of the polymer at lower concentrations resulting in this self-aggregation. 
The hydrodynamic size was shown to decrease at higher levels of hydrophobic grafting 
due to greater hydrophobic interactions occurring in the aqueous phase resulting in more 
compact self-assemblies. Upon quaternization of the polymers, the self-assemblies 
increased in hydrodynamic radius, probably due to the permanent positive charge causing 
weaker hydrophobic interactions to occur resulting in less compact aggregates. The PAA 
amphiphiles were loaded with five model hydrophobic drugs (propofol, prednisolone 
griseofulvin, etoposide and novel anticancer agent BNIPDaoct). The ability of the self-
assemblies to encapsulate the hydrophobic drugs varied with the types of hydrophobic 
pendant group and drug. We observed that the polymer with the aromatic planar fmoc 
pendant (which exhibited excimer stacking at higher concentration) showed low drug 
solubilisation capacities for both the propofol and prednisolone (0.45 and 2.98 mgmL-1 
respectively) compared to the Ch5 (7.82 and 7.05 mgmL-1 respectively) and Dansyl10 
(22.40 and 31.82 mgmL-1 respectively) polymers. This indicates that the stacking pendant 
groups hinder the drug incorporation into the self assembly (Fig. 110). 
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Figure 110. Drug incorporation into Fmoc-PAA self-assemblies. 
The Ch5 and Dansyl10 were shown to be excellent universal drug solubilisers, with a 78–
fold and 223–fold increase in aqueous propofol solubility observed respectively. The 
resultant formulations possessed extremely low excipient:drug  ratios making them very 
efficient systems (as low as 0.77:1 for Ch5, propofol and 0.19:1 for Dansyl10, 
prednisolone). The Ch5 and Dansyl10 polymers did not form excimers due to steric 
hindrance of the pendant groups. The lack of excimer formation allowed for a degree of 
core expansion to occur upon drug encapsulation (Fig. 111). This expansion allowed for a 
greater drug solubilisation concentration. The sizes of the optimal formulations differed 
greatly for both formulations, possibly due to the varying architectures of both the drugs 
and the modified polymers and their ability to accommodate and shield each other from 
the ‘hostile’ aqueous environment. The formulations were shown to achieve sustained 
release of the drugs up to 48 – 96 h. 
 
 
 
Figure 111. Expansion of hydrophobic core of Ch5 and Dansyl10 upon drug loading. 
 
In vitro biocompatibility studies revealed that most of the polymers showed negligible 
haemolytic activity (< 10 %) on red blood cells (0.1 to 1 mgmL-1). At higher hydrophobic 
grafting and upon quaternization the haemolytic effect was reduced, this possibly due to 
Addition of drug Expansion of core with 
drug incorporated 
inside core 
Compact hydrophobic core 
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the reduction of primary amines on the PAA backbone which contribute to the haemolytic 
effect. The quaternized polymers, however caused haemoguttenation of the cells. The low 
haemolytic effect of the unquaternized polymers supports the suitability for intravenous 
administration of drugs.  
In vitro cytotoxicity assays using etoposide and BNIPDaoct formulations of Ch5 and 
Dansyl10 showed that when Caco-2 and HEK293 cells were exposed to the formulations, 
enhanced therapeutic effect was observed compared to the free drugs. The inherent 
fluorescent nature of the dansyl aromatic grafted polymers enabled ease of visualisation 
without the use of a secondary fluorescent marker tag. The Ch5 polymer had to be tagged 
with a rhodamine tag to allow fluorescence analysis. Confocal microscopy was carried out 
using Ch5, BNIPDaoct and Dansyl10, BNIPDaoct formulations in vitro on Caco-2 and 
HEK293 cells. The study showed that Ch5 formulations appeared co-localised within the 
cells after 4 h however the Dansyl10 formulation appeared to have a synergistic effect on 
both the drug and polymer as they appeared co-localised after only 2 h whereas 
separately the drug or polymer alone took 4 h for cellular uptake to occur. 
In vivo administration of Ch5 and Dansyl10 formulations of griseofulvin showed that both 
Ch5 and Dansyl10 significantly enhanced the absorption of griseofulvin in rats compared 
with griseofulvin in water and each other (p < 0.001) without any adverse side effects. The 
Ch5 and Dansyl10 formulations enhanced the CMax for oral absorption of griseofulvin 4.18-
fold and 1.16-fold and the increment increase of total griseofulvin absorbed over the 24 h 
study by 8.89-fold and 5.20-fold respectively. The Dansyl10 was less effective for oral 
delivery of griseofulvin compared with Ch5. The reason for this is perhaps the drug loaded 
self-assemblies experienced disruption upon dilution when they reached the stomach, 
prematurely releasing the drug and hindering its absorption across the stomach wall. This 
data correlates well with the CAC values obtained using surface tension measurements, 
whereby the Dansyl10 had a much higher CAC value than the Ch5 (0.25 and 0.093 mgmL-
1) indicating that the Dansyl10 would experience decreased stability upon dilution when 
compared with Ch5 (Fig. 112). In vivo administration of Ch5, BNIPDaoct formulations was 
also shown to significantly decrease tumour growth when treated on nude tumour bearing 
mice over a 4 week period.  
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Figure 112. In vivo fate of orally administered Ch5, griseofulvin and Dansyl10, griseofulvin 
formulations. 
 
In conclusion, this is the first time novel amphiphilic PAA polymers grafted with aromatic 
pendant groups have been shown to be capable of solubilising poorly soluble drugs such 
as propofol, prednisolone, griseofulvin, etoposide and BNIPDaoct and enhance absorption 
of drugs via oral route and intravenous administration. Overall Ch5 and Dansyl10 show 
great potential as future drug delivery systems. 
6.2. Future Work 
We carried out a short term stability test by storing liquid and freeze-dried preparations of 
the formulations. In the future it would be desirable to carry out further long term stability 
testing of the Ch5 and Dansyl10 formulations in order to determine their potential as 
pharmaceutical excipients. 
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We concluded that variation of the hydrophobic pendant group had a direct impact on the 
properties of the self-assemblies formed in aqueous solutions. Further modification of the 
PAA backbone including the attachment of poly(ethylene glycol) (PEG) could increase the 
biocompatibility and perhaps further influence the drug loading capabilities of the polymer. 
It would also be useful to investigate other aromatic and alkyl pendant group attachment 
to the polymer and test not only the drug solubilisation capacities but also the ability of 
complexation with proteins and genes.  Further drug solubilisation studies of an increased 
number of drugs would also be necessary to back up the hypothesis that the Ch5 and 
Dansyl10 were universal solubilisers.  
Cellular localisation studies enabled determination of time taken for cellular uptake of the 
formulations. It would It may be beneficial to repeat the confocal imaging of the 
formulations in cells, as the pictures could be improved upon. Perhaps it would also be 
valuable to carry out further in vitro intracellular trafficking to determine the mechanism of 
cellular uptake in the cell to visualise exactly where the drug and polymer reside [83,323]. 
This can be carried out by staining the organelles in the cell e.g. Nucleus, cell membrane, 
mitochondria etc. [83] It would also be advantageous to use a range of inhibitors such as 
sodium azide (metabolic inhibitor) or cytochalasin D (endocytosis inhibitor) to allow 
determination of the mechanism of cellular uptake e.g. endocytosis or active transport or a 
different type of transport [312, 323]. A Caco-2 transport study could also be carried out in 
order to determine if paracellular transport is involved. Further in vivo work is also 
necessary for both oral and intravenous delivery of hydrophobic drugs over longer time 
periods in order to elucidate the potential of these drug formulations for pharmaceutical 
therapies. All these studies must be carried out in order to bring the work forward before 
being considered for clinical investigation. 
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1.0 NMR spectra of modified polymers 
 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
10%fmocbatch1
 
 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
10%-Dansyl
 
 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5 ppm
naphth5
 
 
Figure 1.  1H NMR spectra of a) Fmoc10, b) Dansyl10, c)Naphth10 carried out in MEOD on 
400Hz NMR @ 25⁰C 
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Figure 2. 1H NMR spectra of a) QFmoc5, b) QDansyl5 and c) QNaphth5 carried out in 
MEOD on 400Hz NMR @ 25⁰C 
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Figure 3.1H NMR spectra of a) qFmoc10, and  b) QDansyl10 c) QNaphth10 carried out in 
MEOD on 400Hz NMR @ 25⁰C 
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2.0 FTIR spectra of modified polymers 
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Figure 4. FTIR spectra for a) Fmoc10,b) Dansyl10 and c) Naphth10 carried out using a 
diamond powder tip – 20 scans 
b) 
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Figure 5. FTIR spectra for a) QFmoc10,b) QDansyl10 and c) QNaphth10 carried out using a 
diamond powder tip – 20 scans 
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3.0 Photon correlation spectroscopy of self-assemblies 
 
 
 
Figure 6. Photon correlation spectroscopy size correlation chart for 1mgmL-1 a) QCh5, b) 
QFmoc5, and c) QNaphth5 in water 
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Figure 7. Photon correlation spectroscopy size correlation chart for 1mgmL-1 a) QCh5, b) 
QFmoc5, c) QDansyl5 and d) QNaphth5 in water. 
b) 
 
c) 
d) 
a) 
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Figure 8. Photon correlation spectroscopy size correlation chart for 1mgmL-1 a) Fmoc10 
and b) Naphth10 in water. 
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Figure 9. Photon correlation spectroscopy size correlation chart for 1mgmL-1 a) 
QFmoc10, b) QDansyl10 and c) QNaphth10 in water. 
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4.0 Surface tension of self-assemblies 
 
 
 
Figure 10. Surface Tension results for     QCh5 and      QNaphth5 carried out on a 
torsion balance at 25⁰C (n=3, ave±SD). 
 
 
 
 
 
Figure 11. Surface Tension results for    Dansyl10 and      Naphth10 carried out on 
a torsion balance at 25⁰C, (n=3, ave±SD). 
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Figure 12. Surface Tension results for   QFmoc10,  QDansyl10 and    ,,,,,,,,                     
QNaphth10 carried out on a torsion balance at 25⁰C (n=3, ave ±SD). 
 
 
5.0 Synthesis and characterisation of BNIPDaoct 
5.1 Method 
5.1.1. N-Acylation of Naphthalic Acid 
Naphthalic anhydride (6.46 g) was dissolved in Dimethyl formaldehyde (DMF) (70 ml) in a 
round bottomed flask. The solution was stirred and slowly heated in an oil bath until 
homogeneous. 3-Amino 1- propanol (2.45 g) was added to solution forming a dark liquid. 
1,8-diazabicycloundec-7-ene (DBU) (7.45 ml, 1 gmL-1) was added and the solution was 
stirred at 85 ⁰C for 2 h. After cooling the solution was added slowly with stirring to icy 
water (200 ml) forming a precipitate. The resultant precipitate was filtered using a sintered 
glass funnel under pressure before being dried in a vacuum oven overnight. The product 
was recrystallised using ethanol and dried further. Thin layer chromatography (TLC) and 
1H NMR were run to determine the purity of the compound. 
5.1.2. Tosylation of Naphthalimidoalkylpropanol 
Naphthalimidoalkyklpropanol (5.10 g) was added to dry Pyridine (80 ml) and stirred at 0 
⁰C for 10 mins. Tosyl chloride (5.27 g) was added to the solution over 0.5 h and the 
resultant solution was refrigerated overnight at 0 – 5 ⁰C. The refrigerated mixture was 
poured slowly with forceful stirring into icy water (200 ml) producing a visocous liquid 
which solidified on cooling. The solid was filtered using a buchner funnel and washed with 
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deionised water. The solid was recrystallised with ethanol and dried in a vacuum oven 
overnight. NMR spectra were run to enable identification of the compound. 
5.1.3. Protection and activation of polyamine 
1,8- Diaminooctane (4.00 g) was dissolved in Pyridine (70 ml) with stirring. 
Mesitylenesulphonyl chloride (12.73 g) was added and the solution was stirred at room 
temperature for 4 h. The pyridine was removed using a rotary film evaporator (RFE) and 
the remaining solution was poured into icy water (200 ml) with stirring. The resultant 
precipitate was filtered and washed with hydrochloric acid (0.2 M) and deionised water. 
The purity of the compound was checked using TLC. The product was dried in a vacuum 
oven overnight before running 13C and Dept NMR spectra. 
5.1.4. Alkylation 
Bimesitylene–1,8-diaminooctane (2 g) was dissolved in DMF (30 ml) with stirring. O-
Tosylpropylnaphthalimide (3.38 g) was added to solution followed immediately by 
Caesium carbonate (7.04 g) and the mixture was stirred overnight at room temperature. 
The solution was poured into icy water (200 ml) and stirred with a glass rod. A few drops 
of Hydrochloric acid (2 M) were added to ensure any excess caesium carbonate was 
dissolved in the aqueous phase. The solution was filtered using a Buchner funnel and the 
solid precipitate was dried in a vacuum oven overnight. A TLC was run to determine the 
purity of the compound. The solid was recrystallised using ethanol before 13 C and Dept 
NMR spectra were run on the dried product.  
5.1.6. Deprotection of BNIPDaoct 
Bisnaphthalimidobismesitylene-1,8-diaminooctane (2 g) was dissolved in dry 
dichloromethane (47 ml) with stirring. Hydrogen bromide / methanoic acid solution (7.71 
ml) was added and the mixture was left at room temperature overnight. The precipitate 
was filtered using a sintered glass funnel and washed with dry dichloromethane. The solid 
was dried I a vacuum oven overnight. 13C and Dept NMR were run to ensure the 
structure and purity of the final product. 
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5.2. Results 
5.2.1.N-Acylation of Naphthalic anhydride 
 
O
O
O
+ 2HN OH DBU, DMF N
O
O
OH
 
 
Figure 13. Reaction schematic for N-acylation of Naphthalic anhydride. 
 
Amount of product before recrystallisation = 10.17 g 
Amount of product after recrystallisation = 9.99 g (0.0389 moles) 
 
% Yield =  (Moles starting material / Moles product) x100 = (0.0389 / 0.0505) x100 
   = 77 % 
 
 
 
 
Figure 14.1H NMR spectra with peak assignment of namphthalimidoalcohol product 
carried out using in CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
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Peak assignments on the 1H NMR spectra for Naphthalimido alcohol product (Fig. 14) 
were as follows: δ2 = CH2 on alkyl chain, δ3.5 = CH2 on alkyl chain beside O atom and O-H, 
δ4.4 =  CH2 on alkyl chain beside N atom and δ7.8 - 8.6 = CH’s on aromatic rings. 
 
5.2.2.Tosylation of Naphthalimidoalkylpropanol 
 
N
O
O
OH N
O
O
OTosyl
Tosyl Chloride
Pyridine
S
O
O
OR
O-Tosyl structure
 
 
Figure 15. Reaction schematic for tosylation of naphthalimidoalkylpropanol. 
 
 
Amount of product = 5.67 g (0.0138 moles) 
 
% Yield =  (Moles product / Moles starting material) x100 = (0.0138 / 0.020) x100 
   = 69 % 
 
 
Peak assignments for 1H NMR spectra of OTosyl product are as follows (Fig. 16): δ2.2 = 
CH2 on alkyl chain, δ2.5 = CH3 attached to aromatic ring, δ4.3 = CH2’s on alkyl chain beside 
O and N atoms and δ7.3 – 8.5 = CH of aromatic rings. 
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Figure 16.1H NMR spectra with peak assignment of Otosyl product carried out using in 
CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
 
 
Figure 17.13C NMR spectra with peak assignment of Otosyl product carried out using in 
CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
The carbon assignments for the 13C NMR spectra of the OTosyl product as as follows 
(Fig. 17): C20 = CH3 group attached to aromatic ring, C29 = CH2 on alkyl chain, C39 = CH2 
on alkyl chain next to N atom, C69 = CH2 on alkyl chain next to O atom, C122 – 167 = C in 
aromatic rings. 
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Fig. 18 shows the dept NMR spectra for the OTosyl product. The dept is used to 
distinguish between CH, CH2 and CH3 groups in the atom. The peaks assignments for the 
spectra are as follows. The peak at 19 ppm = CH3 on aromatic ring, 20 ppm CH2 on alkyl 
chain, 35 ppm = CH2 on alkyl chain beside N atom, 70 ppm = CH2 on alkyl chain next to O 
atom and the peak occurring 120 – 140 ppm are due to the CH’s of the aromatic rings. 
 
 
Figure 18.DEPT NMR spectra with peak assignment of Otosyl product carried out using 
in CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
5.2.3.Protection and activation of polyamine 
H2N
NH2 Mts.Cl
Pyridine
HN
NH
S
S OO
OO
 
Figure 19. Reaction schematic for protection and activation of polyamine. 
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Amount of product = 9.10 g (0.018 moles) 
% Yield =  (Moles product / Moles starting material) x100 = (0.018 / 0.027) x100 
   = 67 % 
 
 
 
 
Figure 20.13C NMR spectra and peak assignment of Mts-protected diaminooctane 
product carried out using in CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
The peak assignment for 13C NMR spectra of Mts-diaminooctane is as follows (Fig. 20): 
C20 = CH3’s on aromatic group, C23 = CH3’s on aromatic group in proximity to O atoms, C27 
= CH2’s on alkyl chain, C30 = CH2’s on alkyl chain closer to N atom, C41 = CH2’s on alkyl 
chain next to N atom and C130 - 143 = CH’s on aromatic groups. 
The dept NMR spectra for the Mts-diaminooctane  (Fig. 21) showed peaks at 22 and 24 
ppm, these were due to the CH3 groups on the aromatic rings. Four CH2 peaks were 
present at 27, 29, 30 and 43 ppm. CH2’s were present in four different environments on 
the molecule and hence these correlated with the presence of the four peaks (Fig. 21). 
The peaks between 128 – 145 ppm were present due to the CH’s in the aromatic rings. 
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Figure 21.DEPT NMR spectra with peak assignment of Mts-protected diaminooctane 
product carried out using in CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
 
5.2.4.Alkylation
HN
NH
S
S OO
OO
N
O
O
OTosyl
+
N
N
S
S OO
OO
N
N
O
O
O
O
DMF, Cs2CO3
Figure 22. Reaction schematic for alkylation.  
 
Amount of product before recrystallisation = 3.78 g 
Amount of product after recrystallisation = 3.23 g (0.003248 moles) 
% Yield =  (Moles product / Moles starting material) x100 = (0.00328 / 0.0039) x100= 84% 
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Figure 23.1H NMR spectra with peak assignment of alkylated product carried out using in 
CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
 
 
Figure 24.13C NMR spectra with peak assignment of alkylated product carried out using in 
CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
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Figure 25.DEPT NMR spectra with peak assignment of alkylated product carried out 
using in CDCl3 carried out using 400MHz NMR at 25 ⁰C. 
 
5.2.5.Deprotection of BNIPDaoct 
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Figure 26. Reaction schematic for deprotection of  BNIPDaoct. 
Amount of product = 1.92 g (0.0025 moles) 
% Yield =  (Moles product / Moles starting material) x100 = (0.0025 / 0.002034) x100 = 
123 % 
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Figure 27.1H NMR spectra of BNIPDaoct carried out using in CDCl3 carried out using 
400MHz NMR at 25 ⁰C. 
 
Figure 28.13C NMR spectra of BNIPDaoct carried out using in CDCl3 carried out using 
400MHz NMR at 25 ⁰C. 
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Figure 29.DEPT NMR spectra of BNIPDaoct carried out using in CDCl3 carried out using 
400MHz NMR at 25 ⁰C. 
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